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ABSTRACT
Identification of proteins whose expression and/or activities are upregulated in clinical
neoplasias provides insight into the mechanisms underlying carcinogenic transformation and
malignancy. Validation of such proteins as biomarkers through correlation to patient
outcomes can provide novel targets for the development of selective anticancer therapies.
Therapeutics that target phenotypic alterations common to a variety of cancers could have a
broad impact on the treatment of cancer as a whole. Increased invasive capability
accompanying upregulated proteolytic activity is widely recognized as a critical determinant of
metastatic potential and is commonly observed in progressive disease. The urokinase
plasminogen activator (uPA) is a key contributor to cell invasiveness through the activation of
plasminogen and downstream proteases. These proteolytic actions endow cancerous cells
with the ability to degrade extracellular matrix and basement membrane components,
facilitating their invasive spread. uPA and its cognate cell-surface receptor (uPAR) are of
prognostic relevance in a variety of aggressive cancers where their overexpression predicts
adverse patient outcomes and metastatic potential.

A second phenotype observed in virtually all cancers is the reversal of transmembrane pH
gradients relative to healthy tissues. Alkalinization of the intracellular pH (pHi) and the
concomitant acidification of the extracellular space create a permissive environment that
promotes further dysregulated growth, insensitivity to apoptotic checkpoints and increased
motility and invasiveness that propel transformed cells towards malignancy and metastasis.
The Na+/H+ exchanger isoform 1 (NHE1) is upregulated in a wide variety of tumours and is a
primary contributor to the cancer-specific reversal of transmembrane pH gradients.
Hyperactivation of NHE1 is an early event in oncogene-driven carcinogenesis and has been
shown to be essential for maintenance of transformed phenotypes and growth of tumour
ix

xenografts in mice. Amiloride, a commonly prescribed oral potassium-sparing diuretic,
presents a unique opportunity for medicinal chemistry optimization into dual-targeting
uPA/NHE1 inhibitors as anticancer therapeutics as it is a moderate inhibitor of both targets
and shows robust anticancer side activities in vivo.

5-substituted amiloride analogues are known to show greatly improved NHE1 potency relative
to amiloride (e.g. 5-(N,N-hexamethylene)amiloride 27 (HMA) >520-fold) whilst exhibiting
reduced activity against epithelial sodium channels (ENaCs), the target responsible for the
diuretic and antkalliuretic properties of the parent drug. This PhD project explored structureactivity relationships (SAR) of 6-HMA analogues as inhibitors of uPA and NHE1, with the
overall aim of identifying 6-HMA analogues with high (nM) potency against both targets.

Significant increases in uPA inhibitory activity were achieved through addition of various
heteroaryl substituents at the 6-position of HMA (Chapter 2). Two structurally distinct lead
scaffolds with divergent physicochemical properties were discovered that showed excellent
inhibitory potency against uPA (43 IC50 = 143 nM, 50 IC50 = 69 nM). X-ray crystallographic
analysis (Chapter 3) revealed that the potency gains were due to increased binding
interactions in the uPA S1 subsite. Biochemical assays demonstrated a high degree of
selectivity for uPA over closely related trypsin-like serine proteases (Chapter 4). In vitro assays
revealed a diverse spread for cytotoxic activities of the lead inhibitors across a variety of cell
lines.

A novel fluorescence plate reader assay was developed for measuring NHE1 inhibition and
was used to characterize SAR around the HMA scaffold (Chapter 5). In general, introduction of
(hetero)aryl substituents at the 6-position did not decrease potency of HMA analogues against

x

NHE1, and in some cases yielded potent uPA/NHE1 dual-targeting compounds (48 uPA IC50 =
175 nM; NHE1 IC50 = 397 nM), along with uPA-selective inhibitors (49 uPA IC50 = 86 nM; NHE1
IC50 = 21 M).

Research perfomed under contract by Charles River Laboratories using a selection of 6-HMA
analogues and HMA revealed the absence of activity against ENaCs, the diuretic and antikeliuretic target of amiloride.

In summary, this work reports the discovery of potent, selective and non-toxic uPA/NHE1 dual
targeting 6-HMA analogues suitable for entry into in vivo anticancer models. Further work
should involve determining the absence of diuretic/anti-kaliuretic effects in mice to ensure
the successful loss of these activities.
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CHAPTER 1: Introduction
1.1 Overview
Cancer is the leading cause of death in the developed world and the second largest cause of
death in developing countries.1 Cancer occurs when cells progressively accumulate growth
promoting attributes that confer a survival advantage over neighbouring cells, resulting in
dysregulated and disordered proliferation. The reigning paradigm in cancer biology over the
past 25 years describes cancer as a genetic disease arising from mutations in genomic
sequences that cause activation of growth-promoting genes (oncogenes) or inactivation of
growth regulators (tumour-suppressor genes).2 Increased understanding of non-genetic
factors, including epigenetic alterations, heterotypic interactions between cancerous and
stromal cells and dynamic interactions between cancer cells and the tumor metabolic
environment, has challenged the framing of cancer as a purely genetic disorder.2,3 With this in
mind, targeting phenotypes and processes common to the majority of cancers is an attractive
approach towards developing new anticancer agents with broad utility. Drugs able to
simultaneously inhibit multiple cancer-associated processes could dramatically improve
cancer treatment.

The urokinase plasminogen activator (uPA) is a trypsin-like serine protease that is
overexpressed in a wide variety of cancers and plays a key role in cell invasiveness and
metastasis.4,5 uPA functions to activate plasminogen to plasmin and the subsequent activation
of downstream proteases (e.g. pro-MMPs and pro-cathepsins) facilitates degradation and
broad-scale remodeling of the extracellular matrix (ECM) and basement membrane (BM),
serving to promote cancer cell invasiveness and ultimately metastatic spread.6,7
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One phenotype observed in virtually all cancers is reversal of the pH gradient that exists
across the cell membrane. Healthy cells typically feature a cytosolic pH (pHi) lower than that
of their extracellular environment (pHe).8 In cancer cells, the gradient is reversed, with the
interior of cells becoming more alkaline than the immediate surroundings. Alkalinization of
the cytosol and concomitant acidification of the tumour microenvironment has been shown to
be an early event in carcinogenesis and essential for development and maintenance of the
cancerous state.6 A key contributor to transmembrane pH gradient reversal in cancer cells is
the Na+/H+ exchanger isoform 1 (NHE1).9,10 NHE1 facilitates the isoelectronic exchange of
intracellular H+ for extracellular Na+ in a 1:1 ratio. NHE1 becomes constitutively activated in
neoplastic cells, resulting in acidification of the tumor microenvironment and alkalinization of
the cytosol, which both contribute to carcinogenesis and metastasis.11 The lowered pHe of the
tumour microenvironment decreases avidity of cell-extracellular matrix (ECM) interactions,
activates acid-dependent proteases, including members of the urokinase plasminogen
activation system (uPAS), matrix metalloproteinases (MMPs) and cysteine/aspartyl
cathepsins.12

This chapter reviews the role of uPA and NHE1 in carcinogenesis and metastasis and highlights
the potential for dual-inhibition of both targets as a novel anticancer strategy.

1.2 Overview of cancer metastasis
Modern cancer chemotherapy suffers from an inability to successfully treat disseminated
versus localized tumours. In general, patients with localized tumours have good long-term
prognoses following surgical excision and adjuvant radio- or chemotherapy. However, the
outlook for patients with metastatic disease is much less optimistic. 13,14 Formation of

7

secondary tumours via metastatic spread is responsible for ~ 90% of cancer-associated
deaths.6,15

Metastasis is a multistep process where cancer cells disseminate via the circulatory and
lymphatic vasculature from their site of origin (primary tumour) to distant sites in the body,
where they establish secondary tumours in vital organs (Leber & Efferth 2009, Figure 1.1).

Figure 1.1: Overview of cancer metastasis. Altered expression of cell adhesion molecules and
cytoskeletal proteins initiates a shift to a motile mesenchymal phenotype (EMT = epithelial to
mesenchymal transition). Cells that have undergone EMT are able to invade through the local
stroma and intravasate into blood vessels, allowing transport away from the primary site.
Extravasation out of the bloodstream and into secondary tissues can trigger reversion to an
epithelial phenotype. This process results in the establishment of metastases in distant
organs. Figure adapted from reference 15.

An early event in the metastatic cascade is growth of new vasculature in the tumour mass; a
process known as angiogenesis. In healthy tissues, vascularization is tightly regulated by
balanced expression of pro- and anti-angiogenic factors (e.g. pro: vascular endothelial growth
factor (VEGF), anti: angiostatin). This equilibrium is known as the ‘angiogenic switch’ and is
influenced by a wide range of metabolic (e.g. pO2, pH) and mechanical (e.g. compression)
stressors and genetic alterations (e.g. oncogene-driven expression of pro-angiogenic signals,
Figure 1.2). 16,17,18
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Figure 1.2: The angiogenic switch. Angiogenesis is regulated by a dynamic balance between
pro-angiogenic ‘activators’ and anti-angiogenic ‘inhibitors’. Environmental stimuli like pH and
O2 concentration influence the balance through up/downregulation of inhibitors and
activators. VEGF = Vascular Endothelial Growth Factor, FGF = Fibroblast Growth Factor, PDGF = Platelet-derived Growth Factor subunit , EGF = Epidermal Growth Factor, LPA =
Lysophosphatidic acid. Figure adapted from reference 17.

Many of these alterations are observed to occur simultaneously in solid tumours (e.g.
accumulation of acidic metabolites due to increased glycolytic metabolism, compressive stress
due to hyperproliferative and disordered cell growth and overexpression of VEGF). 19,20 This
confluence of factors serves to switch the balance toward formation of new vasculature in the
tumour mass. The circulatory system and lymphatic network satiates the increasing metabolic
needs of the growing tumour mass and provides invasive cells with a pathway for
disseminating to distant sites and seeding secondary metastases.21

The growth of new blood vessels into tumours often occurs in a disordered and dysregulated
manner, creating a structurally and functionally aberrant microvasculature that is unable to
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adequately supply O2 and nutrients to the tissue or remove metabolic waste products. This
deficiency produces regions of hypoxia and acidified tumour microenvironments, which drive
carcinogenic progression.18,22

Genetic mutations and metabolic alterations coinciding with angiogenesis create an invasive
phenotype in cancer cells, where they are able to mobilize and spread throughout the body.
Invasive cells can remodel their extracellular environment through overexpression of
proteolytic enzymes (e.g. uPA, matrix metalloproteinases (MMP) 3, 9, 10, cathepsins B & D),
facilitating degradation of ECM/BM components.23,24,25,26 Accompanying this is a shift from a
sedentary epithelial phenotype to a motile fibroblastic phenotype (EMT).27

In normal epithelia the continued production of pro-survival signals is heavily dependent upon
maintenance of close contacts between neighbouring cells and the basal lamina. Through
altered expression of cell adhesion molecules (e.g. integrins, cadherins, selectins), cells
undergoing EMT are able to avoid the programmed cell death that accompanies loss of cellcell and cell-BM adhesion (anoikis).22,28-31 This shift allows transformed cells to take on a
fibroblastic phenotype that is conducive to motile spread of cells away from the primary
tumour (refer to Figure 1.1). Together with the enhanced proteolytic activity associated with
tumours, these characteristics allow invasive cells to make a path through the primary stroma
and intravasate into the circulatory and lymphatic vasculature. Once in the circulation,
disseminated tumour cells can extravasate and establish life-threatening secondary tumours;
a process that is often accompanied by reversion back to an epithelial phenotype (MET, see
Figure 1.1).32,33

10

1.2.1 The urokinase plasminogen activation system (uPAS) and its role in
cancer
A central contributor to the process of invasion and metastasis is the trypsin-like serine
protease uPA, a component of the uPAS.34,35 The fundamental components of the uPAS are
uPA, its cognate cell-surface receptor uPAR and the endogenous serine protease inhibitors
(serpins) plasminogen activator inhibitor (PAI)-1, -2 and -3 (Figure 1.3).7,34,36

Figure 1.3: Schematic of the urokinase plasminogen activation system (uPAS). Solid arrows
represent activation. ECM = Extracellular matrix, MMP = Matrix metalloproteinase.

The uPAS is an endogenous enzyme cascade that plays a fundamental role in fibrinolysis,
tissue remodeling and cell migration.5,34 Pro-uPA, the inactive zymogen of uPA, is a singlechain 53 kDa multidomain protein consisting of 411 amino acid residues (Figure 1.4).37-40 Upon
excretion from cells, cleavage of pro-uPA at residues Lys158-Ile159, primariliy by the
autocatalytic activity of uPA but also by extracellular proteases (e.g. cathepsin B, kallikrein,
trypsin) yields catalytically active, high molecular weight (HMW)-uPA, also referred to as ‘twochain’ uPA.5,41 Cleavage at this position forms the N-terminal (α) and C-terminal (β) chains of
11

HMW-uPA, which are joined by a single disulfide bridge between Cys148 and Cys279.42,43 The
α-chain consists of a kringle domain and an epidermal growth factor-like domain, the amino
terminal fragment (ATF) of which mediates interactions with its cell-surface receptor uPAR.
The β-chain contains the serine-protease domain, which is formed by the antiparallel
arrangement of two subdomains, each composed of six β-strands, with the interface forming
the active site of the protease.29,44

Figure 1.4: Domain structures of: A) Pro-uPA and B) active-uPA. The single chain zymogen prouPA is activated by a variety of extracellular proteases (e.g. cathepsin B, kallikrein, trypsin)
through cleavage at Lys158-Ile159 to yield active ‘two-chain’uPA.
12

uPAR is an atypical multidomain member of the Ly-6 family.45 The protein lacks a
transmembrane domain, but is able to adhere to the cell surface via a C-terminal glycosyl
phosphatidylinositol (GPI) anchor that is attached during endoplasmic reticulum (ER)
maturation.46 Mature uPAR is 283 amino acids in length and has a molecular weight varying
between 55-60 kDa, depending on its glycosylation state. uPAR features three homologous
domains (D1-D3) that mediate interactions with uPA and ECM components (e.g. vitronectin).47
A highly conserved pattern of intradomain disulphide bonds creates the 3D structure
necessary for high affinity binding of the ATF to uPAR.5

uPA displays a relatively narrow substrate scope, selectively cleaving plasminogen at the
Arg561-Val562 peptide bond to reveal the active, broad spectrum serine protease plasmin.42,48
Plasmin is also a feedback activator of Pro-uPA. Plasminogen binds to cell surfaces
predominantly via interactions between exposed C-terminal Lys residues and binding sites
found within kringle domains 1,4 and 5.37,49 A variety of multifunctional cell-surface proteins
(e.g. α-enolase, dipeptidyl peptidase-4, tissue factor apoprotein, Plg-RKT) bind to plasminogen
with high affinity.41,50-52 The endogenous inhibitor α2-antiplasmin regulates free plasmin
activity through interactions with the kringle domain Lys binding sites of plasmin(ogen).7,53
These inhibitory sites are obscured upon binding to cell surfaces, preventing inactivation of
surface-bound plasmin.54 Cell surface binding of plasminogen via Lys residues also initiates
conformational changes that increase activation by uPA.55

Binding of Pro-uPA to uPAR co-localizes the complex at the cell surface, initiating a reciprocal
activation loop that generates more plasmin and uPA.56 Once activated, plasmin degrades a
variety of matrix proteins (e.g. fibrin, fibronectin, laminins, aggrecan and assorted
proteoglycans) and activates numerous matrix metalloproteinases (e.g. MMPs 1, 2, 3, 9, 10,
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13 and 14) and cathepsins that show broad specificity for many ECM and BM
components.25,26,57,58 uPA-dependent plasmin-mediated activation of this cascade effectively
triggers a proteolytic storm in the pericellular environment, leading to degradation of
surrounding ECM.39

In the context of cancer, overexpression of uPAS allows cancer cells to initiate proteolysis of
the local ECM/BM barriers that confine them within the primary tumour mass, while at the
same time liberating latent ECM-associated growth (e.g. TGF- and Hepatocyte Growth Factor
(HGF) and pro-angiogenic factors (e.g. VEGF and FGF-2).59,60 Once activated, these factors act
in a paracrine manner on neighbouring cells, promoting proliferation, angiogenesis and
further uPA/uPAR overexpression to amplify invasive potential.61,62

uPAS components also regulate cell adhesion and motility via mechanisms distinct from
proteolytic activation of plasminogen.63 uPA binding to uPAR modulates integrin associations
with vitronectin proteins present in the ECM. This occurs through uPAR interactions with the
 subunit of 31, 51, v3 and v5 integrins.38,46 uPAR-mediated modulation of integrin
binding alters cell-ECM adhesion and promotes migration via the integrin-mediated activation
of mitogen-activated protein kinases (MAPK) Erk 1 and 2.64-66 In addition, activation of the
Erk/MAPK signaling pathway via uPAR-integrin binding causes deactivation of the growth
inhibitory p38/MAPK pathway, promoting cell proliferation.67,68 uPAR also modulates cell
adhesion via direct association of its D1 and D2 domains with the somatomedin-B domain of
vitronectin.47,69,70

uPA is efficiently inhibited by three serpins, PAIs 1, 2 and 3. Serpins are highly conserved,
irreversible inhibitors of serine and cysteine proteases that circulate in an unstable high-
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energy conformation. Reaction of the protease active site with the serpin reactive center loop
initiates a rapid conformational change in the complex that distorts the shape of the His57,
Asp102, Ser195 catalytic triad, shutting down proteolysis.71 Covalent inactivation of uPARbound uPA by serpins PAI-1 and PAI-2 leads to internalization of the entire complex via the
Low Density Lipoprotein related (LDLR) protein-1 and other endocytosis receptors of the LDLR
family.72,73 Following lysosomal degradation of the complex, uPAR is recycled back to the cell
surface.40 In spite of it’s physiological role as an inhibitor of the uPAS, the paradoxical
protumourgenic effect of PAI-1 has been attributed to various interactions with ECM
components and endocytosis/signaling co-receptors that promote tumour growth and
metastasis.40

1.2.2 uPA as an anticancer target
The prognostic relevance of overexpressed uPAS components in relation to tumour
aggressiveness has been established over the past three decades. In 1988, Duffy et al.
reported a correlation between uPA activity in primary breast carcinomas and tumour size
and the number of auxiliary node metastases.74,75 Correlations between uPA, uPAR and PAI-1
overexpression and poor patient prognosis (i.e. shortened disease-free interval and shortened
overall survival) have been since observed in breast, ovarian, endometrial, cervical, colorectal,
prostate, gastric, head and neck and renal cancers.76-84

The prognostic relevance of uPAS biomarkers is strongest in breast cancer, where high levels
of uPA and PAI-1 are better predictors of disease progression than commonly used clinical
metrics, including patient age, hormone receptor status, tumour grade and size and HER2/neu expression.85,86 Two retrospective analyses of data pooled from 2780 and 8377
patients, respectively, and a randomized multicenter clinical trial have generated Level 1
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evidence (i.e. highest possible) supporting the use of uPA and PAI-1 as prognostic biomarkers
in breast cancer.76,87-89 Clinically, uPA and PAI-1 can be used to stratify node-negative breast
cancer patients who would benefit from adjuvant chemotherapy (intermediate-high
expression in primary tissue) from those for whom chemotherapy may be unnecessary (low
expression in primary tissue).90,91 Recognition of the prognostic utility of uPA/PAI-1
quantitation is reflected in the breast cancer specific guidelines issued by the American
Society of Clinical Oncology, the European Society of Clinical Oncology and the German
Gynaecological

Society.86,92

(AGO

Website,

http://www.ago-online.de/en/guidelines-

mamma/march-2016/, accessed 29th Jan 2017).

Despite the longstanding standing acceptance of uPA and PAI-1 as valid prognostic biomarkers
for various breast cancers, widespread adoption in the clinic has not yet been realized.93 This
failure has been partly attributed to the need for large amounts of freshly biopsied tissue for
analysis using available diagnostic uPA/PAI-1 ELISAs.93 Improvements in assay sensitivity that
enable use of formalin fixed and paraffin embedded tissue samples would facilitate routine
diagnostic use.

uPA and uPAR Knockout (KO) mice show non-lethal developmental phenotypes and no
impairment of fertility or altered fibrinolytic activity.16,94,95 In comparison, plasminogen KO
mice show severely impaired development and other phenotypes, including aberrant fibrin
deposition, impaired wound healing and formation of spontaneous thromboses. 96,97
Redundancy in plasminogen activation in uPA/uPAR KO mice is thought to occur through
compensatory activation by tPA.98 As such, it is predicted that on-target inhibition of uPA
would not cause significant adverse side effects in vivo. Importantly, uPA and uPAR-deficient
mice show significantly reduced tumour growth and metastasis in xenograft models.99-101
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Specific inhibition of uPA proteolytic activity produces antitumour and antimetastatic effects
in a variety of murine models (Table 1.1 and Figure 1.5). Xing et al. found that inhibition of
uPA in Fisher rats bearing MAT-BIII syngeneic breast xenografts with benzothiophene-based
inhibitor 1 decreased primary tumour volume by ~ 40 % and lung, liver and auxiliary lymph
node metastases by up to 66% over a 14 day continuous i.p. infusion.

102

. An earlier study

demonstrated a 60% reduction in lung metastases for C57b mice bearing B16 murine
melanoma xenografts that had been previously treated with anti-uPA antibodies.103

Figure 1.5: Structures of uPA inhibitors 1-4.

Following on from this work, Ossowski et al. reported a significant decrease in local primary
site invasion in BALB/c mice bearing anti-uPA treated HEp3 human squamous cell carcinoma
xenografts.104 More recently (2010), Hennekke et al. observed

>40% decrease in lung

metastases and more than 60% reduction in primary tumour volume with the peptidomimetic
inhibitor CJ-463 2 in C57b/N mice bearing murine Lewis Lung carcinoma xenografts.105

Similar results have been reported for compounds that show trypsin-like serine protease
(TLSP) inhibitory activity beyond just uPA inhibitory effects. The combination of tranexamic
acid 3 with cisplatin completely inhibited ascites formation and prolonged overall survival by
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70% in BALB/c mice bearing HRA human cystadenocarcinoma xenografts.106 Treatment of
BALB/c mice receiving SW1990 human pancreatic adenocarcinoma xenografts with the
guanidine-containing broad spectrum TLSP inhibitory small molecule gabexate 4 resulted in a
50% decrease in liver metastases.107 Taken together, these findings support uPA as an
attractive target for the development of novel anticancer drugs.

Table 1.1: Representative in vivo data demonstrating the anticancer effects of uPA inhibitors.
TLSP = trypsin-like serine protease.
Mode of inhibition
Small molecule active
site inhibitor – B428

Model
Allograft with Mat BIII Rat breast
carcinoma cells or
Dunning 3227 Rat
prostate carcinoma
cells

Result
Significant decrease
in tumour volume
and number of lung,
liver and auxiliary
node metastases.

Reference
103, 168

Anti-uPA antibodies

Xenograft with B16
melanoma cells
preincubated with
antibodies

Up to 60%  in lung
metastases

104

Xenograft with HEp3
squamous cell
carcinoma cells

Significant inhibition
of local invasion at
primary site

105

Xenograft with
murine Lewis Lung
Carcinoma cells

106
 number of lung
metastases, 
primary tumour
volume and number
of metastatic nodules
and clusters

Peptidomimetic
inhibitor – CJ-463

Broad spectrum TLSP
inhibitors
Small molecule –
tranexamic acid in
combination with
cisplatin

Xenograft with HRA
Significant inhibition
ovarian
of ascites formation
adenocarcinoma cells and prolonged
survival

107

Small molecule – pan
specific protease
inhibitor gabexate

Xenograft with
SW1990 hepatic
carcinoma

50%  in number of
mice showing liver
metastases

108
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1.3 Regulation of cellular pH in cancer and the role of NHE1
Regulation of transmembrane pH gradients is a tightly controlled aspect of cell physiology that
involves the concerted action of multiple transmembrane ion transporters and enzymes. In
the vast majority of cell types, intracellular pH (pHi) is slightly more acidic (pH 7.0-7.1) than the
alkaline extracellular environment (pHe 7.3-7.4).108,109 In contrast, a key hallmark of
transformed cells is a reversed transmembrane pH gradient, where pHi can exceed pHe by as
much as one log unit (tumour pHi 7.1-7.7, tumour pHe 6.2-6.9).110,111 Acidification of the
tumour microenvironment and the concomitant increase in pHi create a vicious cycle that
promotes dysregulation of cell growth and progression towards malignancy. In cancerous
cells, an assembly of proteins coordinate their actions to maintain the reversed pH gradient.
These include H+-ATPases, monocarboxylate transporters (MCTs), HCO3--transporters,
carbonic anhydrases and the Na+/H+-exchanger isoform 1 (NHE1).12,108 NHE1 is considered an
early and primary contributor to the dysregulated pH dynamics that fuel neoplastic
progression.10,112

NHE1 is a ubiquitously expressed transmembrane ion transporter that functions primarily to
protect cells from intracellular acid. It is a 12-helical protein comprised of 815 amino acids.
Residues 1-500 make up the N-terminal transmembrane domain responsible for transporter
function. Residues 501-815 constitute the C-terminal cytoplasmic regulatory tail that features
numerous serine/threonine phosphoregulatory sites (Figure 1.6).112,113 NHE1 is one of 10
characterized isoforms of the SLC9A subfamily of Na+/H+-exchanger proteins. Isoforms 2-5 and
10 show limited tissue and organellar distribution, whereas NHE1 is expressed in the plasma
membrane of virtually all mammalian cell types.114,115
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Figure 1.6: Schematic of NHE1. Oncogenic modulation of the affinity of the C-terminal tail for
intracellular protons leads to constitutive hyperactivation of NHE1 activity. Binding sites on
the C-terminal tail for ezrin/radixin/moesin (ERM) family members enable interactions with
cytoskeletal proteins, allowing NHE to mediate pseudopodial protrusion and directed cell
motility. Figure adapted from reference 6.

NHE1 functions in a number of physiological processes, including regulation of cell volume,
Na+ flux and glycolysis, alteration of functional states and promotion of cell growth, cellular
proliferation and differentiation. The transporters primary role, however, relates to
maintenance of pHi homeostasis.116-120

NHE1 mediates an isoelectronic 1:1 exchange of extracellular Na+ for intracellular H+ ions,
exploiting the inward Na+ electrochemical gradient to drive extrusion of protons against their
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concentration gradient (Figure 1.6). In addition to their role as substrates in the exchange
process, intracellular protons act as allosteric modulators of NHE1 activity.121

Under normal conditions NHE1 exists in a quiescent state, becoming activated only when pH i
drops below a threshold value, referred to as the activation ‘set point’.11 In transformed cells,
alterations in the cytoplasmic H+-allosteric binding site, believed to occur via
phosphoinositide-3-kinase-dependent mechanisms, increase affinity for intracellular protons
to lower the set point for exchange activation.121,122 These events lead to constitutive
hyperactivation of NHE1, driving acidification of the extracellular environment and
alkalinization of the cytosol (Figure 1.7).

Expression of functionally active NHE1 has been shown to be necessary for development of
transformed phenotypes (e.g. anchorage-independent growth, growth in serum-deprived
media, preference for glycolytic metabolism) in E7 oncoprotein-induced NIH3T3 fibroblasts
and HPKIA keratinocytes.123

Reversal of transmembrane pH gradients driven by NHE1 hyperactivation promotes
progression of transformed cells towards an invasive and malignant phenotype. A wellestablished hallmark of transformed cells is their preference for glycolytic metabolism over
oxidative phosphorylation (OxPhos), even in the presence of sufficient O 2 (aerobic glycolysis),
a phenomena known as the “Warburg effect”.2,124 Originally thought to be a primary cause of
neoplastic transformation, Warburg metabolism is increasingly being recognized as a
consequence of pro-oncogenic mutations and alterations that drive dysregulation of energy
metabolism.85
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Figure 1.7: Summary of NHE1 activity in normal and transformed cells. In normal cells NHE1 is
quiescent until pHi decreases below the activation set point, after which NHE1 rapidly
exchanges extracellular Na+ for excess intracellular H+. Oncogene-driven alterations increase
the affinity of the NHE1 cytoplasmic tail for H+, lowering the set point and triggering
constitutive activation of the exchanger. Hyperactive NHE1 drives acidification of the
extracellular space (ECS) while simultaneously alkalinizing pHi, resulting in the characteristic
reversal of transmembrane pH gradients relative to normal cells. Increased pHi promotes
aerobic glycolysis, creating acidic metabolites like lactate (Lac-) that activate monocarboxylate
transporters (MCT) and maintain the reversed transmembrane pH gradient. Figure adapted
from reference 6.

Oncogene-driven activation of NHE1 and subsequent alkalinization of the cytosol cause
upregulation of key glycolytic enzymes, including lactate dehydrogenase and the glucose
transporter GLUT-4, supporting aerobic glycolytic metabolism.117 The preference for glycolysis
is reinforced by reliance of glycolytic enzymes (e.g. phosphofrucokinase-1) on alkaline pHi for
optimal activity, compared to the acid-activated OxPhos pathway.10 The production of acidic
metabolites (e.g. lactate) from increased glycolytic metabolism provides an intracellular H+
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pool that further drives NHE activity, creating a positive feedback loop that delivers steady
alkalinization of pHi, decreased pHe and increased glycolytic metabolism.125

Increased pHi protects transformed cells from acid-dependent apoptosis through a variety of
mechanisms. For instance, acidic pHi upregulates DNAse II activity to promote apoptosisassociated DNA fragmentation and stabilization of the pro-apoptotic BAX protein, triggering
the formation of pores in the mitochondrial membrane and release of cytochrome-c (cytc).112,126,127 Apoptotic effector caspases activated by cytosolic cyt-c show maximal activity at
acidic pH (pH ~ 6.8).128,129 High pHi has also been shown to destabilize acid sensitive mutants
of the canonical tumour suppressor gene p53.130,131 In this way, NHE1 upregulation is
considered an adaptive strategy that protects cancer cells from apoptosis and promotes
progression towards malignancy.11,132

NHE1 driven alkalinization of the cytosol drives cell proliferation by facilitating cell-cycle
progression past the G2 checkpoint into mitosis.133 It was shown that ras p21 or v-mos-driven
oncogenic activation of NHE1 in quiescent NIH 3T3 fibroblasts results in entry into S phase and
increased DNA synthesis.134,135 Intracellular alkalinization also creates optimal conditions
thymidine kinase and thymidylate synthase activities, the rate-limiting enzymes in DNA
synthesis.136,137

Dysregulated cell proliferation causes disordered growth of an expanding tumour mass,
creating regions of hypoxia as the increasing O2 demands fail to be met by passive diffusion
from the surrounding (aberrant) vasculature. This effect supports the shift to glycolytic
metabolism and encourages angiogenesis as the tumour attempts to satiate it’s increasing
need for nutrients and O2.138 The functionally poor and chaotic blood vessels fail to adequately
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remove acidic metabolic byproducts (e.g. carbonic acid, lactate) from the intratumoural space,
further acidifying the extracellular environment.17 The pro-proliferative, pro-angiogenic and
anti-apoptotic effects of NHE1 hyperactivation synergize with the increased proteolytic
capabilities that accompany acidification of the tumour microenvironment, creating a selfperpetuating cycle that promotes carcinogenic progression and ultimately metastatic spread.

Cancer cell invasiveness requires polarization of cells, a key feature of EMT (Figure 1.1).
Rearrangement of the cytoskeleton and altered interactions with ECM components leads to
formation of a migratory ‘leading edge’ at the front of moving cells.139 NHE1 is intrinsically
involved in the formation and function of pseudopodia and invadopodia, two pro-invasive
structures at the leading edge.140 Pseudopodia are specialized finger-like structures that
project in the direction of the circulatory vasculature, creating a path for cell migration.
Invadopodia are discrete acidic, protease-rich microdomains that facilitate focal remodeling of
ECM and BM attachments.141

NHE1 localizes to invadopodial structures, where its activation leads to acidification of pHe
and increased in pHi.142 Acidification of pHe promotes secretion and activation of co-localized
proteases (e.g. MMPs-2, 9, MT1-MMP, cathepsins D & B, uPA etc.), allowing remodeling of
cell-matrix attachments and degradation of confining ECM components.60,140,143 Local
acidification of pHe is partially driven by upregulated glycolytic enzymes in the invadopodia.10
Alkalinization of pHi facilitates the dynamic reorganization of cytoskeletal components (e.g.
cofilin association with cortactin) within invadopdial structures.143 These concerted processes
allow successive protrusion of pseudopodia and degradation of ECM at the leading edge of
cells, enabling directed invasion of tumour cells through the stromal environment.144 NHE1
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hyperactivation is thus considered as a key contributor to cell invasiveness in addition to its
central role in the initiation and maintenance of underlying carcinogenic transformation.

Direct interplay between the uPAS and NHE1 at the invasive edge of cells has been studied in
non-small cell lung carcinoma (NSCLC). Upon binding of uPA, the uPA/uPAR complex localizes
to invadopodial structures, where it facilitates directed uPA-mediated proteolysis. The process
is supported by the activity of co-localized NHE1.145,146 In addition to its proteolytic activity,
uPA binding to uPAR promotes pro-invasive stress-fibre formation, increased cell proliferation
and MMP 9 release via activation of the ras/ERK pathway.147 Stimulation of downstream ERK
signaling following uPAR occupation by uPA was shown to be due to NHE1-mediated increases
in pHi in HL460 NSCLC cells, with NHE1 knockdown cells showing significantly decreased stress
fibre formation and MMP-9 activity.148

NHE1 is overexpressed in cervical cancer and hepatocellular carcinoma and its activity is
upregulated in breast tumor and glioma cells.149-151 In 1989, Rotin et al. demonstrated the
importance of NHE activity in tumourigenesis by showing that bladder carcinoma cells lacking
functional NHE fail to grow or show greatly reduced tumour growth in murine xenografts.152
Tumours able to grow in this model consisted of cells that had reverted through gain-offunction mutations to normal NHE1 activity. Taken together, these findings support NHE1 as a
promising anticancer target.
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1.4 Small molecule inhibitors of uPA
Active site inhibition of uPA proteolytic activity presents unique challenges and opportunities
compared to other members of the trypsin-like serine protease (TLSP) family. TSLPs show high
homology in the structure of their protein folds and they all feature the canonical His57Asp102-Ser195 catalytic triad and a deep S1 binding pocket with a highly conserved Asp189 at
its base.153 Asp189 forms an essential salt-bridge interaction with the positively charged side
chains of P1 amino acid residues (e.g. Arg, Lys) in their various protein substrates.154 Substrate
specificity in TLSPs is largely dependent on the strength of the P1-S1 interaction.153

The TLSP family is divided into subgroups based on the identity of residue 190. In uPA,
plasmin, trypsin and factor VIIa this residue is serine, while in tPA, thrombin and factor Xa it is
alanine and in kallikrein it is threonine.155,156 These differences contribute to the selectivity of
small molecule inhibitors as the OH sidechain of Ser190 can form hydrogen bonds to ligands.
This H-bond partially compensates for interactions lost through displacement of a water
molecule from the S1 site upon inhibitor binding.155,157

The unique insertion of Thr98A and Leu98B in uPA (termed the “99-loop”), greatly reduces the
size of its S3 and S4 sites relative to other TLSPs. The S2 site is also reduced in size by the
imidazole side-chain of His99 in uPA (Figure 1.8).158 Reduced access to these regions, which
are commonly targeted in TSLP inhibitor design, provides excellent scope for generation of
uPA-selective small molecule inhibitors.159
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Figure 1.8: Schematic representations of the active sites of trypsin, factor Xa, tPA, uPA. The
S2, S3 and S4 sites in uPA are reduced in size relative to the other TLSP due to the Thr98A,
Leu98B and His99 insertions which collectively form the ’99-loop’. Figure adapted from
reference 158.

Rational design of uPA inhibitors was advanced after publication of the uPA catalytic binding
site by Spraggon in 1995 and later through the availability of higher resolution X-ray crystal
structures of a re-engineered recombinant uPA (‘micro-urokinase’).160,161 The structures
revealed a novel subsite in uPA termed S1β.161 S1β is flanked by the Cys191-Cys220 disulfide
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bond, residues Gly216, Gly219, Ser145 and the side chain of Lys143. The site is unique to uPA
making it a prime region to target for achieving uPA-selective small molecule inhibitors.

Development of uPA inhibitors began in the 1980’s with early inhibitors based on ε-caproic
acid 5, as well as (benz)amidine and phenylguanidine that showed sub-micromolar potencies
(Figure 1.9).162-165 In 1987 Vassalli and Belin reported that amiloride 6 is a moderately potent
(Ki = 7 μM) and selective inhibitor of soluble uPA.166 Potent and selective 4-substitutedbenzo[b]thiophene-2-carboxamidine inhibitors were reported with IC50 values as low at 70 nM
(e.g. 7).284 4-Iodo-benzo[b]thiophene-2-carboxamidine (B428, 1) inhibited tumour cell growth
and invasion in syngeneic mouse breast and rat breast and prostate cancer models.102,167,168
The S1β subsite was identified as a major contributor to the high uPA affinity of 4-substitutedbenzo[b]thiophene-2-carboxamidines, where interactions between the substituent at the 4position on the benzothiophene ring and S1β was critical.161
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Figure 1.9: Small molecule inhibitors of uPA, including amiloride 6 (red box).

Inhibitors based on a 2-naphthamidine scaffold were designed to specifically target S1β with
substituents at the 8-position.4 Additional substitution at the 6-position created potent
inhibitors with improved uPA selectivity.169 Optimization of the 8-substituted-2napthamidines yielded very potent inhibitors (e.g. 8, Ki = 4.7 nM) that showed further
improvements in selectivity for uPA and high oral bioavailability (Foral = 55% in rats).170
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The high selectivity of 6,8-disubstituted 2-napthamidine inhibitors was attributed to
interactions that complemented those made in the S1 and the S1β subsites, namely Hbonding between the 6-substituents and Asp60A.156 Asp60A is a component of the 60-loop
region, an area of the uPA binding site that shows large sequence diversity across different
TLSPs. Targeting interactions at this site in addition to making the key interactions at the
larger sites (i.e. S1, S1β) is thus an attractive strategy for achieving potency and selectivity in
uPA inhibitors.

Despite the high potency and selectivity of several reported small molecule inhibitors of uPA,
only a single example (to our knowledge) has progressed to clinical evaluation in the cancer
setting. WX-UK1 9, a peptidomimetic derivative of 3-amidinophenylalanine, (uPA Ki = 410 nM),
showed

demonstrable

antitumor

efficacy

in

phase

II

trials

http://www.wilex.de/portfolio-english/mesupron/phase-i-ii-with-mesu/,

(Wilex
Published

website,
2015,

accessed 29th Jan 2017). Phase II evaluation of an orally bioavailable prodrug form
(MESUPRON) in combination with gemcitabine led to a 17% increase in 1-year survival in
pancreatic cancer patients compared to patients treated with gemcitabine alone. 171 Similar
results were found when the prodrug was trialed in combination with capecitabine in the
treatment of HER2-negative breast cancer.172

3-Amidinophenylalanine-based inhibitors (including MESUPRON) show low selectivity,
inhibiting both plasmin and trypsin with similar or higher potency than uPA.173 Lack of
specificity of the compounds confounds interpretation of the clinical data as antitumour and
antimetastatic effects may arise from inhibition of multiple cancer-relevant proteases. Since
completion of Phase II studies the rights to MESUPRON were acquired by Red Hill Biopharma,
who are currently raising funds for further clinical development. (RedHill Website,
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http://www.redhillbio.com/Mesupron, accessed 29th Jan 2017). No clinical data with truly
selective uPA inhibitors have been reported to date.

Early small molecule inhibitors of uPA were mostly arginine mimetics containing a mono or
biaryl core with an appended amidine or guanidine group. These basic functional groups are
positively charged at physiological pH (pKa ~ 11-13) and serve to anchor the inhibitor in the S1
binding site via the salt-bridge with Asp189. Basic groups were considered essential for potent
uPA inhibition until recently.156,157 High basicity of these groups can restrict efficient intestinal
uptake and oral bioavailability and promote rapid clearance. Less basic groups that are able to
maintain the Asp189 salt-bridge interaction have long been sought after.157,174 The uPA
inhibitor amiloride uses the much less basic acylguanidine moiety (pKa = 8.71) to make the
key interaction, suggesting it could serve as an attractive scaffold for development of novel
inhibitors.295 Amiloride’s long history as an oral K+-sparing diuretic provides clear evidence of
its excellent drug properties further supporting its potential utility.175

Recent efforts have attempted to address the poor pharmacokinetic properties of positively
charged arginine mimetic inhibitors by replacing the amidine/guanidine groups with
uncharged moieties. Heynekamp et al. developed potent uPA inhibitors based on an
isocoumarin scaffold bearing an uncharged bromopropyloxy group after docking simulations
predicted that the terminal bromine would interact with Asp189.175 3-Bromoalkoxy-4-chloro7-benzamidoisocoumarin 10 was synthesized and found to inhibit uPA with a Ki of 34 nM.
Selectivity of 10 for uPA over other TLSPs was not reported.176

Primary amines have also been investigated as replacements for amidine/guanidine groups.
Fragment-based screening by X-ray crystallography identified the (R)-enantiomer of the
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antiarrhythmic drug mexiletine as a possible uPA inhibitor.177 Although mexiletine displayed
low affinity for uPA (IC50 >1mM), the favourable orientation of the interactions it made with
the protein coupled with its high bioavailability justified further investigations. Medicinal
chemistry efforts led to the development of 11 a potent and moderately selective uPA
inhibitor (Ki = 72 nM).177 The favourable pharmacokinetic profile of this compound (Foral (rat) =
60%, t1/2 = 7.5 hours, high volume of distribution) indicates this was an effective strategy for
reducing basicity of the S1-occupying moiety. In 2009 West et al. reported a potent and
selective uPA inhibitor 12 (IC50 = 39 nM) based on a linear poly-aryl scaffold that used a
primary amine group to make the interaction with Asp189.178 Unfortunately this series
showed poor bioavailability and high clearance rates in vivo (12, Foral (rat) = 18%, t1/2 = 0.26
hours).178

Linear, cyclic and bicyclic peptide inhibitors of uPA have been described, with some showing
single digit nM potencies.179-181 However, unmodified peptidic inhibitors often suffer from
poor bioavailability and short half-lives.156 Inclusion of non-natural, chemically modified amino
acids (e.g. phenethylsulfonamidino-D-serine) were used to address these issues in some
recent peptidomimetics (e.g. 13, Ki 20 nM).182 Compound 13 displayed high antimetastatic
activity in mice with HT-1080 fibrosarcoma xenografts, decreasing the number of pulmonary
metastatic foci by over 95% and significantly increasing animal lifespan (>3-fold).182 Lownanomolar irreversible peptidic inhibitors of uPA bearing electrophilic diarylphosphonates
that react with the active site Ser195 hydroxyl have been reported.183 Second generation
diarylphosphonates (e.g. 14, IC50 = 3.1 nM) showed in vivo efficacy in rat cancer models,
decreasing primary breast tumour weight by up to 27% and lung metastases by up to 70%.184
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1.5 Small molecule inhibitors of NHE1
Due to the difficulties in crystalizing membrane proteins, a complete X-ray crystal structure of
NHE1 has not yet been described, which has complicated efforts to define the exact target
site(s) for small molecule inhibition. Mutagenesis studies and comparisons with prokaryotic
homologues identified residues in transmembrane helix IV (TM-IV), TM-IX and TM-X as being
involved in inhibitor and/or Na+binding.185,186,187-191 Crucially, Phe161 of TM-IV was identified
as a key determinant of susceptibility to small molecule inhibition as non-neutral missense
mutations cause dramatic increases in inhibitor Ki (see Table 1, Slepkov et al., 2007 for
details).192 Amiloride and related inhibitors likely bind at or near the Na+ binding site via
interactions with Glu346 (TM-IX).193,194

The design of small molecule inhibitors of NHE1 effectively began with amiloride in 1982,
when it was reported by Benos et al. as an inhibitor of Na+ entry into cells that acted through
inhibition of the NHE and ENaC families of Na+ transporters (Figure 1.10).175 Modification of
amiloride by double substitution at the 5-NH2 group yielded NHE inhibitors that have become
standard tools for investigating Na+ transport. These include

HMA 27 (5-N,N-

hexamethyleneamiloride), DMA 28 (5-N,N-dimethylamiloride), EIPA 29 (5-(N-ethyl-Nisopropylamiloride) and MIBA 30 5-(N-methyl-N-isobutylamiloride) (Figures 1.10 and 1.11).195
These inhibitors show greatly improved potency towards NHEs and reduced activity against
ENaCs and other Na+ transporters (e.g. NCX). Amilorides tend to show only moderate
selectivity for NHE1 over other NHE isoforms.196,197
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Figure 1.10: Reported small molecule inhibitors of NHE1, including amiloride 6 (red box).

Direct replacement of the pyrazine core of amiloride with an isosteric pyridine produced the
more potent 15 (IC50 = 1.2 µM). Use of a phenyl acylguanidine led to highly selective NHE1
inhibitors cariporide (16, IC50 = 120 nM) and eniporide (17, IC50 = 30 nM). These compounds
underwent clinical trials, Phase III in the case of cariporide 16 and Phase II in the case of
Eniporide 17, for the treatment of post-ischemic cardiac reperfusion injury.198-201 Second
generation orally-active phenyl and heteroaryl acyl guanidines have since been reported,
including 18 (EC50 31 = nM, Foral = 73%, t1/2 = 3.2 h) and the eniporide analogue rimeporide (19,
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IC50 = 300 nM), which recently received orphan drug designation from the European Medical
Administration (EspeRare.org) for the treatment of Duchenne Muscular Dystrophy.202,203

Cyclopropyl acylguanidine BMS-284640, 20 (IC50 9 nM, Foral = 63%, t1/2 = 3 h) and
carboximidamide T-162559 21 (IC50 = 0.96 nM) inhibitors have also been reported.
Cyclohepta[b]pyridine-3-carbonylguanidine derivative TY-12533 (22, IC50 = 32 nM) showed
strong inhibition of NHE1 in vivo along with decreased neural toxicity; a significant issue with
earlier NHE1 inhibitors.204,205 Uncharged inhibitors include the substituted benzamide
SL59.1227 (23, IC50 = 3.3 nM) and aminopyrimidine compound 9t (24, IC50 = 6.5 nM).206

Clinical studies with NHE1 inhibitors have focused exclusively on treating myocardial
infarction-related reperfusion injuries.207-209 Reperfusion injury results from NHE1
hyperactivation that occurs during ischaemia and reperfusion following myocardial
infarction.210 Excess accumulation of intracellular Na+ drives the rapid influx of Ca2+ by Na+gradient-linked transporters (e.g. NCX), leading to apoptosis of cardiac cells.211 NHE1
inhibitors are thought to prevent cardiac tissue damage following ischaemia by preventing the
toxic accumulation of Ca2+, provided they are administered within a suitable timeframe
following a heart attack.199,212 The potential of these molecules in cancer treatment has only
recently attracted interest, with several authors now calling for investigation of NHE1
13,85,213

inhibitors as anticancer agents and, more generally, NHE1 as an anticancer target.

1.6 Amiloride analogues
Amilorides as a class show broad utility in the clinic and the research laboratory. More than
1000 amiloride derivatives have been synthesized to date and their pharmacology examined
across a wealth of biological platforms. Some analogues have become valuable chemical
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biology tools for probing cation transport mechanisms and related processes. 175,214,215 Potent
and selective amiloride based inhibitors have been discovered for epithelial sodium channels
(ENaC), sodium hydrogen exchangers (NHEs) and sodium calcium exchangers (NCX). A
summary of the structural determinants underpining activity of amiloride analogues against
these exchangers is provided in Figure 1.11.

The parent drug amiloride 6 is a potent inhibitor of ENaC but shows only low/moderate
activity against NCX. N-substitution of the guanidine in amiloride with alkyl and aryl groups, as
in DCB 25, significantly increased potency against both ENaC and NCX.175 Alkyl or aryl
substitution of the 5-NH2, as in HMA 27, selectively removed ENaC activity while greatly
enhancing NHE1 inhibition. Aryl/alkyl substitution on both the guanidine nitrogen and 5-NH2
group yielded potent and selective NCX inhibitors that lack activity against ENaC (e.g. CBDMB
26).183 Despite the plethora of amiloride analogues bearing substitutions on the amines in the
3 and 5 positions, or on the acyl guanidine nitrogens, very few 6-substituted amilioride
analogues have been described (<20). A single patent describing the synthesis of 6-phenyl
HMA, the sole example of a 6-HMA analogue, has been reported.216

In addition to tunable activities against cation transporters, amiloride analogues show a host
of side activities against a variety of extracellular and intracellular targets. These include
protein kinase-C, serine-threonine kinases, adenylate cyclase, monoamine oxidase, several
adrenergic and purinergic receptors and other GPCRs.217-223 At a functional level, amiloride
analogues have been shown to inhibit DNA, RNA and protein synthesis. 224
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Figure 1.11: Structural determinants for differential activity of amiloride analogues against
various cation transporters. ENaC = epithelial Na+ channel, NCX = Na+/Ca2+ exchanger, NHE =
Na+/H+ exchanger. Data summarized from reference 195.

Inhibition of diverse biological targets by amiloride is due, at least in part, to the cation
mimetic properties of its pendant acyl guanidine. Protonation of the guanidine moiety at
physiological pH confers analogues with a net positive charge that is functionally similar to a
monovalent cation (e.g. Na+). This cation mimetic property permits interactions with the
monovalent cation binding sites prevalent in many proteins, as evidenced by the competition
observed between amiloride analogues and monovalent cations with a variety of
targets.166,195,225-227

37

Amiloride.HCl was first approved for clinical use in 1967.228 The drug acts as an inhibitor of
ENaCs in the distal nephron of the kidney. As a relatively weak diuretic, amiloride is more
commonly used as an antikalliuretic in combination with thiazide or loop diuretics (e.g.
frusemide), particularly in patients suffering from hepatic cirrhosis or congestive heart
failure.229,230 Amiloride is also used in combination with other diuretics to control K+-levels.231
The antikaliuretic qualities of amiloride arise as a downstream consequence of ENaC
inhibition, which diminishes the Na+ gradient needed to drive Na+-K+ ATPase-mediated K+
excretion.232,233

Use of amiloride at normal doses (<20 mg/day) produces few side effects and it is generally
well tolerated. The drug is contraindicated in patients displaying hyperkalemia, acidosis or
impaired renal function. Hyperkalemia and associated cardiac arrhythmias are potentially life
threatening side-effects of amiloride overdose due to the increased blood potassium levels,
however, when used in combination with thiazide diuretics incidences of these events are
rare (<2%).234

Since the early 1980s numerous studies have demonstrated the antitumour properties of
amiloride in a variety of animal models. Sparks et al.235 first reported on its antitumor effects
in 1983 after demonstrating that amiloride produces dose-dependent decreases in tumor
growth and tumor cell proliferation in A/J mice bearing H6 hepatocellular carcinoma (HCC) or
DMA/J mammary adenocarcinoma xenografts. Later reports showed that amiloride
suppresses metastasis and primary tumour growth in allo/xenograft and mutagen-induced
murine cancer models. Very high oral doses (200 mg/kg/day) reportedly produced complete
remission in a prostate carcinoma xenograft model.236 For a comprehensive review on the
antitumor effects of amiloide in animals see Matthews et al., 2011.13

38

In addition to the many observations in animal models, sporadic reports also exist of
spontaneous remission of cancers in patients who have received chronic amiloride
treatment.85 Amiloride (5-10 mg three times daily) administered as the sole chemotherapeutic
treatment following failure of cyclophosphamide and cisplatin therapy achieved complete
remission in a patient with metastatic ovarian carcinoma (i.e. disease free interval >11
years).237

1.7 Hypothesis: Anticancer effects of amiloride arise through dual inhibition of
uPA and NHE1
There is considerable evidence to support the hypothesis that the in vitro and in vivo
anticancer effects of amiloride arise through dual inhibition of both uPA and NHE1.

1.7.1 Amiloride and analogues as uPA inhibitors
As described earlier, amiloride is a moderately potent, reversible and competitive active site
inhibitor of uPA. Inhibition of uPA by amiloride has been shown to produce antimetastatic
effects in several models.166,238 Highly invasive PC-3 prostate adenocarcinoma cells exhibiting
amplified expression of PLAU (gene encoding uPA) showed reduced invasiveness in the
presence of amiloride compared to cells lacking PLAU amplification (DU145 and LNCaP).239
Similar results were observed with the small molecule uPA inhibitor B428 1.240

Amiloride 6 significantly inhibited in vitro plasmin formation and invasion by highly invasive
(UCT-2) and non-invasive (UCT01) transitional cell carcinomas. UCT-2 cells showed
significantly higher uPA mRNA expression, uPA protein levels and uPA activity relative to
UCT01 cells.241 Amiloride also inhibited IGF-1 and HGF-stimulated migration and invasion of
L3.6pi pancreatic carcinoma cells.242 Inhibition of invasiveness was equivalent to treatment
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with uPA-specific monoclonal antibodies. Amiloride and B428 1 caused dose-dependent
decreases in cell migration and invasion in MDA-MB-231 and MDA-MB-436 breast
adenocarcinoma cell lines, with the effects attributed to uPA inhibition. 243

A recent report found that amiloride causes dose-dependent decreases in uPA mRNA and
protein levels and activity in MKN45 gastric carcinoma cells.244 Oral administration of
amiloride reduced tumour growth and prolonged survival in BALB/c mice with MKN45
xenografts. Similarly, amiloride suppressed human fibrosarcoma cell invasion in vitro (HThi/diss, highly intravasating variant of HT-1080 cell line) through inhibition of uPA. In vivo
experiments using a chick embryo chorioallantoic membrane HT-hi/diss xenograft model
showed amiloride treatment decreased tumour weight, intravasation and metastasis. 245
Amiloride also prevented formation of secondary lymph node metastases and decreased
tumour volume in rats bearing with highly metastatic, uPA-overexpressing R3327-AT3
prostatic tumour xenografts.246 Finally, oral amiloride administration significantly decreased
the number of pulmonary metastatic foci in MATB 13762 rat breast adenocarcinoma
xenograft models.247-249

1.7.2 Amiloride analogues as NHE1 inhibitors
Amiloride 6 is a moderately potent inhibitor of NHE1 (IC50 range = 7-84 µM), although specific
values for inhibitory constants vary between experimental techniques and species.215 It is
known from NHE1 SAR data that amiloride analogues bearing alkyl substitutions at the 5-NH2
group show dramatically increased potency against NHE1 (Figure 1.12).250
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Figure 1.12: Summary of 5-N,N-disubstituted amiloride analogues as NHE1 inhibitors. DMA =
5-(N,N-dimethyl)amiloride,
EIPA
5-(N,N-ethylisopropyl)amiloride,
MIBA
5-(N,Nmethylisobutyl)amiloride, HMA 5-(N,N-hexamethylene)amiloride. Apparent Ki values were
derived from 22Na+-efflux experiments conducted using N-formyl-methionyl-leucylphenylalanine stimulated human primary neutrophils.197

As described in section 1.3, NHE1 overexpression and hyperactivation provides cancer cells
with an adaptive advantage over neighbouring healthy cells because the high Na+/H+ exchange
activity protects from pro-apoptotic lowering of pHi.19 251 252 Experimentally, hyperactivation
of NHE1 was found to selectively sensitize murine KHT sarcoma and EMT-6 breast
adenocarcinoma cells to intracellular acidification following NHE1 inhibition with EIPA 29.253
To explore this concept further, amiloride analogues have been tested in combination with
nigericin, a H+-ionophore that equilibrates pHe with pHi. Inhibition of NHE prevents pHi
recovery (i.e. pHi) following nigericin treatment in acidified media. Nigericin in combination
with amiloride or its analogues DMA 28, EIPA and MIBA 30 caused cell death in MGH-U1
Human or EMT-6 breast adenocarcinoma cells at pH < 7, whereas no cytotoxic effect was
observed for each amiloride in isolation. The effect was confirmed as being NHE-1 dependent
using NHE-deficient PS120 cells.254 Nigericin in combination with amiloride or EIPA was shown
to significantly reduce tumour cell viability following radiotherapy in vivo. 255
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NHE1 inhibition by amiloride analogues potentiates thermosensitivity in cancer cells.256,257 For
example, SCK murine mammary caricinoma cell killing is enhanced by treatment with
amiloride, HMA 27 or EIPA in pH 6.6 media at 43 C, relative to cells in pH 7.5 media.258 HMA
can delay tumour growth in vivo and it significantly increases SCK cell killing post heating of
xenografted mice, as determined by clonogenic assay of excised tumours.259

NHE1 overexpression in HCC correlates with increased tumour size, invasion, tumour stage
and shortened survival.260,261 Amiloride analogues have been shown to inhibit HCC motility
and invasion through inhibition of NHE1.150 Oral EIPA produced dose-dependent decreases in
HCC primary tumour weight in nude mice receiving HepG2 xenografts.261 Alkalinization of pHi
in response to tumour promoting xenobiotics (e.g. phorbol esters) or growth factor
treatments promoted hepatocyte proliferation through upregulation of DNA synthesis and
transcription via an NHE1-driven process.262 Amiloride, HMA and EIPA suppressed hepatocyte
proliferation in a dose-dependent manner via inhibition of NHE1. Similarly, NHE1-driven
hepatocyte proliferation triggered in residual liver tissue following hepatectomy is blocked by
HMA.263 These results highlight the central role NHE1 in hepatocyte proliferation and suggest
the potential of amiloride analogues as possible treatments for HCC.

NHE1-mediated acidification of pHe causes selective activation of acid sensing ion channels
(ASICs) in adenoid cystic carcinoma cells.264 ASICs form part of the ENaC/degenerin
superfamily of ion channels and are primarily found on neurons.265 The physiological roles of
ASICs continue to be elucidated but specific isoforms are thought to be involved in
nociception and mechanosensation.266 In the context of cancer, it has been proposed that
ASIC upregulation may help tumour cells cope with increasingly acidic extracellular
environments driven by NHE hyperactivation. Constitutive activation of ASICs regulates cell
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volume in glioma cells, allowing alterations in cell size and shape that contribute to high
invasive capacity.267 Inhibition of ASICs by amiloride disrupts volume regulation in glioma cells,
reducing migration in vitro.267-269 ASIC1 regulation of cell-cycle progression and migration via
the ERK1/2 pathway is disrupted by benzamil, leading to potent inhibition of D54-MG
glioblastoma cell migration in vitro.269

A recent publication demonstrating the role of ASIC1 in cell invasiveness with a panel of
breast cancer cell lines showed that amiloride significantly suppresses LM-4142 tumour
growth in an orthotopic murine xenograft model.270 Aside from the downstream effects of
NHE inhibition on ASIC activation, various amiloride analogues inhibit ASICs in their own
right.266 In 2009 scientists from Merck (the original developers of amiloride) published
structure-activity relationship (SAR) study exploring 5-substituted amiloride analogues as
ASIC3 inhibitors for the treatment of chronic pain.271

Tumour selective effects of amiloride analogues on NHE inhibition have been noted in
leukemic cell lines relative to healthy hematopoietic cells. Constitutive activation of NHE1 in
leukemic cells and leukemic patient primary blood samples results in a higher resting pHi
relative to normal hematopoietic tissues, which sensitizes these cells to the effects of NHE1
inhibition.272 HMA treatment was found to trigger apoptosis in >90% of KG-1a leukaemic cells
and primary acute lymphoblastic leukaemia cells, while equivalent doses caused no cell death
in healthy hematopoietic cells.272 Sequence comparison of cDNA from peripheral blood
mononuclear cells (PBMCs) of leukaemic patients and leukaemia cell lines relative to healthy
primary PBMCs revealed greater rates of nucleotide polymorphisms, which could contribute
to pathogenesis. However leukaemia specific NHE1 sequence mutations were not detected.273
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In an earlier study, amiloride was found to block cell cycle progression in murine L 1210
lymphocytic leukaemia cells without effects on cell viability.274

The NHE1 inhibitor cariporide 16 was found to reduce the colony forming ability of primary
PBMCs taken from BCR-abl-positive leukaemia patients following relapse after imatinib
treatment.3 Cariporide treatment was also able to resensitize K562 BCR-abl-positive cells to
imatinib-mediated apoptosis via inhibition of NHE1.3 Another report found that amiloride
causes alternate splicing of apoptosis regulators Bcl-x and HIPK3 and oncogenic BCR-abl,
leading to potentiation of imatinib-induced apoptosis in K562 and BaF3/Bcr-Ablt315l cells.275
Alternative splicing was not seen with EIPA, leading the authors to suggest that modulation of
apoptosis by amiloride occurs via NHE1-independent mechanisms, although this was not
tested experimentally.

Tescalin-mediated NHE1 upregulation was recently shown to play a key role in sorafenib
resistance observed in FLT3-ITD acute myeloid leukaemia patients.276 HMA treatment showed
increased cell killing of sorafenib-resistant primary AML cells relative to sorafenib-naïve
samples, whilst showing no effects on healthy hematopoietic cells. Selectivity for resistant
cells was attributed to inhibition of NHE1 by HMA and the associated acidification of pHi. In
combination with sorafenib, HMA potentiated sorafenib-mediated apoptosis in MOLM-13
sorafenib-resistant cells. HMA alone suppressed engraftment of sorafenib-resistant primary
acute myeloid leukaemia cells in nude mice and engraftment was completely abolished when
HMA was combined with sorafenib.276

Amiloride, HMA and EIPA decrease pHi-dependent DNA synthesis in rat hepatocytes treated
with tumour-promoting 12-O-tetradecanoylphorbol-13-acetate, while EIPA decreased
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metastasis and invasion of hepatocellular carcinoma cells.10,150,262 HMA-induced acidification
of pHi by NHE blockade promotes maturation of leukocyte elastase inhibitor into its proapoptotic form L-DNAse II, leading to the apoptotic fragmentation of DNA in corneal
endothelial cells.277

1.8 Dual uPA/NHE1 inhibitors derived from amiloride
Several lines of evidence support investigation of amiloride 6 or one of its analogues as an
anticancer therapeutic in the clinical setting.13 The repeated demonstration of antitumour and
antimetastatic effects of amiloride and analogues across a plethora of in vitro and in vivo
cancer models would typically provide a strong motivation for clinical studies. Impressive preclinical efficacy coupled with oral bioavailability and a long history of safe usage in humans
should make amiloride an attractive clinical candidate. Furthermore, anecdotal reports of
amiloride treatments causing remission of neoplastic disease in human patients should bolster
interest in clinical anticancer investigations with the drug.237 Despite this, only a single report
exists of amiloride undergoing clinical evaluation for cancer. In this study, no significant
difference in cancer risk was observed in 6614 elderly hypertensive patients receiving a fixedratio of 2.5 mg amiloride/25 mg hydrochlorothiazide per day compared to age-matched nonrecipients over a 5-year period.278

Assuming that the bulk of amiloride’s anticancer effects arise through dual inhibition of uPA
and NHE1, the relatively modest in vitro potency of amiloride against these targets presents
significant challenges to its successful use clinically as an anticancer drug. Amiloride has a
relatively low maximum allowable daily dosage (20 mg/day) due to the risk of hyperkalemia
and potentially life-threatening cardiac arrhythmias at higher doses. As a result, cancer
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patients receiving amiloride would require costly and inconvenient monitoring of blood K+levels over a prolonged period, making out-patient administration impractical. Indeed, coadministration with a kalliuretic agent (e.g. a thiazide diuretic) might be necessary to mitigate
the risk of adverse events. Moreover, administration at the maximum allowable dosage (e.g.
20 mg/day) would be unlikely to afford sufficiently high plasma concentrations to strongly
inhibit these two targets and evoke a robust antitumour effect in humans.

A possible solution would be to create an analogue that shows decreased affinity for ENaCs,
the target responsible for the drug’s diuretic and antikalliuretic effects. This would allow
administration of higher doses without the risk of hyperkalemia. Equally desirable would be to
increase the potency of amiloride towards both uPA and NHE1 so that lower plasma
concentrations could achieve the desired anticancer effects. Medicinal chemistry campaigns
of this type, known as Selective Optimization of Side Activity (SOSA), are a popular modern
approach in drug development.279,280

Fortunately, structure activity relationships of amiloride analogues as ENaC inhibitors are well
characterized.195,281 As mentioned in section 1.7.2, substitution of the NH2 group at the 5position reduced activity against ENaCs, which would be expected to diminish the diuretic and
antikalliuretic effects of these analogues in vivo.281 The dramatically reduced inhibition of
ENaCs by HMA relative to amiloride is highlighted in Figure 1.13.
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Figure 1.13: Inhibition of ENaC-mediated Na+ currents across an electrically tight monolayer of
FRTL-5 Rat Fischer Thyroid Epithelial cells by amiloride and HMA. Amiloride inhibition is more
than 3 orders of magnitude higher than HMA. Data (unpublished) courtesy of A. Dinudom
(University of Sydney, Australia).

Another significant issue facing development of an amiloride analogue into an anticancer drug
is the lack of chemical novelty around the scaffold. As the cost of bringing a new drug to
market can exceed $1.5 billion dollars (USD), investors are afforded the opportunity to recoup
this expenditure and generate profits by securing exclusive rights for 20 years to the
manufacture and sale of new drugs through patenting.282 In order to secure patent rights, an
inventor must create a new chemical entity (NCE), a novel chemical structure that is
considered non-obvious and for which there exists no prior reference in the scientific or
patent literature (prior art). As patent protection for amiloride has long since expired, the
incentive to invest in development of amiloride as an anticancer drug is significantly reduced.
If, however, novel amiloride-based structures could be discovered that show increased
antitumour effects, for example, by improving activity against uPA/NHE1, such compounds
would be more attractive in terms of patentability and commercialization.
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Previous work from the Kelso and Ranson Labs at UOW saw completion of a comprehensive
SAR study of amiloride analogues as inhibitors of uPA. Diverse compounds were synthesized
to investigate the effects of various substitution patterns on uPA affinity, including isosteric
replacement of the acylguanidine group and pyrazine core, removal of 3 and 5-position
exocyclic amines and substitution at the 5 and 6-positions.6 Key SAR findings from this work
are summarized in Figure 1.14.

The authors concluded that amiloride analogues featuring short aryl/alkyl amino substituents
at the 5-position and/or bulky substituents at the 6-position show slightly increased affinity
for uPA. Specifically, the 5-substituted amiloride analogues HMA and EIPA and the 6substituted 6-iodoamiloride and 6-phenylacetyleneamiloride showed improved potency
against uPA (HMA IC50 = 6 µM, EIPA IC50 = 6 µM, 6-iodoamiloride IC50 = 6 µM and 6phenylacetylenyl amiloride IC50 = 2 µM).6

Figure 1.14: Summary of amiloride SAR study completed by Matthews et al. from the Kelso
Group.6 Regions of amiloride altered in each approach are highlighted in red.

48

This study suggested that further activity gains might be possible by combining favourable
substitutions at the 5- and 6-positions (i.e. additive SAR). HMA represents an excellent starting
point for exploration of 5,6-disubstituted amilorides due its very high potency against NHE1 (Ki
= 162 nM) and greatly reduced activity against ENaCs relative to amiloride.197,281 Additionally,
HMA has been shown to exhibit a variety of anticancer properties in its own right (see section
1.7). Importantly, the 6-Cl substituent on amiloride is oriented towards the S1β subsite of
uPA, forming predominantly hydrophobic interactions with residues Gln192, Gly219 and the
Cys220-Cys191 disulfide bond (Figure 1.15).238

Figure 1.15: X-ray co-crystal structure of amiloride bound to the active site of uPA. S1β subsite
is labelled. The 6-Cl atom (Green stick) forms favourable hydrophobic interactions with the
S1β residues. Substituents bulkier than Cl may be better able to fill the subsite, improving
affinity for uPA. (Image generated from PDB #:1F5L, originally reported in reference 226).

Amiloride analogues bearing substituents larger than Cl at the 6-position will likely show more
complete occupancy of S1β leading to increased uPA affinity. Provided HMA occupies a similar
pose to amiloride upon binding to uPA, it is likely that similar or greater increases in potency
might be achieved upon substitution of HMA at the 6-position.
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1.9 Thesis Aims
Despite significant advances in targeted anticancer therapeutics over the past 20 years,
relatively small gains have been made in chemotherapeutics that could provide general
treatments for diverse neoplastic conditions, especially in advanced disease. For this reason,
therapeutics able to target phenotypes observed in many different tumour types would
provide significant benefits in the clinic. Drugs able to simultaneously inhibit different aspects
of carcinogenesis and metastasis processes are particularly well suited to this aim.
uPA is a key regulator of metastatic potential and is overexpressed in many aggressive
cancers.5 Small molecule inhibitors of uPA show potent antimetastasis activities in vivo, with
one compound showing efficacy in Phase II clinical trials.182 NHE1 activation is an essential
contributor to the ‘pro-malignant’ reversal of transmembrane pH gradients observed in
virtually all cancers and is upregulated in many cancer cell types.10

The amiloride analogue HMA is an ideal starting point for development of novel, dualtargeting uPA/NHE1 inhibitors as anticancer drugs due to its low- µM inhibition of uPA, potent
inhibition of NHE1 and demonstrated ability to selectively inhibit multiple cancer-related
processes, both in vitro and in vivo. Identification of novel 6-substituted HMA analogues that
show increased potency against uPA whilst maintaining high potency against NHE1 and low
activity against ENaCs would be attractive candidates for development towards a new class of
anticancer drugs with a novel ‘dual’ mechanism of action.

6-Substituted HMA analogues were synthesized in this work with the aim of increasing
potency through enhanced binding interactions in the S1β subsite. Targeting S1β to increase
ligand affinity was a successful strategy in previous uPA inhibitor programs.161 Since S1β is
unique to uPA, increasing interactions at this site will likely improve selectivity of the
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compounds for uPA over other TLSPs. Synthesis of 6-HMA analogues was approached using
Pd-catalyzed cross-coupling chemistries (e.g. Suzuki-Miyaura and Sonogashira reactions) due
to their wide functional group tolerability, mild reaction conditions and generally high yields.
This type of chemistry has not been reported previously in the synthesis of 6-amiloride
analogues (6-phenyl HMA). It should be noted that to date only a single example of a 6-HMA
analogue has been reported.216 As such, generation of a library 6-HMA analogues using this
approach represented a significant novel contribution to amiloride/HMA chemistry.

The overall aim of the work was to use the tools of medicinal chemistry to discover novel 6HMA analogues that show high potency against both uPA and NHE1 and low activity against
ENaCs, along with other interesting anticancer properties in vitro. Discovery of such
compounds could pave the way for further studies of anticancer efficacy in animal models and
eventually pre-clinical development of an optimized candidate.
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1.9.1 Specific aims
The specific aims of the thesis were to:



Synthesize a library of 6-HMA analogues through a novel application of Pdcatalyzed cross-coupling chemistry (Chapter 2).



Evaluate the inhibitory potency of synthesized analogues against uPA using
solution-phase enzyme inhibition assays (Chapter 2).



Obtain X-ray co-crystal structures of lead inhibitors bound to uPA (Chapter 3).



Measure TLSP selectivity and cytotoxicity of leading compounds (Chapters 2
and 4).



Characterize the effects of leading compounds on cell growth and behavior
(Chapter 4).



Develop a new medium-throughput assay for quantitating the NHE1 inhibitory
potency of 6-HMA analogues (Chapter 5).
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CHAPTER 2: Synthesis and in vitro evaluation of 6-HMA analogues
Previous efforts in the Kelso/Ranson laboratories focused on the synthesis and evaluation of
amiloride analogues bearing substitutions at the 2, 3, 5 and 6 positions of the pyrazine core,
with an emphasis on novel 5-amino substituted compounds.6 Key insights from the SAR
included the requirement for exocyclic amines at the 3 and 5-positions and retention of the
pyrazine core. Slight increases in uPA potency were achieved when short, uncharged alkyl or
aryl amines occupied the 5-position and groups larger than Cl occupied the 6-position (Figure
1.12). With this in mind, it was hypothesized that analogues bearing substituted amines at the
5-position were suitable scaffolds for structural elaboration at the 6-position, with the goal to
increase uPA affinity by establishing new contacts within the S1 subsite.

Of the 5-substituted amiloride analogues examined, HMA 27 was selected as a starting
scaffold due to its improved potency against both uPA (~ 2-fold) and NHE1
(~ 520-fold) relative to amiloride.13 Superposition of the HMA-uPA X-ray co-crystal structure
(Jiang et al., unpublished) onto the published AML:uPA structure indicated that the two
compounds adopt almost identical binding poses within the uPA active site (Figure 2.1), with
the 6-Cl groups of both compounds projecting directly into towards S1.160 This provided
compelling evidence that 6-HMA analogues would similarly project other 6-substituents into
S1, potentially leading to increased uPA/affinity. In this chapter the synthesis and in vitro
evaluation of 6-HMA analogues were explored.
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Figure 2.1: X-ray co-crystal structures of AML and HMA bound to the serine protease domain
of human uPA. A) AML-uPA complex (PDB:1F5L)226, B) HMA-uPA co-crystal structure (Jiang et
al., FJIRSM, Fuzhou, China, unpublished), C): Backbone superposition of the AML:uPA and
HMA:uPA structures highlighting the similarity between the binding poses of AML and HMA in
the uPA active site. Orientation of the pyrazine core and 2-acylguanidine regions are virtually
identical and the 6-Cl substituents project towards S1 in both structures.

2.1 Synthesis of 6-HMA Analogues
The route to 6-HMA analogues commenced with a nucleophilic aromatic substitution at the 5position of dichloropyrazine methyl ester 31 with hexamethyleneimine to yield the HMA
precursor 32 (Scheme 2.1). Pd-catalyzed Suzuki-Miyaura was used to install aryl and
heteroaryl substituents at the 6-position to provide 6-HMA methyl esters 33a-55a. The methyl
esters were reacted with guanidine.HCl and the products purified by preparatory reverse
phase HPLC (rp-HPLC). Anion exchange yielded the 6-substituted acyl guanidines as HCl salts.

The late-stage common intermediate 32 was accessed on multigram scale from the
commercially available 3-amino-5,6-dichloropyrazine methyl ester 31 via nucleophilic
aromatic substitution with hexamethyleneimine in DMF at 80 C (Scheme 2.1).
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Scheme 2.1: Strategy for the synthesis 6-HMA analogues. Reaction of pyrazine methyl ester 31
with hexamethyleneimine afforded the late-stage common intermediate 32. Reaction of 32
with aryl boronic acids or boronic acid pinacol esters via Suzuki-Miyaura-cross coupling
afforded the 6-substituted methyl esters 33a-56a. Reaction of 33a-56a with guanidine
afforded the 6-substituted acyl guanidines 33-56. Preparative rp-HPLC followed by anion
exchange yielded the final products as HCl salts.
A total of 10.42 g of 32 was obtained from 7 reactions in a combined yield of 56% (yield range
for individual reactions 46%-74%). The reaction conditions had been previously developed in
the Kelso group by Dr. Ghazala Yacoub, who adapted the original method of Cragoe et al.
where hexamethyleneimine is reacted with 1 in isopropanol (iPrOH) at reflux.281

Selective reaction of hexamethyleneimine at the 5-position (as opposed to the 6-position)
occurs due to increased resonance stabilization of the nascent anion in the transition state
afforded by the electron withdrawing carbonyl group located at the para position (Figure 2.2).
Nucleophilic attack of the amine at the 6-Cl position cannot delocalize the anion into the
carbonyl group.
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Figure 2.2: Additional resonance stabilization from the electron withdrawing carbonyl group
para to C5 favours substitution at the 5-position in 31 rather than the 6-position.283

Intermediate 32 was subjected to Suzuki-Miyaura cross-coupling reactions using a variety of
commercial aryl/heteroaryl boronic acids or pinacol boronate esters (Scheme 2.1). The
mechanism of the Pd-catalyzed reactions is outlined in Figure 2.3.

Figure 2.3: Proposed mechanism for Suzuki-Miyaura cross-coupling reactions with 32.

The initial step involves formation of an organopalladium intermediate via oxidative addition
of the Pd(0) catalyst into the carbon-chlorine bond of 32 (Figure 2.3).283 Attack of the newly
formed Pd(II) centre by the base (CO32-) displaces the Cl- ion. Transmetalation between the
activated organopalladium(II) intermediate and the boronate species in situ yields the aryl-aryl
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Pd(II) complex. The cross-coupled product is formed in the final step via reductive elimination,
which regenerates the Pd(0) catalyst.

The first attempt at a Suzuki-Miyaura cross-coupling employed the conditions reported by
Reyes et al., 2008 (Table 2.1) with phenylboronic acid as the coupling partner.284 One
equivalent of 32 was reacted with 1.5 mole equivalents of phenylboronic acid in the presence
of a 10-fold excess of K2CO3 and 5 mole % Pd(PPh3)4. The reaction was carried out in a 4:1
toluene:EtOH mixture at reflux for 1 h. This initial attempt yielded the desired product along
with the transesterified ethyl ester. Substituting EtOH with MeOH solved the problem and the
modified conditions were employed in the synthesis of all methyl ester intermediates 33a55a. Yields for the reactions ranged between 36-98%.

In the majority of cases, reactions were complete after 2 h, as evidenced by the consumption
of starting material (SM) by thin layer chromatography (TLC) and electrospray ionization mass
spectrometry (ESI-MS). Reaction mixtures were cooled and the catalyst removed by vacuum
filtration through celite. After concentration in vacuo the crude products were purified by
silica gel column chromatography using gradients of EtOAc in pet. spirit.

Of the two reactions that used aryl pinacol boronates, 4-isoquinoline analogue 37a formed at
a similar rate to reactions that used boronic acids (i.e. 2 h total reaction time). In comparison,
N-ethylmorpholinopyrazole 39a formed more slowly, requiring 16 h at reflux for complete
consumption of the SM.
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Table 2.1: Suzuki-Miyaura cross-coupling reactions of 32 with aryl boronic acids to give methyl
esters 33a-55a.*Compounds synthesized as described in reference 216. †Reaction conducted
using aryl pinacol boronate.
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The methyl esters were generally not soluble in CH2Cl2 or EtOAc:pet.spirit mixtures and
required adsorption of the crude products onto silica gel for loading onto silica gel columns.
All compounds were obtained in pure form and comprehensively characterized. Spectroscopic
data for a representative compound 49a are provided in Figure 2.4.

The 1H spectrum was referenced to a tetramethylsilane (TMS) internal standard at δ 0.00
(Figure 2.4). The singlet at δ 8.66 integrated to two protons and was assigned to the 2’ and 6’
protons on the pyrimidine ring. A singlet at δ 4.05 with an integration of 3H was assigned to
the methyl protons of the para methoxy group. This signal was shifted downfield by the
deshielding effects of the pyrimidine ring nitrogens. Further upfield, a second 3H singlet at δ
3.89 was assigned to the methyl ester CH3. Assignment of the methoxy versus methyl ester
signals was provided by the observation that the methyl ester peak appeared at δ 3.89 for all
methyl ester products. A triplet with an integration of 4H (J =5.75 Hz) at δ 3.36 was assigned
to the 2” and 7” methylene protons positioned α to the tertiary amino group. Two singlets,
each with an integration of 4H at δ 1.67 and δ 1.48, were assigned to the 3”/6” and 4”/5”
methylene protons, respectively. Signals observed at δ 1.26 and δ 0.88 were assigned to
‘grease’ impurities from solvents. The methyl ester and methylene signals were observed in
the 1H spectra of all methyl ester products 33a-56a, with variations in chemical shift generally
<0.04 ppm.
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Figure 2.4: 1H and 13C-APT spectra for 49a.
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13

C-APT spectra were referenced to CDCl3 at δ 77.2 and phased such that CH3 and CH carbon

signals are positive and carbonyl groups, CH2 and carbons with no protons attached are
negative (Figure 2.4). The carbonyl signal appeared in the expected region at δ 167.0. The 4”
pyrimidine carbon was heavily deshielded by the two adjacent nitrogen and one oxygen
atoms, appearing at δ 164.5. The single positive peak appearing in the aromatic region (δ
158.1) was assigned to the symmetrical 2’ and 6’ carbons of the pyrimidine ring. These signals
were deshielded by inductive electron withdrawal from the neighbouring ring nitrogens. The 5
and 3-position pyrazine carbons were assigned based on their attachment to either a more
deshielding cyclic tertiary amine in the case of 5 (δ 155.2), or a less deshielding primary amine
in the case of 3 (δ 153.7). The negative signals found at δ 128.7 and δ 125.1 were assigned to
the 6 and 1” aromatic carbons respectively. The signal at δ 113.8 was assigned to the carbon
at position-2 of the pyrazine ring, this signal being significantly shielded by resonance
contributions from the exocyclic amines at the ortho and para positions. The positive peaks
observed at δ 55.1 and δ 52.1 were assigned to the methoxy group and methyl ester protons,
respectively. The negative peak at δ 51.2 corresponded to the 2’ and 7’ hexamethylene ring
methylene units, the signal being significantly deshielded by the neighbouring tertiary amine.
The negative peaks at δ 28.0 and δ 27.2 were assigned to the 3’ and 6’ methylene carbons and
4’ and 5’ methylenes carbons, respectively, as the deshielding effects decreased with
increasing distance from the electron withdrawing group.

Methyl esters 33a-56a were next subjected to guanidinylation reactions using free base
guanidine formed in situ from guanidine.HCl in iPrOH in the presence of Na metal (Scheme
2.1). A proposed mechanism for the guanidinylation reactions is provided in Figure 2.5
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Figure 2.5: Proposed mechanism for the guanidinylation of methyl esters 33a-56a to yield acyl
guanidines 33-56. The mechanism is exemplified with the p-methoxypyrimidine analogue 49.

Addition of sodium metal to iPrOH forms sodium propoxide and liberates H2 gas in the
process. Next guanidine.HCl is added to obtain the nucleophilic free guanidine by the
neutralization of HCl by iPrO-. The free guanidine attacks the carbonyl of the methyl ester via
nucleophilic acyl substitution, expelling methoxide (MeO-) as the leaving group. Loss of a
proton on the amide-like NH2+ group affords the desired acyl guanidine (e.g. 49).

Crude reaction products were purified by preparative rp-HPLC and the acylguanidines
obtained as trifluoroacetate (TFA) salts after lyophilization. The TFA salts were stirred with the
quaternary ammonium Cl- anion exchange resin in MeOH to yield the targets 33-56 as
hydrochloride (HCl) salts. Acyl guanidines were fully characterized and their structures
confirmed by spectroscopic analysis. Spectroscopic data for a representative acyl guanidine 49
is provided in Figure 2.6. Yields from the guanidinylation reactions and overall yields from 32
over 2-steps for all compounds are provided in Table 2.2.
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Figure 2.6: 1H and 13C-APT spectra for 49.
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The 1H spectrum for 49 was referenced to a TMS internal standard at δ 0.00 (Figure 2.6).
Guanidinylation of the methyl ester 49a to give 49 was inferred by the loss of the methyl ester
peak at δ 3.89 and the appearance of three heavily deshielded signals in the aromatic region
(δ 8.00-11.00). The singlet at 10.76 with an integration of 1H was assigned to the amide NH of
the acyl guanidine sidechain, this proton being deshielded by the electron withdrawing
carbonyl and guandino NH2 groups. The broad singlets at δ 9.27 and δ 8.48, each with an
integration of 2H, and were assigned to the two guanidino NH2 groups. The singlet at δ 8.51
showed an integration of protons and was assigned to the 2’- and 6’- aromatic protons. The
broad singlet at δ 6.75 with an integration of 2H and was assigned to the 3-position NH2
group. In concordance with assignments for 49a, signals for the aromatic OCH3 group (δ 9.27,
3H) and azepane ring methylene protons appeared in the same chemical shift regions, with
each signal integrating to give the expected number of protons (δ 3.35, 4 H, 2’ and 7’; δ 1.66,
4 H, 3’ and 6’; δ 1.47, 4 H, 4’ and 5’).

Analysis of the 13C-APT spectrum of 49 supported observations from the 1H data (Figure 2.6).
As expected, an additional peak at δ 161.9 was observed for to the guanidine carbon, and the
OCH3 signal observed at δ 52.0 for 49a was absent. All other signals varied from the
assignments made for methyl ester 49a by less than 1.5 ppm. Accordingly, the negative signals
at δ 166.6 and δ 164.0 were assigned to the carbonyl and 4” carbons, respectively. The
positive peak at δ 157.8 corresponded to the 2’ and 6’- carbons of the pyrimidine ring. The 5and 3- pyrazine carbons were observed at δ 156.1 and δ 153.8, respectively. The aromatic
peaks at δ 127.8, δ 124.7 and δ 112.5 corresponded to the pyrazine 6- carbon, pyrimidine 1”carbon and pyrazine 2- carbons, respectively. The positive peak observed at δ 55.6 was
assigned to the CH3 group and the negative peak at δ 51.6 corresponded to the 2’ and 7’
methylene carbons. Signals for the 3’ and 6’ and 4’ and 5’ methylene carbons were observed
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at δ 27.8 and δ 27.1, respectively. A small impurity signal at δ 4.9 was also present in the
spectrum.

Low to moderate yields were obtained for guanidinylations due to competing formation of
side products common in all reactions. 1H NMR and MS analysis of samples obtained from
preparative rp-HPLC fractions revealed the presence of the isopropyl esters, presumably
formed via transesterification with the reaction solvent under the basic reactions conditions.
Lower reactivity of the isopropyl esters towards guanidinylation significantly decreased
formation of desired products, with transesterification in effect creating a reservoir of
unreactive material.

Complete consumption of the methyl ester SM was not observed over the reaction times
employed (1-3 h). Closer analysis of the guanidinylation reaction of 42a revealed that longer
reaction times were required (up to 18 h) for complete consumption of the methyl ester but
this was accompanied by increased formation of isopropyl ester and an unidentified polar side
product. Attempts to substitute iPrOH for MeOH as the reaction solvent led formation of
complex mixtures, as determined by TLC analysis.
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Table 2.2: Guanidinylation of methyl esters 33a-56a to provide target acyl guanidines 33-56.
Yields over 2-steps from the starting methyl ester 31 are also shown.
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Previous work from the Kelso and Ranson Labs had shown that 6-phenylacetylenyl amiloride
(IC50 = 2 µM) is ~ 5-fold more potent against uPA than amiloride (IC50 = 10 µM).6 Sonogashira
cross-coupling was employed to obtain the equivalent 6-phenylacetenyl HMA methyl ester
56a and the target acyl guanidine 56 to see whether similar increases in potency were
observed with the azepane ring present at C5 (Scheme 2.2).

Scheme 2.2: Sonogashira cross-coupling of phenylacetylene with 32 yielded 56a (58%), which
was converted to acyl guanidine 56 in 14% isolated yield.

Methyl ester 32 was reacted with phenylacetylene using a Pd(PPh3)Cl2:CuI catalytic system in
DMF with trimethylamine (TEA) present as base. The reaction was stopped by filtering
through celite after 24 h and the product isolated by silica gel chromatography. The methyl
ester 56a was obtained as a bright yellow solid in 58% yield. Ester 56a was then subjected to
the above guanidinylation procedure to give 56 in 14% yield.

With the exception of 33a and 33, all methyl ester and acyl guanidine products were novel
compounds that had not reported in either the patent or scientific literature (SciFinder search,
1st December, 2016). For 33a and 33, specific methods had been described in a single patent
concerned with the use of aroylguanidines as HIV and HCV ion channel inhibitors.216
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2.2 Solution phase uPA inhibition assays
The synthesized acyl guanidines 33-56 were subjected to a fluorometric solution phase uPA
activity assay to measure inhibitory potencies. Assays were conducted in black 96-well plates
using a commercially available fluorogenic substrate (Calbiochem 672159, Z-Gly-Gly-Arg-AMC,
Merck Millipore, Massachusetts, USA), Urokinase from human kidney cells (Sigma-Aldrich, Cat
# U4010) and a POLARStar fluorescence plate reader (BMG-Labtech, Ortenberg, Germany)
(Figure 2.7). Compounds were dissolved in anhydrous DMSO to create 10-50 mM stock
solutions. Stocks were serially diluted in assay buffer in the 96-well plate then added to a
separate black assay plate containing fluorescent substrate (in assay buffer) via multichannel
pipette. Assays were conducted such that each well contained a final concentration of 1%
DMSO (v/v). Detailed experimental methods for the assays are provided in Chapter 7.3. Two
compounds were assayed in each plate with each dilution was carried out in triplicate. Drug
blanks were included to correct for intrinsic fluorescence in the compounds. An inhibitor-free
vehicle control was included in each assay to determine maximal enzymatic activity, allowing
for correction of day to day and enzyme batch variations. Assay plates were prepared and
kept on ice until final addition of enzyme immediately prior to first reading. Assays were
conducted at 37 °C with double orbital shaking before each read. Wells were excited at 355
nm and the emitted fluorescence at 460 nm was measured. Data points from the linear
portion of reaction progress curves were averaged and used to determine initial velocities,
which were then blank corrected and plotted to calculated IC50 values for each compound.
IC50 is defined as the concentration of compound needed to inhibit one half of enzyme activity
under the conditions used. Representative concentration-response curves for compounds 42
and 50 are provided in Figure 2.8. Modification of the assay allowed determination of Ki
values for selected inhibitors (Table 2.3, as described in detail in Chapter 7.3), where Ki is the
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concentration of compound at which the reaction rate is one half of the maximal reaction rate
(Vmax) under saturating substrate conditions.

Figure 2.7: Schematic of uPA activity assay. uPA cleaves the pro-fluorogenic tripeptide
substrate to liberate the highly fluorescent 7-amino-4-methylcoumarin (AMC), providing a
quantifiable measure of enzymatic activity. When 6-HMA analogues are added, reversible
competition with the substrate for binding to the uPA active site inhibits proteolytic activity,
reducing fluorescence. Decreased fluorescence in the presence of 6-HMA analogues was used
to calculate IC50 values, and in some cases Ki values.
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Figure 2.8: Curves from solution-phase uPA inhibition assays with representative compounds
42 and 50. Data points represent the mean ± SEM (n = 3) from a representative experiment.

The aryl-boronic acid coupling partners for the Suzuki-Miyaura cross-coupling reactions were
selected based on commercial availability and structural diversity. To probe the SAR of the 6position of HMA, boronic acids were initially chosen to cover a breadth of structural diversity
that appeared to have the correct size for occupancy of the S1 subsite. Later compounds
were chosen as the SAR trends emerged and as X-ray co-crystal structures came to hand
(Chapter 3).
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Table 2.3: Inhibitory potencies of 6-HMA analogues 33-56 against Human uPA. For
compounds where n >1, values represent the mean ± SEM from identical repeat assays
conducted on different days.
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2.2.1 Structure-activity analysis
The 6-Phenyl derivative 33 (33 IC50 = 8,158 nM) showed a ~ 3.7-fold decrease in potency
relative to HMA (IC50 = 2,206 nM). Addition of a methylthioether group at the para position 34
resulted in a ~ 12.1-fold decrease in potency (IC50 = 26,717 nM). Substitution of the
methylthioether of 34 with a trifluoromethyl group 35 produced a ~ 3.1-fold decrease in
potency (IC50 = 6,914 nM). Methylenedioxy derivative 36 showed a ~ 1.5-fold increase in
activity over HMA (IC50 = 1,518 nM). The 4-isoquinoline compound 37 showed ~ 2.6-fold lower
activity than HMA (IC50 = 5,751 nM) while the N-methylpyrazole 38 showed increased activity,
~ 2.7-fold higher than HMA (IC50 = 825 nM). Substitution of the N-methyl group of 38 with Nethylmorpholine 39 (IC50 = 1,070 nM) did not improve activity.

The 2-Indole derivative 40 (IC50 = 9,214 nM) showed ~ 4.2-fold lower activity than HMA.
Similarly, substitution of the indole N with S to yield benzothiophene 41 did not afford potent
inhibition, with 41 showing ~ 2.4-fold decreased activity relative to HMA (IC50 = 5,375 nM).
However, substitution of the ring heteroatom with O to yield benzofuran 42 provided a ~ 7.4fold boost in potency (IC50 = 297 nM). Potency was further increased by fluorination of 42 at
the benzofuran 4-position to give compound 43, which showed ~ 15.4-fold greater potency
than HMA (IC50 = 143 nM).

The 2-thiophene derivative 44 was slightly better than its benzothiophene analogue 41 (IC50 =
3,927 nM). The 3-thiophenyl isomer 45 slightly more potent (IC50 = 1,669 nM). Removal of the
phenyl ring of 42 to yield the 2-furanyl derivative 46 had little effect on activity, with both
compounds showing similar potency (IC50 = 254 nM). Similarly, 3-furanyl isomer 47 (IC50 = 270
nM) showed activity comparable to 42 and 46.
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The 5-pyrimidine derivative 48 (IC50 = 175 nM) showed ~ 12.6-fold higher activity than HMA.
Methoxy substitution at the para position of 48 to yield 49 increased potency into the <100
nM range, affording a ~ 25.6-fold increase relative to HMA (IC50 = 175 nM). Dimethoxy
substitution of the 5-pyrimidine to give 50 afforded the most potent inhibitor arising from this
work, some 32-fold more potent than the parent HMA (IC50 = 69 nM). The importance of the
5-pyrimidinyl scaffold for high potency was highlighted with the 2,3-dimethoxy-3-pyridinyl
analogue 51. Here, removal of the second ring N resulting in a dramatic loss in potency (IC50 =
1,437 nM). The 2-fluoro-3-pyridinyl derivative 52 was ~ 1.3-fold less potent than HMA.
Removal of ring nitrogens altogether from 50 carbocyclic analogue 53 reduced activity ~ 1.6fold relative to HMA (53 IC50 = 3,571 nM). The 3,5-dimethoxyphenyl isomer 54 (IC50 = 2,143
nM) was approximately equipotent with HMA. The 3,6-Dimethoxypyridazine derivative 55
showed ~ 4.3-fold greater potency than HMA (IC50 = 512 nM). The phenylacetylene derivative
56 proved to be the least potent inhibitor studied (IC50 = 29,816 nM). In comparison, the
analogous 6-phenylacetylamiloride reported by Matthews et al., showed a 5-fold increase in
uPA inhibitory activity relative to amiloride (6-phenylacetylamiloride IC50 = 2 µM; Amiloride
IC50 = 10 µM, using a chromogenic assay).6 It is possible that the steric bulk of the azepane ring
at the 5-position of 56 prevents the 6-phenylacetylene substituent from orienting favourably
in the S1 subsite.

Inhibitory constants (Ki) were determined for HMA and 11 inhibitors using a modified
fluorogenic assay (Table 2.3). Double reciprocal plots of initial reaction velocities (1/RFU.min-1)
versus substrate concentration (1/S) for representative inhibitors 43 and 48 confirmed
competitive inhibition of uPA, since Km increased with increasing [inhibitor] while Vmax
remained unchanged (Figure 2.9).166,285
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Figure 2.9: Double reciprocal plots of uPA inhibition by 6-HMA analogues 43 and 48. Data
points represent the mean from duplicate wells at each concentration and are representative
of three repeat experiments.

The rank order of potencies according to Ki agreed well with the IC50 values obtained earlier
(Table 2.3). Compounds 43 and 48 were exceptions, however, occupying slightly different
positions in their two rank orders. With the exception of HMA, all values indicated affinities
that were higher than the IC50 concentrations determined for each compound, as expected for
competitive inhibitors.286

2.3 Selectivity for uPA over related trypsin-like serine proteases
A shortcoming of previous small molecule inhibitors of uPA has been their lack of selectivity
for uPA over related trypsin-like serine proteases, such as thrombin, plasmin and tPA.157 Offtarget inhibition of these proteases raises the risk of unwanted side effects being observed if
the compounds were to be used as cancer drugs in humans.

To examine the uPA selectivity of the 6-HMA analogues, three examples were screened against
a panel of human TLSPs using chromogenic enzyme inhibition assays (detailed experimental
methods in Chapter 7.3). Representative inhibition curves from these experiments are
presented in Figure 2.10. In experiments using the chromogenic uPA substrate S-2288
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(Chromogenix, Massachusettes, USA) benzofuran analogue 42 showed IC50 = 529 nM, or
approximately 2-fold higher than the value observed in the fluorogenic assay (IC50 = 297 nM).
This general trend was observed across all inhibitors, with the chromogenic assay IC50 values
only 2 to 4-fold higher than those obtained from assays from fluorescence-based assays. The
exception was compound 49, which showed IC50 = 39 nM (n = 1) in the chromogenic assay and
IC50 = 86 nM in the fluorescence assay. Nevertheless, the rank order of inhibitor potencies
against uPA was preserved across both assays (e.g. 49 < 43 < 48 << HMA). The variation
between assays likely arises from difference in the affinity of the two substrates for the uPA
active site. Differences in assay buffer composition may have also contributed to the
variations. For all other TLSPs tested, half-maximal inhibitory concentrations were not reached
at the highest concentrations tested (10 M). Compound 42 showed slight inhibition of trypsin,
but this was only 24% inhibition at 10 µM.

Similar results were observed for compounds 43 and 49 (Table 2.4), where half-maximal
inhibition of tPA, plasmin or thrombin was not reached. Of the enzymes tested, plasmin
activity was inhibited to the greatest extent by 43 (16%) and 49 (48%) at 20 M. These results
clearly demonstrated that 6-HMA analogues with high uPA inhibitory potency are 10-100-fold
less potent against closely related TLSP off-targets.
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Figure 2.10: Activity of 42 against uPA and related trypsin-like serine proteases determined
using chromogenic enzyme activity assays. Data represent the mean ± SEM (n = 3).
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Table 2.4: Inhibitory potencies of 6-HMA analogues 42, 43 and 49 against uPA and related
trypsin-like serine proteases. N/C = Experiment not conducted.

A wider selection of 6-HMA analogues were also screened against a panel of TSLPs involved in
the blood coagulation cascade, including human plasma kallikrein, Factor Xa, Factor XIa and
Activated Protein C (Table 2.5). Experiments used the chromogenic substrates S-2288, S-2366
or S-2444 (Chromogenix, Massachusetts, USA), depending on their suitability for each enzyme
based on manufacturer Vmax values. Due to time constraints (experiments were performed
during a three week international research visit to the laboratory of the Prof. Mingdong
Huang, Fujian Institute for Research into the Structure of Matter (FJIRSM), Fuzhou (China),
compounds were not tested simultaneously against wildtype human uPA, thus a
determination of fold-change in activity relative to uPA was not possible. Nevertheless, a
similar profile to that observed with 43, 48 and 49 against tPA, plasmin and thrombin was
seen with most of the compounds, where half-maximal inhibition was not observed at the
highest concentration tested (50 M).
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Half-maximal inhibition of Factor Xa activity was not observed for any of the compounds in
the range of concentration range tested (50 nM-50 M). For Factor XIa, half-maximal
inhibition was achieved at concentrations lower than 50 M for 5 of the 12 compounds
screened. The 3,6-dimethoxy-4-pyridazine 55 the showed greatest inhibition, returning an IC50
of 8.7 M. The 4-fluoro-2-benzofuran analogue 43 (IC50 = 23.3 M) showed slightly higher
inhibition of Factor XIa than the unadorned 2-benzofuran 42 (IC50 = 31.0 M). The 2,4dimethoxypyrimidine analogue 50 showed intermediate potency (IC50 = 25.8 M) and IC50 was
not reached for any of the other compounds against Factor XIa. The 5-pyrimidine analogue 48
was the only compound for which an IC50 could be calculated against Activated Protein C (IC50
= 26.9 M).

While slight activity was observed for some of the compounds against Factor XIa, Plasma
kallikrein and Activated protein C, a >10-fold difference in potency was generally seen
between uPA potency and potency against the off-targets.
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Table 2.5: Inhibitory potencies of selected 6-HMA analogues against TLSPs from the blood
coagulation cascade.
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2.4 Selectivity of inhibitors for human versus murine uPA
Species specificity and potency differences of active site inhibitors against human and murine
uPA have been noted in the literature.22,287,288 Smaller inhibitors that interact primarily with
the S1 binding pocket tend to show similar potencies against the two enzymes, (selectivity
ratios = 0.5-5), whereas Inhibitors that make contacts in other sites (e.g. S1, S2) show a
pronounced preference (10-100 fold or more) for the human enzyme.22 These trends arise
because the four active site amino acid substitutions between the species are located in sites
outside S1. HuPA:MuPA D60Q is located near the catalytic triad, H99Y is on the edge of S2/S4,
S146E is in S1 and Q192K is on the boundary of S1/ S1.22

The preference of inhibitors for human over murine uPA presents challenges for conducting
studies with compounds in mouse xenograft tumour and metastasis models. This is because
enzymes derived from both the xenografted human tissue and the murine host may
contribute to plasminogen activation, invasion and metastasis. The issue is further
complicated by the variable propensity of uPA/uPAR-upregulating tumour cells from different
tissues to recruit uPA from the surrounding stromal environment. For example, breast
carcinomas recruit the majority of their uPA complement from surrounding stromal cells.289,290
The differing affinities of human uPAR for human and murine uPA and the higher rate of
activation of both human and murine plasminogen by the human enzyme add even more
complexity.291

If an inhibitor being studied in vivo showed a marked preference for HuPA there is a possibility
that a xenograft model may underestimate its efficacy, making it difficult to demonstrate in
vivo proof-of-concept. The activity of two of the more potent analogues 42 and 50 analogues
against wild-type murine uPA was therefore assessed using a fluorogenic assay. Comparative
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data for the two compounds, amiloride and HMA against the human and murine enzymes is
presented in Table 2.6.

As expected amiloride, which binds to uPA primarily through contacts within the S1 pocket,
showed virtually no difference in activity against the two enzymes. HMA was found to lose the
most potency against MuPA (IC50 = 13.3 M), experiencing a ~ 6-fold drop in activity. As
amiloride and HMA differ only in the identity of the 5-amino substituent, the drop in potency
can be attributed to unfavourable interactions between the 5-azepane ring of HMA and the
active site of MuPA. Assuming that HMA adopts a similar binding pose when bound to both
enzymes, the 5-substitutent would occupy space corresponding to the junction of S1 and S2
and the oxyanion hole (Figure 2.11).

Table 2.6: Inhibitory potencies of amiloride, HMA and 6-substituted analogues 42 and 50
against human and murine uPA.
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In murine uPA, the S2 residue His99HuPA is substituted by a bulkier Tyr (His van der Vaal’s
volume =118 Å3; Tyr =141 Å3), with the three other active site substitutions lying outside of
this area.292,293 Assuming that these distant substitutions do not cause major structural
differences in the S1/S2 and oxyanion hole regions, it is possible that the drop in activity
observed for HMA and 6-HMA analogues relative to amiloride is due to unfavourable
interactions between the 5-hexamethyelene ring and the side chain of Tyr99 in murine uPA.

Figure 2.11: X-ray co-crystal structure of HMA bound to WT human uPA highlighting the
position of His99, presented in coral, and its close proximity to the azepane ring. In Murine
uPA, residue 99 is substituted with a larger Tyr. Unfavourable interactions between the Tyr99
sidechain and the azepane ring of HMA and analogue(s) may be responsible for reducing
activity against MuPA. Gln192 and Ser146, two other active site residues that differ between the
human and murine enzymes, are presented in purple and orange respectively.

Benzofuran analogue 42 showed improved potency relative to HMA against both human (IC50
= 297 nM, c.f. 2,206 nM ~ 7.4-fold increase) and murine uPA (IC50 = 2,579 nM, c.f. 13.3 M for
HMA, ~ 5.2-fold increase). This compound showed ~ 8.7-fold selectivity for Human uPA.
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Species differences were most pronounced for the dimethoxypyrimidine analogue 50, where
33-fold greater potency was observed against (IC50 = 69 nM vs. MuPA IC50 = 2,305 nM). The
compound showed 5.8-fold higher potency than HMA against MuPA. Taken together, these
results indicate that substitution of HMA at the 6-position is beneficial for activity against
MuPA. The presence of the 2-benzofuranyl and 2,4-dimethoxypyrimidinyl groups in 42 and 50
restored some of the activity lost due to the presence of the of the 5-azepane ring.
Restoration of potency is likely due to the new favourable interactions established between
the 6-substitutents and the S1 subsites in both enzymes.

The similarity in inhibitory potencies of 42 and 50 (42 IC50 = 2,579 nM, 50 IC50 = 2,305 nM)
against MuPA suggests that the S1 subsite of this enzyme is less able to make favourable
contacts with 6-substituents relative to HuPA, where increases in inhibitory potency
approaching two orders of magnitude were observed upon varying the 6-substituent against
the human enzyme (see Table 2.4).

Decreased tolerability of these substituents in MuPA is likely due to the Ser146Glu and
Gln192Lys substitutions in S1, as these residues define part of the pocket boundary in HuPA
(Figure 2.11). These data corroborate previously described selectivity trends for S1-targeting
small molecule inhibitors, where the subsite was generally more accepting of ligand
substituents in the human enzyme.22

To further explore the effect of H99Y substitution on inhibitory potency, selected, analogues
were screened against a recombinant human uPA mutant carrying the H99Y mutation
(HuPAH99Y, Table 2.7).294 In line with predictions, the “murinized” H99Y uPA substitution
decreased the activity of all 6-HMA analogues relative to WT HuPA (e.g. HMA IC50H99Y > 50 M,
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HMA IC50WT 2206 nM). While amiloride was not tested against HuPAH99Y, the results suggest
that the ~ 4-fold lower potency of HMA relative to amiloride against MuPA is, at least in part,
a result of unfavourable interactions with Tyr99. The losses in activity observed for HMA and 6HMA analogues against HuPAH99Y generally aligned with those observed between WT HuPA
and MuPA.

The observation that 6-substitution was generally beneficial to interactions in both WT HuPA
and MuPA was recapitulated with compounds 38, 42, 43, 48, 50 and 55, which returned IC50
values in the range 3.0-9.7 M. Supporting X-ray co-crystal structures of some 6-HMA
analogues bound to H99Y are presented in Chapter 3.2.
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Table 2.7: Inhibitory activities of 6-HMA compounds against a site-specific mutant of human
uPA featuring a His to Tyr substitution at position 99 (HuPAH99Y).
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2.5 Physicochemical properties of 6-HMA analogues
In order to understand how the intrinsic properties of 6-HMA analogues affect uPA potency,
relationships between inhibitory activity (pIC50) and a variety of physicochemical parameters
were calculated for each using Biovia Insight for Excel (Dassault Systemes, Velizy-Villacoublay,
France, Figure 2.12).

A weak positive correlation (r2 = 0.2025) between polar surface area (PSA) and pIC50 (Figure
2.12A) was observed for compounds 33-56.29 A stronger correlation (r2 = 0.3141) was found
between the number of hydrogen bond acceptors, which ranged between 8 and 12, and
inhibitory potency (Figure 2.12C). Sub-micromolar IC50 values (pIC50 > 6) were achieved only
for compounds bearing more acceptors than HMA (i.e. > 8). All compounds contained the
same number of hydrogen bond donors (i.e. 6) except indole analogue 40 (7 H-bond donors),
making correlation analysis for this variable uninformative. No correlation was found between
inhibitory potency and the number of rotatable bonds present in each structure (r 2 = 0.001),
with clustering of data around 4 and 6 rotatable bonds (4 rotatable bonds: 15 of 25
compounds; 6 rotatable bonds: 5 of 25 compounds). Likewise, no relationship was observed
between molecular weight and pIC50 (r2 = 0.0005, Figure 2.12B).

Due to the basic nature of the acyl guanidine moiety (amiloride pKa = 8.71) present in all
analogues a significant proportion of each compound would exist in a charged state in
solution at physiological pH.295 For this reason, LogD values were calculated at pH 7.4 to
account for the contributions of both the charged and uncharged species to the partitioning
coefficient. Comparison of CLogD to CLogP values (which considers partitioning of uncharged
species only) for each compound revealed that both metrics were virtually equivalent, with
cLogD values < 0.04 units higher for all analogues. The exception was 4-isoquinoline analogue
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37, whose CLogD was affected by the basic isoquinoline ring nitrogen (pKa ~ 5.4-5.5). This
comparison suggests that the identity of the distal 6-substituent does not strongly influence
the pKa of the acyl guanidine. 6-substituents bearing ionizable functional groups featuring pKa
values closer to 7.4 would experience greater shifts in LogD relative to LogP due to the
functional group contribution to the total molecular pKa, as observed with 37 (ClogP 2.37 vs.
ClogD 2.60).

An inverse correlation was found between uPA inhibitory potency and ClogD (Figure 2.12D, r2
= 0.2772). This correlation was strengthened by exclusion of the hydrophobic 2-benzofuranyl
analogues 42 and 43 (r2 = 0.5158). The presence of 2-benzofuranyl 42 or 4-fluoro-2benzofuranyl 43 substituents at the 6-position caused large increases in ClogD relative to HMA
(HMA ClogD 1.52; 42 3.19; 43 3.39). The finding that two structural classes of 6-HMA
analogues that differ significantly in hydrophobicity (5-pyrimidinyl 48 ClogD 0.82, IC50 = 175
nM; 4-fluoro-2-benzofuranyl 42 ClogD 3.39, IC50 = 143 nM) are nearly equipotent suggests
that uPA inhibition with this class is not a function of ClogD and that affinity is instead driven
by specific intermolecular interactions between the inhibitors and uPA.

The physicochemical differences between 2-benzofuranyl 42 and 5-pyrimidinyl 48 were
further highlighted by their lipophilic ligand efficiencies (LLE) (Figure 2.12D, diagonal lines).
LLE is an estimation of the preference of a compound for a target over partitioning into 1octanol, and is used to evaluate the benefit of increasing hydrophobicity relative to effects on
potency.32 For compounds showing properties typical of orally active drugs (ClogD ~ 2.5-3,
target potency ~ 1-10 nM) LLE is typically > 5, which is considered an indicator of a well
optimized drug candidates.34 A compound with LLE 6 will have a 106-fold greater affinity for
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interaction with a given target than 1-octanol.34 The diagonal lines in Figure 2.12D indicate LLE
units.

Only the pyrimidine-based analogues displayed LLEs >5, with the unadorned 5-pyrimidinyl 48
showing the highest LLE (LLE: 48 5.94, 49 5.74, 50 5.32). The 2-benzofuranyl analogues 42 and
43 showed LLEs below 4 (42 3.33, 43 3.45), or lower than the parent HMA (LLE 4.13). Increases
in potency associated with inclusion of the benzofuranyl moieties was thus not sufficient to
offset the concomitant increases in hydrophobicity. Inclusion of the 2-benzofuranyl
substituent would require a 46-fold increase in potency relative to HMA (required IC50 = 48
nM, observed IC50 = 297 nM, observed fold-increase 7.4-fold) to maintain an LLE equivalent to
the parent structure (HMA LLE 4.13). additionally, to match the ‘well optimized’ LLE of the 5pyrimidinyl 48 (LLE 5.94) the potency of 48 would have to increase 2,997-fold, giving an IC50 =
741 pM.

Despite the increases in potency afforded by 6-substitution, none of the 6-HMA analogues
were able to match the high LLE of amiloride (LLE 6.16). This finding illustrates the effect of
polarity relative to potency on LLE calculations. In the case of amiloride, high LLE arising from
its negative ClogP (ClogP -0.76) dramatically offsets its moderate potency (IC50 = 3,954 nM).
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Figure 2.12: Relationship between uPA inhibitory activity (pIC50) and calculated
physicochemical parameters for a library of 6-HMA analogues. A) pIC50 vs polar surface area.
B) pIC50 vs molecular weight. C) pIC50 vs number of H-bond acceptors. D) LLE plot, solid lines
represent linear regression fits for each data set and dotted curves describe 95% confidence
intervals. Analogues lying above the blue line (LLE >5) are considered well optimized in terms
of their activity against uPA relative to their intrinsic hydrophobicity.
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The changes in CLogD and inhibitory potency relative to HMA further highlights the intrinsic
differences between the 2-benzofuranyl and 5-pyrimidinyl-based lead classes (Figure 2.13, red
and green boxes, respectively). During the optimization process it is desirable for leads to
progress towards the top left corner of a pIC50/CLogD plot.34 The 2-benzofuranyl class
clearly deviates from this trajectory due to accompanying increases in CLogD, while the 5pyrimidinyl analogues clearly localize in the correct region. Relative to HMA, 5-pyrimidinyl
analogue 48 and the p-methoxy-5-pyrimidinyl 49 showed improvements in both CLogD and
potency.

Figure 2.13: Changes in ClogD and pIC50 for 6-HMA analogues relative to HMA.

Based on calculated physicochemical properties (Table 2.8), the 6-HMA analogues were
evaluated for ADMET liabilities using a set of predictive computational tools within the Biovia
Insight for Excel software suite (Dassault Systemes, Velizy-Villacoublay, France). The majority
of 6-HMA analogues (56%, 14/25 compounds) were predicted to cause dose-dependent
hepatotoxic injuries (e.g. hepatitis, zonal necrosis, cholestasis etc.) or trigger elevated blood
levels of aminotransferase enzymes in over 10% of the human population.37
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In contrast, the 5-pyrimidinyl analogues 48, 49 and 50 were predicted to be non-hepatotoxic.
Compounds with CLogP values exceeding 3, including benzofuran 42 and 43, were predicted
to have very low aqueous solubility (at the lower limit of 95% of orally active drugs). All other
compounds, including the 5-pyrimidinyl leads 48, 49 and 50 and HMA, were predicted to have
low solubility (towards the lower end of 95% of orally active drugs), with the exception of N1-methyl-1H-4-pyrazole 38, which was predicted to have good solubility.41

The 5-pyrimidinyl leads 48, 49 and 50 and structures featuring methoxy (51, 53, 54 and 55),
morpholino (39) or methylenedioxy (36) substituents, were predicted to show very low
passive intestinal absorption following oral administration (outside 99% confidence ellipse for
orally active compounds). Good-moderate (within 95% confidence ellipse) absorption was
predicted for the 2 and 3-thiophenyl analogues 44 and 45, HMA and phenyl analogue 33. All
other compounds, including the 2-benzofuran leads 42 and 43, were predicted to exhibit low
passive intestinal absorption (between 95% and 99% confidence ellipses).

Predictions regarding favourable solubility and absorption characteristics for small molecules
are often made using the well-known Lipinski’s “rule of five” (MW <500 g.mol-1, CLogP < 5, ≤
10 H-bond acceptors and ≤ 5 H-bond donors).42 HMA and the 6-HMA analogues all exceed the
H-bond donor criteria as the guanidine and 3-NH2 groups provide 6 potential donors.
Compounds 36, 38, 39, 51, 54 and 55 and the 5-pyrimidines 48, 49 and 50 violate both the Hbond donor and acceptor criteria.

Reliable predictions of blood-brain barrier permeability were not possible as the compounds
were predicted to lie outside of the 99% confidence ellipse in the model used by Biovia Insight
for Excel. All compounds were considered unlikely to be substrates for cytochrome P450
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isozyme CYP2D6 and no compound was predicted to bind strongly to human plasma proteins.
(strong binder = > 90% bound).
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Table 2.8: Summary of uPA inhibitory potencies, predicted physiochemical properties and calculated ADMET metrics for 6-HMA
analogues. All physicochemical parameters and ADMET predictions were calculated using Biovia Insight for Excel v2.6. tPSA =
topographical polar surface area.27 HAC = Heavy atom count. LE = ligand efficiency ((1.37/heavy atoms)*pIC50).296 Rotatable bonds =
number of bonds within structure that possess meaningful rotational freedom for molecular mechanics, excluding terminal hydrogens.
Liver toxicity = Predicted dose-dependent hepatotoxicity.35 Predicted aqueous solubility (see reference 41). Predicted intestinal
absorption (see reference 53).
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2.6 Summary and Conclusions
The new synthetic methods described herein provided divergent access to 6-substituted HMA
analogues using common, commercially available reagents. Based on published X-ray co-crystal
structures of amiloride bound to uPA, we correctly hypothesized that 6-substitution of HMA 27
may afford increases in inhibitory potency by establishing new interactions within the S1 subsite
of uPA. Screening the synthesized library of analogues against Human uPA revealed that, in
general, the S1 subsite is able to tolerate a variety aryl and heteroaryl substituents. The greatest
increase in potency was observed with the dimethoxypyrimidine analogue 50 (IC50 = 69 nM). The
2-benzofuranyl and 5-pyrimidinyl classes emerged as two structurally and physicochemically
distinct lead classes.

Screening of selected inhibitors against a variety of potential TLSP off-targets revealed good uPA
selectivity across all analogues. As half-maximal inhibition was not achieved for trypsin, plasmin
and tPA, retesting against these enzymes at higher concentrations would be needed to determine
selectivity factors. We conclude that off-target TLSP inhibition should not be a major issue with
this class of compounds if used as drugs.

Experiments with murine uPA revealed that the 6-HMA analogues show substantially lower
potency against the murine enzyme relative to human uPA. Experiments with a ‘murinized’ variant
of human uPA carrying a H99Y substitution suggested that the decreased potency was at least
partially caused by unfavourable interactions between the larger, Tyr99 side chain in mouse uPA
and the 5-azepane ring present in all HMA analogues. These findings have significant implications
for in vivo xenotransplantation studies in mice as the decreased activity may lead to
underestimation of the antimetastatic efficacy of the inhibitors since both human and endogenous
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murine uPA will play roles in this process. Ongoing studies in the Kelso and Ranson Labs are
seeking to identify compounds that potently inhibit both mouse and human uPA to address this

Analysis of the calculated physicochemical properties of the 6-HMA analogues suggested that high
potency is not reliant on intrinsic hydrophobicity, given that nM inhibitors were generated from
structures varying widely in ClogD. Indeed, strong correlations were not found between potency
and a range of physicochemical and structural parameters, suggesting that uPA affinity likely arises
from a combination of specific and non-specific interactions, in addition to hydrophobicity. LLE
analysis revealed that the large increases in hydrophobicity associated with inclusion of 2benzofuranyl moieties cancelled out the moderate increases in potency in terms of LLE.
Conversely, all members of the 5-pyrimidine class were calculated to have LLE values in the ‘well
optimized’ range (LLE > 5), supporting further studies with these compounds in particular.
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CHAPTER 3: X-ray co-crystal structures of HMA and 6-HMA analogues
bound to uPA
X-ray crystallographic analysis of ligand-protein complexes occupies a central position in modern
drug discovery.297,298 Three dimensional visualization of drug-target interactions allows the
rationalization of SAR trends arising from biological assays and can be used to guide the direction
of chemical synthesis towards analogues with improved potency and selectivity. This process is
known as structure-based drug design.299 Collaborative efforts between the Kelso/Ranson
laboratories at UOW and scientists at the Fujian Institute for Research into the Structure of Matter
(FJIRSM), Fuzhou (China), allowed for integration of X-ray structural data into the selection of
synthetic targets. Novel co-crystal structures were obtained for HMA 27 (Figures 2.1 and 3.1) and
the 6-HMA analogues 38, 42, 43 and 46-50 at resolutions ranging from 1.6-3.0 Å. Complexes were
obtained by soaking each inhibitor into pre-formed Human uPA crystals over a period of 14 days
prior to X-ray diffraction experiments. All co-crystals were obtained and their structures solved by
Dr. Longguang Jiang at the FJIRSM. A summary of the data collection and refinement statistics is
provided in Appendices 9.1 and 9.2.

3.1 HMA:uPA co-crystal structure
The expected salt bridge was observed between the positively charged acylguanidine of HMA and
the Asp189 side chain at the base of the S1 binding pocket (Figure 3.1). H-bonds were present
between the backbone carbonyl of Gly219 and the terminal NH2 and amide NH groups of the acyl
guanidine. The other guanidino NH2 formed a H-bond to the Ser190 side chain OH and the
exocyclic NH2 group at C3 was H-bonded to the side chain OH of Ser195. A bridged H-bonding
network was formed between a surface-bound water molecule, the acyl guanidine carbonyl, the
Ser190 side chain hydroxyl, and possibly the guanidino NH2.
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Figure 3.1: A) X-ray co-crystal structure of HMA bound to the serine protease domain of uPA (1.6
Å). The electron density map (2mFo-DFC) is contoured at 1.5 σ. Electrostatic potential surfaces of
uPA are shown with blue = negative and red = positive. A bridging water molecule is shown as a
red ball. All non-bridging water molecules have been omitted for clarity. A sulfate from the
cyrstalization buffer is bound to the oxyanion hole and is presented in stick representation. B)
Equivalent structure to A) with surfaces coloured according to electrostatic potential (uPA) or cyan
(HMA). C) Summary of the binding interactions between HMA and uPA. Residues comprising the
S1 subsite are labeled in blue. Dashed lines represent H-bonds and ionic interactions. Curved
dashed lines represent van der Waals contacts.

The hydrophobic nature and compact size of the S1 subsite is highlighted by the electrostatic
potential surface map in Figure 3.1A. The accessibility to S1 from the 6-position of the HMA
scaffold was clear. The 6-Cl group of HMA interacted primarily at the mouth of S1, participating
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in van der Waals interactions with the Cys191-Cys220 disulfide bond, Gly219 and Gln192C (Figure
3.1C).

3.2 Co-crystal structures of 6-HMA analogues
Evaluation of the 6-HMA analogue:uPA X-ray co-crystal structures revealed that the hydrogen
bonding and ionic interactions observed between the acyl guanidine of HMA and Asp189, Gly219,
Ser190 and the H-bond from the exocyclic NH2 group at C3 and Ser195 in the HMA-uPA structure
were preserved, showing only slight variations in bond distances (measured as the distance
between the two heteroatoms in all cases). Participation of the terminal guanidino NH2 in the
bridging network comprised of the surface H2O, Ser190 and the acyl guanidine carbonyl showed
more variation as prospective H-bonds distances for these interactions exceeded accepted limits
in some cases (i.e. >3.3 Å). The SAR trends observed for the 6-HMA analogues can largely be
rationalized in terms of formation of new favourable (or unfavourable) interactions between the
6-substitutent and the S1β subsite.

3.2.1 Furanyl analogues 46 and 47
2-Furanyl analogue 46 (IC50 = 254 nM) showed 8.7-fold higher potency than HMA (IC50 = 2,206
nM). The increase in affinity appeared to arise, at least in part, by formation of new H-bonds
between the furanyl O, a bridging water molecule and the amide NH of Gly219 (Figure 3.2C).
Interactions were also observed between the furan ring and Gly219, Cys191-Cys220, Ser146
backbone carbonyl and the side chain C and Cγ of Gln192. Figure 3.2B highlights the increased
occupation of the S1 subsite by the 2-furanyl substituent relative to the Cl atom in HMA.
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Figure 3.2: A) X-ray co-crystal structure of 46 bound to the serine protease domain of human uPA
(1.7 Å). The electron density map (2mFo-DFC) is contoured at 1.5 σ. Electrostatic potential surfaces
of uPA are shown with blue = negative and red = positive. Bridging water molecules are
represented as red balls. All non-bridging water molecules have been omitted for clarity. A sulfate
from the cyrstalization buffer is bound to the oxyanion hole and is presented in stick
representation. B) Equivalent structure to A) with surfaces coloured according to electrostatic
potential (uPA) or cyan (46). C) Summary of the binding interactions between 46 and uPA.
Residues comprising the S1 subsite are labeled in blue. Dashed lines represent H-bonds and ionic
interactions. Curved dashed lines represent van der Waals contacts.
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Altering the position connecting the furan ring to produce the 3-furanyl analogue 47 had little
effect on the activity (IC50 = 270 nM). Movement of the furanyl oxygen abolished the H-bond
interaction with the bridging water molecule bound to Gly219, as seen in the 2-furanyl 46:uPA
structure (Figure 3.3C). Flexibility of the Arg217 side chain was apparent in this structure as it had
moved significantly to participate in the Gly219-bridging water H-bonding network (Figure 3.3A).
Relative to 46, the plane of the furan ring in 47 had tilted 11˚, adopting a pose that appears to
facilitate van der Waals interactions with Cys220. Interactions between S1 residues Cys191Cys220, Ser146 and the Gln192 side chain were preserved and there appeared to be a polar
interaction between the side chain carbonyl of Gln192 and the δ+ CH at the 2-position of the
furanyl ring. The new combination of interactions appeared to compensate for the lost H-bonding
interaction to the Gly219-bridging water-Arg217 bonding network seen for 46.
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Figure 3.3: A) X-ray co-crystal structure of 47 bound to the serine protease domain of uPA (1.7 Å).
The electron density map (2mFo-DFC) is contoured at 1.5 σ. Electrostatic potential surfaces of uPA
are shown with blue = negative and red = positive. Bridging water molecules are represented as
red balls. All non-bridging water molecules have been omitted for clarity. B) Equivalent structure
to A) with surfaces coloured according to electrostatic potential (uPA) or cyan (47). C) Summary of
the binding interactions between 47 and uPA. Residues comprising the S1 subsite are labeled in
blue. Dashed lines represent H-bonds and ionic interactions. Curved dashed lines represent van
der Waals contacts.
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3.2.2 1-Methyl-pyrazolyl analogue 38
In contrast to furanyl analogues 46 and 47, 1-methyl-pyrazolyl analogue 38 positioned its ring
coplanar with the pyrazine core, reducing its penetration into S1 (Figure 3.4). This orientation
limited potential interactions between the N-methyl group and the Lys143-Gln192-Ser146
hydrophobic dimple, instead projecting it out towards solvent. Interactions appeared to exist
between the pyrazole C3 and C5 CH groups and the Gly219 backbone and Gln192 side chain,
respectively. The surface water bound to Gly219 in the furanyl structures was observed, however
it did not interact with the 6-substituent of 38. The decreased occupation of S1 due to the
coplanar orientation of the pyrazole with the pyrazine core probably contributed to its lower
activity against uPA (IC50 = 825 nM) relative to the furanyl analogues.
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Figure 3.4: A) X-ray co-crystal structure of 38 bound to the serine protease domain of human uPA
(1.9 Å). The electron density map (2mFo-DFC) is contoured at 1.5 σ. Electrostatic potential surfaces
of uPA are shown with blue = negative and red = positive. Bridging water molecules are
represented as red balls. All non-bridging water molecules are omitted for clarity. B) Equivalent
structure to A) with interacting surfaces coloured according to electrostatic potential (uPA) or cyan
(38). C) Summary of the binding interactions between 38 and uPA. Residues comprising the S1
subsite are labeled in blue. Dashed lines represent H-bonds and ionic interactions. Curved dashed
lines represent van der Waals contacts.

3.2.3 Benzofuran analogue 42
Fusion of a phenyl ring to the 2-furanyl ring of 46 to create benzofuran 42 resulted in a slight
decrease in potency (42 IC50 = 297 nM). Figure 3.5B shows that the benzofuran ring system
extends well into S1, almost completly filling the subsite. The plane of the benzofuran ring was
almost perpendicular to the pyrazine core, but the ring oxygen appeared to have moved to the
opposite side of the pyrazine relative to the furanyl oxygen of 46. This orientation allowed the
benzofuran 7-position CH to fill the Lys143-Gln192-Ser146 hydrophobic dimple. Additional
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hydrophobic contacts were observed between the benzofuran 3- and 4-position CHs and Gly219.
As seen with the HMA:uPA and 46:uPA structures, the Arg217 side chain adopted a conformation
well away from S1. The surface water bound to the Gly219 carbonyl O, as present in other
structures, was not observed.
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Figure 3.5: A) X-ray co-crystal structure of 42 bound to the serine protease domain of human uPA
(1.6 Å). The electron density map (2mFo-DFC) is contoured at 1.5 σ. Electrostatic potential surfaces
of uPA are shown with blue = negative and red = positive. Bridging water molecules are
represented as red balls. All non-bridging water molecules have been omitted for clarity. B)
Equivalent structure to A) with interacting surfaces coloured according to electrostatic potential
(uPA) or cyan (42). C) Summary of the binding interactions between 42 and uPA. Residues
comprising the S1 subsite are labeled in blue. Dashed lines represent H-bonds and ionic
interactions. Curved dashed lines represent van der Waals contacts.
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3.2.4 4-F Benzofuran analogue 43
A 2-fold improvement in uPA-inhibitory potency was achieved by adding fluorine to the 4-position
of the benzofuranyl ring of 42 to yield 43 (IC50 = 143 nM versus IC50 = 297 nM for 42).
The X-ray co-crystal structure with 43 revealed that the increased potency possibly arises from
favourable interactions between the 4-fluoro group and the side chain guanidine of Arg217 and
the backbone amide NH of Gly219 (Figure 3.6A). These interactions were not observed in the
42:uPA structure as the sidechain of Arg217 adopted a position away from S1, as observed with
38, 46 and HMA. The interaction between the 4-fluoro group and Arg217 caused a slight rotation
about the benzofuran-pyrazine axis, where the dihedral angles were 78 for 42 and 68 for 43
(Figure 3.7). Similar to the 42:uPA structure, the surface water interacting with the Gly219
backbone carbonyl was not observed.
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Figure 3.6: A) X-ray co-crystal structure of 43 bound the serine protease domain of human uPA
(1.9 Å). The electron density map (2mFo-DFC) is contoured at 1.5 σ. Electrostatic potential surfaces
113

of uPA are shown with blue = negative and red = positive. A bridging water molecule is
represented as a red ball. All non-bridging water molecules have been omitted for clarity. B)
Equivalent structure to A) with interacting surfaces coloured according to electrostatic potential
(uPA) or cyan (43). C) Summary of the binding interactions between 43 and uPA. Residues
comprising the S1 subsite are labeled in blue. Dashed lines represent H-bonds and ionic
interactions. Curved dashed lines represent van der Waals contacts.

Figure 3.7: Superposition of 42 (gold) and its 4-fluorinated analogue 43 (green). The plane of the
benzofuran moiety relative to the pyrazine ring is rotated slightly in 43 (dihedral angle = 78)
compared to 42 (dihedral angle = 68), allowing formation of a favourable interaction between the
polarized fluorine and the positively charged sidechain of Arg217.

3.2.5 Pyrimidine analogues 48, 49 and 50
X-ray diffraction data sets of varying quality (1.7-3.0 Å) were obtained for the three 5-pyrimidinebased compounds 48, 49 and 50. Analysis of the unadorned 5-pyrimidine 48:uPA structure at 2.0 Å
showed that this substituent partially fills S1 (Figure 3.8). Interactions with the Cys191-Cys220
disulfide, Ser146 and Gln192 residues were preserved with the addition of an apparent dipole
interaction between the δ+ CH at the 4-position of the pyrimidinyl and the Gln192 side chain
carbonyl (Figure 3.8A). A H-bond was observed between the backbone amide NH of Gly219 and
the lone pair of electrons on the pyrimidine nitrogen. The pyrimidine ring was oriented favourably
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to form a polar interaction between the δ+ CH at 6-position and the Gly219 backbone carbonyl.
The sidechain of Arg217 was positioned close to the pyrimidine 6-substituent, potentially forming
a favourable polar interaction with the ring. The bridging water molecule contributing to the Hbonding network between the acylguanidine carbonyl, NH2 groups and the side chain hydroxyl of
Ser190, which was consistently observed in other structures, was not present. This may have been
due to the lower resolution of the 48:uPA structure.
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Figure 3.8: A) X-ray co-crystal structure of 48 bound to the serine protease domain of human uPA
(2.0 Å). The electron density map (2mFo-DFC) is contoured at 1.5 σ. Electrostatic potential surfaces
of uPA are shown with blue = negative and red = positive. Water molecules have been omitted for
clarity. B) Equivalent structure to A) with interacting surfaces coloured according to electrostatic
potential (uPA) or cyan (48). C) Summary of the binding interactions between 48 and uPA.
Residues comprising the S1 subsite are labeled in blue. Dashed lines represent H-bonds and ionic
interactions. Curved dashed lines represent van der Waals contacts. The backbone NH of the
Gly219 was observed to donate a H-bond to the pyrimidine nitrogen lone pair.
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Methoxy derivatization at the pyrimidine 2-position of 48 to create 49 resulted in a 2-fold increase
in potency (49 IC50 = 86 nm, 48 IC50 = 175 nM). Superposition of the 48:uPA and 49:uPA co-crystal
structures revealed that the inhibitors adopt very similar poses, with rotation about the plane of
pyrimidinyl ring relative to the pyrazine core varying by only 22 (Figure 3.9).

Figure 3.9: Superposition of the uPA:48 (green, uPA in orange) and uPA:49 (magenta, uPA in
mauve) structures. In both structures the sidechain of Arg217 is positioned close to the pyrimidine
substituents to form dipolar interactions.

The methoxy CH3 group of 49 was oriented towards bulk solvent (Figure 3.10A). Compared to 48,
the Gly219 NH-pyrimidine nitrogen H-bond was lengthened considerably, weakening the
interaction (2.9 Å in 48 versus 3.4 Å in 49, Figure 3.10C). The sidechain of Arg217 had again flipped
into close proximity with the substituent to make polar interactions with the pyrimidine nitrogen.
The bridging water molecules observed in other structures were not present, most liekly due to
the low resolution of this data set (3.0 Å).
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Figure 3.10: A) X-ray co-crystal structure of 49 bound to the serine protease domain of human uPA
(3.0 Å). Electron density map (2mFo-DFC) is contoured at 1.5 σ. Electrostatic potential surfaces of
uPA are shown with blue = negative and red = positive. Water molecules have been omitted for
clarity. B) Equivalent structure to A) with interacting surfaces coloured according to electrostatic
potential (uPA) or cyan (49). C) Summary of the binding interactions between 49 and uPA.
Residues comprising the S1 subsite are labeled in blue. Dashed lines represent H-bonds and ionic
interactions. Curved dashed lines represent van der Waals contacts.
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Introduction of a second methoxy substituent onto the 5-pyrimidinyl ring (48) resulted in a small
increase in potency relative to the mono-methoxy 49 (50 IC50 = 69 nM, 49 IC50 = 86 nM), affording
the most potent 6-HMA analogue identified in this study. Compared to pyrimidine analogues 48
and 49, compound 50 displayed greater rotation about the pyrimidine-pyrazine axis, adopting a
dihedral angle of 80(c.f. 66 for 49 and 44 for 48). This led to increased occupancy of S1 and
allowed the o-methoxy CH3 to fill a small hydrophobic dimple formed by the side chains of Lys143,
Gln192 and the Ser146 backbone (Figure 3.11). The p-methoxy substituent was projected towards
bulk solvent, with its CH3 group (δ+) appearing to interact with the Gly219 backbone NH lone pair
(3.0 Å). The pyrimidine ring appeared to make an additional hydrophobic contact with the Gly219
C. In contrast to 48 and 49, the Arg217 side chain was positioned away from S1, apparently to
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avoid a steric clash with the p-methoxy substituent. It would appear that loss of favourable
interactions with the Arg217 sidechain, as observed in the uPA:48 and uPA:49 structures, was
compensated for by the new interaction between the o-methoxy CH3 group and the hydrophobic
dimple in S1, as indicated by the higher potency of 50.
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Figure 3.11: A) X-ray co-crystal structure of 50 bound to the serine protease domain of Human
uPA (1.7 Å). The electron density map (2mFo-DFC) is contoured at 1.5 σ. Electrostatic potential
surfaces of uPA are shown with blue = negative and red = positive. A bridging water molecule is
represented as a red ball. All non-bridging water molecules have been omitted for clarity. A sulfate
from the cyrstalization buffer is bound to the oxyanion hole and is presented in stick
representation. B) Equivalent structure to A) with interacting surfaces coloured according to
electrostatic potential (uPA) or cyan (50). C) Summary of the binding interactions between 50 and
uPA. Residues comprising the S1 subsite are labeled in blue. Straight dashed lines represent Hbonds and ionic interactions. Dashed lines represent van der Waals contacts. Favourable
interactions were observed between the o-methoxy CH3 and the small hydrophobic dimple of S1
formed by the side chains of Lys143, Gln192 and the Ser146 backbone. The sidechain of Arg217
was positioned away from S1, preventing interaction with 50.
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3.3 X-ray co-crystal structures of HMA, 42 and 50 in complex with H99Y
‘murinized’ uPA
A key active site difference between murine and human uPA is the substitution at residue 99
(occupying S2 and S4), where His in the human enzyme is replaced by the bulkier Tyr in the mouse
equivalent. X-ray co-crystal structures of HMA, 42 and 50 in complex with HuPA H99Y were solved
to aid explanation of the SAR trends for HuPAH99Y (and by extension MuPA) presented in Chapter
2.4.

The Tyr99 sidechain OH was found to be located close to the proximal methylene group of HMAs 7membered ring (3.2 Å). In the equivalent huPA structure, the closest distance from the same CH2
group to His99 was 4.1 Å (Figure 3.12). Similar observations were made for 42 and 50, where the
Tyr99 OH resided closer to the proximal CH2 group (3.5 Å versus 5.3 Å for 42, 3.4 Å versus 5.1 Å for
50).
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Figure 3.12: Superpositions of X-ray co-crystal structures of H99Y uPA with WT HuPA; A) HMA,B)
42 and C) 50. H99Y X-ray co-crystal structures HuPA structures. The H99Y is presented in orange
and the WT backbone in mauve. Residue 99 in each variant (His99 in WT, Tyr99 in H99Y mutant) is
highlighted by a black box. Positioning of backbone residues in each uPA variant was preserved
across all structures and inhibitor binding poses were very similar across matched complexes. In
the H99Y structures, the Tyr sidechain is positioned closer to the proximal CH2 of the azepane ring
than in the HuPA structures, potentially creating unfavourable interactions. Structures were
obtained at the following resolutions: HMA 2.3 Å, 42 2.9 Å and 50 2.4 Å.

This close orientation suggests that an unfavorable interactions between the polar Tyr99 sidechain
and the hydrophobic azepane ring may be occurring, which could explain the greatly decreased
potency of these analogues against H99Y relative to HuPA. The topology of the S1 subsite was
preserved across both co-complexes for all three inhibitors. The binding poses of HMA and 50
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were very similar across the WT and mutant structures and the two methoxy groups of 50
occupied virtually identical positions. Interestingly, the pyrazine core and azepane ring of 42 were
shifted towards the S2 pocket in the H99Y structure, apparently to present the 6-benzofuranyl
substituent in identical configurations in both structures. The positioning of the sidechain of
Arg217 was similar in both the HMA and 42 structures. However, the Arg217 sidechain in the 50
H99Y structure was positioned close to the pyrimidine methoxy group of 50. In the HuPA structure
it was positioned well away from S1. Despite the potential for H-bonds allowed by this
positioning, potency was actually decreased against the murinzed enzyme (H99Y IC50 = 9.7 M).

3.4 Summary and conclusions
The X-ray co-crystal data presented herein allowed rationalization of some of the potency trends
observed for the 6-HMA series. In general, appending substituents to the 6-position did not alter
the binding pose or interactions formed between the parent structure and the HuPA active site.
Favourable interactions between the 6-substituents and S1 were observed in all examples,
confirming that this subsite is accessible from the 6-position of HMA and that increased S1
occupancy can drive increases in potency.

The observation that significant modifications (e.g. 46 vs 43 and 48 vs 50) resulted in modest
changes in potency may reflect contributions from bulk effects, such as differences in desolvation
energies for the respective substituents as the formation of specific and distance-dependent
interactions appeared not to fully explain the observed trends. Experiments with the H99Y
‘murinized’ human uPA suggested that unfavourable interactions between the Tyr99 sidechain
and the 5-azepane ring of 6-HMA analogues may be contributing to the decreased activity relative
to HuPA. By extension, analogous (unfavourable) interactions between the 6-HMA analogues and
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MuPA may be responsible for the generally lower activity observed with these compounds against
murine uPA.
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CHAPTER 4: In vitro and ex vivo characterization of 6-HMA analogues
Solution phase enzyme inhibition assays and X-ray crystallographic analysis allowed identification
of promising lead structures from the synthesized library of 6-HMA analogues. The effects of
selected leads on various aspects of cancer cell biology were characterized using multiple in vitro
and ex vivo platforms. As is common practice during evaluating novel drug leads, cytotoxicity was
also evaluated against human established cell lines.

4.1 Effects on cell proliferation and cytotoxicity
The cytotoxic effects of 2-benzofuranyl and 5-pyrimidinyl leads were investigated using the
Promega CellTitre 96® Aqueous One Solution Cell Proliferation Assay. The assay measures the
extent to which intracellular dehydrogenase enzymes convert a tetrazolium reagent (MTS) into a
chromogenic formazan dye that can be quantified using a spectrophotometer. As the assay relies
on the activity of enzymes upregulated during growth, the technique is unable to differentiate
between cells that have died or entered senescence in response to drug treatment.300 As such, the
assay is not strictly a measure of treatment-induced cytotoxicity, but rather is a measure of cell
viability. Microscopic examination of cell cultures immediately prior to addition of MTS reagent
provides a way of confirming cytotoxic effects, as indicated either by loss of cells or induction of a
granular appearance. Despite their shortcomings, MTS and equivalent assays are commonly used
as surrogate measures of compound cytotoxicity.

Compounds from the 2-benzofuranyl (42) and 5-pyrimidinyl (50) lead classes differed markedly in
their effects on U-937 human histiocytic lymphoma cell viability (Figure 4.1). Inhibition of U-937
cell viability by 42 first appeared at concentrations between 1 and 10 M (28% inhibition at 10
M), with complete inhibition observed at 100 M. In contrast, no inhibition was observed for the
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2,4-dimethoxypyrimidine analogue 50 in the range 1 nM-100 M. Microscopic analysis of cultures
post-treatment revealed a rapid onset for the cytotoxic effects of 42 at 100 M, with cells
exhibiting phenotypes characteristic of cytotoxic shock (e.g. decreased cell number, granular
appearance, decreased surface area).301 The cells did not recover over the course of the
experiment (50 h).

Figure 4.1: Effects of 42 and 50 on viability of U-937 Human histiocytic lymphoma cells. Cells were
harvested 48 h post-passage, plated at a density of 5000 cells/well and incubated at 37 °C, 5% CO 2
for 18 h prior to drug treatment. Vehicle (DMSO) was present in all solutions at 1% (v/v). Cells
were cultured for 48 h post-drug treatment, incubated for 2 h with MTS reagent and absorbance
readings obtained at 490 nm. Bars represent the mean ± SEM (n = 4).

To determine whether similar results were observed in adherent cells, compound 42 was tested
for cytotoxicity against MDA-MB-231 human epithelial breast adenocarcinoma cells. As seen with
U-937 cells, 42 exhibited a pronounced inhibitory effect at 100 μM (Figure 4.2). HMA was similarly
cytotoxic at this concentration, while no significant effects were observed for amiloride or the
selective NHE1 inhibitor cariporide.
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Figure 4.2: Effects of 42, HMA, amiloride and cariporide on viability of MDA-MB-231 human breast
adenocarcinoma cells. Assays were conducted as described in Figure 4.1. Data represent the mean
± SEM (n = 4).

Microscopic analysis of the cells confirmed the cytotoxicity of 42 and HMA at 100 μM, as indicated
by the greatly decreased cell numbers and (dead) appearance of cells (Figure 4.3). It appeared that
the compounds elicited an immediate cytotoxic effect as very low cell numbers were present at
the time of imaging, indicating that mitotic duplication had not occurred (i.e. the cells had died
prior to initial doubling).
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Figure 4.3: Phase-contrast photomicrographs of MDA-MB-231 cells 48 h after treatment with compound 42 or HMA. A pronounced decrease in cell
number was observed with 42 and HMA at 100 µM relative to vehicle control (1% DMSO v/v).
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To examine whether the anti-proliferative/cytotoxic effects were consistent within the 2benzofuranyl and 5-pyrimidinyl lead classes, other analogues from each class were next
investigated using MDA-MB-231 cells. 4-Fluoro-2-benzofuranyl analogue 43 was found to be more
toxic than the unsubstituted analogue 42 in the same cell line, exhibiting almost complete loss of
viability at 10 M (Figure 4.4). In agreement with the low cytotoxicity of 50 observed in U-937
cells, pyrimidine-based analogue 48 exhibited only a slight anti-proliferative effect on MDA-MB231 cells (30% inhibition) at 100 M.

Figure 4.4: Effects of compounds 43 and 48 on viability of MDA-MB-231 human breast
adenocarcinoma cells. Assays were conducted as described in Figure 4.1. Data represent the mean
± SEM (n = 4).

To examine whether the cytotoxic effects of the compounds were species-specific, compounds 42
and 50 were tested in MTS assays using murine macrophage RAW 264.7 cells. The murine myeloid
cells displayed greater sensitivity to both lead classes relative to human U-937 cells, with complete
loss of cell viability observed at 100 M for both 42 and 50 (Figure 4.5).
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Figure 4.5: Effects of 42 and 50 on viability of RAW 264.7 murine macrophage cells. Assays were
conducted as described in Figure 4.1. Data represent the mean ± SEM (n = 4).

To complement the data obtained using the MTS assays, analogues 42 and 50 were investigated
using the Roche Cytotoxicity Detection kit PLUS LDH release assay. Compromised plasma
membrane integrity and resulting loss of cytoplasmic contents is a well characterized marker of
cytotoxic cell death.302 The assay functions by detecting activity of lactate dehydrogenase (LDH),
an enzyme released from the cytoplasm of necrotic cells in response to drug treatment. Catalytic
turnover of a chromogenic substrate provides a quantifiable response. To obtain a representative
maximal signal (control) for cytoplasmic LDH activity, vehicle-treated cells were lysed at the assay
endpoint using a detergent solution (9% v/v Triton-X100), referred to as lysis control. A matched
negative control was also included to confirm that LDH is not secreted into the cell culture
supernatant by healthy cells (vehicle control).

The amount of LDH activity in U-937 cells treated with 42 and 50 (1 nM-100 M) was measured 48
h after initial compound exposure (Figure 4.6). In line with MTS assay results, only the 2benzofuranyl analogue 42 caused a significant release in LDH activity at 100 µM, indicative of cell
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death. Evidence of slight LDH release at 10 µM was apparent. No significant LDH release was
observed with 50 at any concentration.

Figure 4.6: Effects of 42 and 50 on LDH release from U-937 cells. Abs490 corresponds to the degree
of cytotoxic cell death in response to drug treatment. Cells were harvested, cultured and treated
as described in Figure 4.1. Lysis control cells were subsequently treated for 15 min with 5 µl lysis
Buffer, incubated for 10 min with reagent mixture and readings obtained at 490 nm. Data
represent the mean ± SEM (n = 4).

Microscopy immediately prior to LDH assay revealed that 100 µM 42 had caused a substantial loss
of cells relative to the lower doses or vehicle-treated controls, further confirming that 42 is
cytotoxic at this concentration (Figure 4.7).
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Figure 4.7: Phase contrast photomicrographs of U-937 cells 48 h after treatment with 42 or 50. A
pronounced decrease in cell number was observed for 42 at 100 µM relative to the vehicle control
(1% DMSO v/v).

Taken together, these results indicate a marked difference in the cytotoxic effects of the two lead
series, with the 2-benzofuranyl analogues being clearly more cytotoxic than the pyrimidines. It is
unclear whether the cytotoxic effects of the benzofuran compounds arose from specific
interactions with pro-cytotoxic target(s) or whether they were simply a function of their higher
lipophilicity relative to 5-pyrimidinyl class (benzofurans 42 and 43 ClogD 3.19-3.40; pyrimidines 48,
49 and 50 ClogD 0.82-1.85), or a combination of these factors.

HMA is known to trigger dose-dependent apoptosis via depletion of endoplasmic Ca2+ stores in
human umbilical vein endothelial cells (HUVEC).303 In some recent reports, HMA (40 M) was used
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as a specific inducer of apoptosis.304,305 To examine whether the cytotoxic effects of the
benzofuran analogues are caused by induction of apoptotic cell death, compound 42 was tested
using the Promega APO-One Homogenous Caspase 3/7 Assay.

The assay probes the release of pro-apoptotic cysteine aspartic acid proteases (Caspase) 3 and 7
into the cytoplasm by measuring turnover of a rhodamine-conjugated fluorogenic substrate of
these enzymes. Cariporide is a potent and selective inhibitor of NHE1 and was included to examine
whether NHE1 inhibition was also able to induce apoptosis (Cariporide uPA IC50 >> 100 M, see
Appendix 9.3). Of the compounds 42, HMA and cariporide, only 42 at the highest concentration
tested (30 M) produced a significant increase in caspase 3/7 activity in HEK-293 cells after 5 h of
treatment exposure (Figure 4.8). This result supports the cytotoxic effects of 42 being linked to
induction of apoptosis.

Figure 4.8: Caspase 3/7 activation in HEK-293 cells following treatment with 42, HMA and
cariporide. Cells were plated at 2.0x104 cells/well in black 96-well cell culture plates and incubated
for 18 h at 37 C, 5% CO2. Cells were treated with compounds or vehicle (1% v/v DMSO) for 5 h,
shaken for 1 h at 500 rpm using a motorized plate shaker and incubated for 2 h at RT. Caspase 3/7
fluorogenic substrate in lysis buffer was added and after incubation at RT for 3 h the plates were
read (ex. 485 nm, em 520 nm). Data represent the mean  SEM (n = 3).
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4.2 Effects on cell proliferation in real time via xCELLigence assay
To further investigate the cellular effects of the benzofuranyl class, cells were examined in
response to treatment with 42 using the xCELLigence Real Time Cell Analyzer (Roche Diagnostics
Australia Pty. Ltd., NSW, Australia). The xCELLigence system measures changes in electrical
impedance inside a specialized multiwell plate and can be used to monitor various aspects of cell
behavior, including viability and proliferation rate. As cells proliferate they impede the flow of
electrons between electrodes fused to the bottom of each well. The impedance change is
measured and used to calculate a cell index (CI); a dimensionless value that allows relative
comparison of different compound treatments and conditions on cell behavior (e.g. growth rate).

A highly metastatic variant of the MDA-MB-231 breast adenocarcinoma cell line (MDA-MB231HM) was used as it is known to overexpress both uPA and uPAR (M. Ranson, personal
communication). Cells were plated into proprietary E-plate culture plates and allowed to grow for
24 h prior to drug addition. Figure 4.9 shows that cells in all treatment groups showed similar
proliferation rates prior to drug addition at 24 h. Compound 42 at 10 M caused an immediate
toxic shock to cells with no recovery over time, indicative of cell death. This confirmed the rapid
onset of cytotoxicity induced by the benzofuranyl analogues, as observed earlier with MTS/LDH
assays and microscopic analyses.

HMA at 10 M slowed the proliferative rate of MDA-MB-231HM cells, but the cells were able to
recover and achieve a CI comparable to the vehicle control by the 72 h endpoint. Recovery of HMA
treated cells suggests that it is not cytotoxic at this dose, corroborating results from the MTS, and
Caspase 3/7 activation assays and microscopic analysis. Amiloride and cariporide showed minimal
differences to vehicle control cells. These results highlight intrinsic differences between the
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cytotoxic effects of HMA, the parent compound amiloride and 6-benzofuran analogue 42. The
negligible effect of cariporide showed that inhibition of NHE1 does not effect proliferation in
MDA-MB-231HM cells.

Figure 4.9: xCELLigence real-time analysis of the antiproliferative effects of compounds on MDAMB-231HM human breast adenocarcinoma cells over 72 h. Cell index (CI) is a dimensionless
measure of changes in electrical impedance caused by proliferation of cells. Cells were plated at
5x103 cells/well. Data points represent the average of two intra-assay replicates. The sharp
decrease observed at the time of drug addition (24 h) is caused by requilibration of the system
after mechanical perturbation.

To examine whether the antiproliferative effects of HMA and 42 in MDA-MB-231HM cells were
uPA-mediated, the xCELLigence assay was repeated using uPA/uPAR-null HEK-293 human
embryonic kidney cells.59 As seen in MDA-MB-231HM cells, treatment with 10 M 42 caused
immediate cell death with no recovery over 72 h (Figure 4.10). Likewise, HMA treatment slowed
proliferation of HEK-293 cells without evidence of cytotoxicity, with CI recovery approaching the
vehicle control by the end of the assay. Amiloride or cariporide treatment had no effect on
proliferative rate or final CI. Recapitulation of the MDA-MB-231HM results in uPA/uPAR-null HEK-
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293 cells indicates that the cytotoxic effects of 42 (and modest cytostatic effects of HMA) operate
via uPA/uPAR-independent mechanisms.

Figure 4.10: xCELLigence real-time analysis of the antiproliferative effects of compounds on the
uPA/uPAR-null HEK-293 human embryonic kidney cells over 72 h. Assays were conducted as
described in Figure 4.9. The plateau in cell index after ~ 60 h indicates cells reaching confluence.

Dose-dependency of the effects of 42 and HMA was probed by repeating the assay with
uPA/uPAR-null HEK-293 cells at lower concentrations. Compound 42 at 1 M did not show the
dramatic cytotoxic effects observed at 10 M, although CI was reduced by 22% relative to vehicle
control cells after 70 h (Figure 4.11), suggesting a mild-antiproliferative effect. HMA at 10 M was
again found to inhibit the rate of cell proliferation, with CI recovering to approximately half that of
control cells by the assay endpoint. Amiloride treatment at 1 M and 10 M had no effect on CI.
Compound 42 showed no difference to control cells when present at 100 nM. These findings
complemented results from the cytotoxicity and apoptosis assays showing that compound 42 has
no effect at concentrations below 10 M.
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Figure 4.11: Real-time analysis of the dose-dependent antiproliferative effects compounds. Assays
were conducted as described in Figure 4.9.

4.3 Effects of 6-HMA analogues in a 3D organotypic cell invasion model
Despite their prevalence, two-dimensional models for studying cancer cell migration and invasion
do not accurately reflect the dynamic three-dimensional (3D) environment experienced by cancer
cells in vivo. This shortcoming has fueled much research into the development of 3D cell culture
models that capture the spatiotemporal milieu of invasive cancers.306 To this end, and to examine
the extent to which 6-HMA analogues are able to inhibit invasion in an ex vivo setting, a recently
described collagen I organotypic cell invasion model was employed.307

In this model, a preparation of collagen I isolated from rat tail tendons is seeded with fibroblasts
and grown in culture. Due to their ECM-component secreting and ordering behaviors, the seeded
fibroblasts contract the collagen I into a solid, dermal-mimicking plug. Once formed, the
contracted plugs are overlaid with invasive epithelial cells that form a contiguous monolayer along
the upper surface. The epithelial cells are then induced to invade into the collagen I matrix by
transferring the plug to a steel grid and raising the cell culture medium to contact the bottom of
the matrix, establishing an air-liquid interface. Growth factors and nutrients present in the culture
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media diffuse into the matrix, providing a chemotactic gradient and trophic incentive that attracts
epithelial cell invasion downwards into the plug. After an incubation period (3-21 days), cell plugs
are formalin fixed and paraffin embedded, sectioned and stained, providing a measure of cell
invasion. This system is an excellent model for examining the effectiveness of uPA inhibitors
against epithelial cells that rely on the plasminogen activation pathway for invasiveness as
inhibition of uPA and plasminogen activation should decrease migration of cells into the collagen I
matrix.

Overexpression of uPAS components is a key determinant of metastatic potential in malignant
ovarian disease, where uPA levels correlate with FIGO (International Federation of Gynaecology
and Obstetrics) grade and poor progression-free survival and overall survival.308,309 Differences in
uPA expression between primary tumour and peritoneal metastasis have been validated as a
prognostic biomarker for surgical outcome and overall survival.67 These findings suggested
invasive SKOV-3 ovarian carcinoma cells as being suitable for use in the 3D organotypic model.

SKOV-3 cells seeded at a density of 1.875x105 cells per plug were allowed to invade for 21 days.
Compound or vehicle containing media was replaced every 72 h, with all compounds present at 2
M. Cell invasion was quantified by calculating the invasion index (II) for each image, where II =
number of epithelial cells invaded into collagen plug/number epithelial cells forming a contiguous
monolayer along top of the plug x 100% (Figures 4.12 & 4.13).

A small but significant decrease in invasion index was observed for the 2-benzofuranyl analogue 42
relative to the DMSO control group (Figure 4.12, mean II DMSO control = 63.65, 42 = 57.83, p
0.0287). The difference between HMA and 42 did not reach significance (mean II HMA = 62.41, p
0.1099).
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Figure 4.12: Inhibition of SKOV-3 ovarian adenocarcinoma cell invasion by compounds. Collagen I
plugs contracted by human skin-derived fibroblasts were seeded with SKOV-3 cells at a density of
1.875x105/plug and allowed to invade for 21 days prior to fixing. Stained plug sections were
imaged and the images quantified for invasion index (II). Compounds were present at a
concentration of 2 M. Data points represent invasive indices from 10 individual images across
identically treated plugs. Central lines represent the mean ± SEM.

No significant differences in invasion index were detected for amiloride, HMA, cariporide or the
2,4-dimethoxy-5-pyrimidinyl compound 50 versus the DMSO control. The lack of effect of both
amiloride and HMA on SKOV-3 invasion is likely due to too a low a concentration being used given
the moderate potency of each compound against uPA (amiloride IC50 = 3954 nM, HMA IC50 =
2206). The finding that both HMA and cariporide did not inhibit cell invasion suggests that NHE1
does not play a role in invasion in this model. The lack of inhibition of cell invasion by compound
50 is surprising as this analogue is an ~ 4.3-fold more potent uPA inhibitor than 42 (50 IC50 = 68
nM, 42 IC50 = 297 nM). Analytical HPLC analysis of the DMSO stock from which compound 50
treatment was prepared revealed the appearance of 3 peaks in addition to the peak for the pure
compound, suggesting degradation of 50 had occurred. As such, the concentration of 50 present
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during the experiment would have been lower than 2 M. Higher doses of 50 (and 42) may be
needed in future experiments to demonstrate inhibition of uPA-mediated cell invasion in this
model.

It is possible is that the small decrease in II caused by 42 arose not from inhibition of uPAmediated cell invasion but instead from cytotoxic effects of the compound on SKOV-3 and/or TIF
cells. MTS assays showed that 42 is cytotoxic to both human and murine cells at concentrations >
7.5 M. While plausible, this explanation is unlikely given that the concentration used (2 M) was
well below the threshold for cytotoxicity observed in MDA-MB-231 and HEK-293 cells (10 M).
Experiments measuring the effects of 42 on SKOV-3 and TIF cell viability would be necessary to
disprove this hypothesis.

Variations in collagen plug density and integrity between experiments and batches of collagen I
have been identified by colleagues in our laboratory (Nathanial Harris, personal correspondence).
Degree of contraction, plug width and matrix density is heavily dependent on the functional state
of fibroblasts, where contraction times can vary significantly between cultures (6-14 days). As
shown in Figure 4.13, matrices were imperfect and contained small gaps. These variables may
have contributed to the variability of responses observed between experiments.
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Figure 4.13: Representative images showing SKOV-3 human ovarian carcinoma cell invasion matrices contracted by human skin-derived fibroblasts.
Cells were allowed to invade for 21 days prior formalin fixing. Cytokeratin stained plugs were imaged using bright-field microscopy with 10 images
collected across three plugs for each treatment group. All compounds were present at 2 M, with compound-containing media refreshed every 72 h.
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SKOV-3 cells are known to overexpress large amounts of uPAR.310 However, relative to other
ovarian cancer cell lines, SKOV-3 cells secrete only moderate amounts of HMW-uPA (full-length,
active uPA that’s able to bind uPAR).69 In addition, telomerase-immortalized fibroblasts do not
secrete large amounts of HMW-uPA, making endogenous uPA expression by SKOV-3 cells the sole
source of the enzyme in this system (Harris et al., manuscript submitted). It is therefore possible
that uPAR occupancy and uPA-mediated cell invasion was low, decreasing the dynamic range for a
measurable effect. Addition of exogenous HMW-uPA in future experiments would ensure
complete occupation of uPAR has been used previously in our laboratory with success (N. Harris,
personal communication).

SKOV-3 cells are considered to be moderate to highly invasive but they showed only mild
invasiveness in this model, requiring a long time (21 days) for sufficient invasion.74 Selection of a
more aggressive cell line that relies on uPA/plasminogen for invasion (e.g. MDA-MB-231 breast
adenocarcinoma cells, 10 day invasion) may provide a more sensitive platform for measuring the
anti-invasive effects of 6-HMA analogues and other uPA inhibitors in general.
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4.4 Effects of 6-HMA analogues in combination with chemotherapy drugs on
neoplastic cell phenotypes
The acidic tumour microenvironment is increasingly being linked to the responsiveness of
cancerous cells to a variety of conventional chemotherapy drugs.311,312 Drugs with pKa values near
the pH range observed in tumour microenvironments will exist as charged or neutral species,
depending on their acidic/basic groups.313 Maximizing the proportion of drug present in an
uncharged state is crucial for compounds that act on intracellular targets as the neutral species is
able to passively diffuse across the plasma membrane.314

NHE1 blockade has been suggested as a possible approach for sensitizing tumour cells to weakly
basic drugs acting on intracellular targets. The theory is that preventing NHE1-driven acidification
of the extracellular space will increase the amount of drug present in the membrane-permeable
neutral form.85 A commonly used, weakly basic anticancer drug is the vinca alkaloid vinblastine
(pKa ~ 8.8).295 Vinblastine is an antimitotic agent that binds to -tubulin subunits, preventing
functional microtubule assembly and mitotic spindle formation that leads to cell cycle arrest
during mitosis, and ultimately apoptosis.87 Clinically, vinblastine is often used in combination with
cisplatin or mitomycin C for ovarian, lung and brain tumours and Hodgkin’s lymphoma. It is also
used as a salvage therapy in metastatic breast cancers non-responsive to first-line therapies.315,316

To test this hypothesis, the effects of combinations of 6-HMA analogues 42, 43 and 49 and
vinblastine on MDA-MB-231 cell growth and viability were explored using MTS assays. NHE1
activity in cells was stimulated by serum starvation (0.2% FCS).122 The use of low serum media
increased the cytotoxic effects of benzofuran compounds 42 and 43, with complete cell death
observed at 5 M for both compounds (c.f. 10 M using 10% FCS media, section 4.3). Vinblastine
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alone at 5 M decreased cell viability by ~ 25% relative to vehicle treated cells and 1 nM
vinblastine had no effect (Figure 4.14 A). The cytotoxicity of Vinblastine at 5 nM was increased by
36% and 30% when combined with 1 M and 0.25 M 42, respectively (p 0.0039 and 0.0002).
Slightly less potentiation was observed with 1 nM vinblastine and 42 at 1 M or 0.25 M,
respectively (19% and 29% decreases in cell viability, p 0.0196 and p 0.001). In contrast, no
potentiation of the effect of 5 nM vinblastine was observed with any combination of 43. However,
small but significant increases were observed with 1 nM vinblastine and both 1 M and 0.25 M
43 (18% and 11% decreases in cell viability, p 0.0004 and p 0.0039). The differences between the
benzofuran and 4-fluorobenzofuran analogues suggest that potentiation of vinblastine cytotoxicity
is probably not general for the 2-benzofuranyl class.

No significant potentiation was observed for any combination of vinblastine with the pyrimidine
analogue 49 compared to vinblastine alone. Compared to the benzofuran analogues 42 and 43,
the highest concentration of 49 (5 M) showed no effects on cell viability, again highlighting the
differences in the intrinsic cytotoxicity of the 5-pyrimidine versus 2-benzofuranyl lead classes.

Contrary to expectation, potent NHE1 inhibitor cariporide appeared to protect MDA-MB-231 cells
from the effects of vinblastine, increasing viability by 69% at 5 M cariporide compared to when
vinblastine was present at 5 nM alone (Figure 4.14). In cells treated with cariporide alone viability
was decreased in the range 19-35%.
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Figure 4.14: Effects of vinblastine/6-HMA analogue combinations on MDA-MB-231 cell viability
using MTS assays. Data represent the mean ± SEM (n = 4). Statistical significance between groups
was tested using the unpaired parametric t-tests in GraphPad PRISM v6.0. Level of significance
was denoted as: * p < 0.05, ** p < 0.02, *** p < 0.005.

When co-administered with cariporide, 1 nM vinblastine showed negligible effects at all cariporide
doses. At 5 nM vinblastine alone cell viability was decreased by ~ 60%. The incomplete killing of
cells at this high dose of vinblastine suggested the existence of a resistant subpopulation.

A concentration-response experiment conducted to determine the effects of vinblastine on MDAMB-231 cell viability gave an IC50 value of 2.33 M and showed the presence of a resistant
subpopulation of ~ 45% the total cell population (Figure 4.15).
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Figure 4.15: The effect of vinblastine treatment on cell viability as determined by analysis of total
cell area using the Incucyte ZOOM Live-Cell Analysis System. Data represent the mean ± SEM (n =
4).

MDA-MB-231 cell growth was also monitored in real time using the Essen Biosciences Incucyte
ZOOM Live-Cell Analysis System, which allowed real time evaluation of the effects of the
compound combinations on cell confluency (Figure 4.16). An immediate and potent cytotoxic
response was observed with 5 M 42, both alone and in combination with vinblastine (Figure 4.14
A & B, 4.16 A). Vinblastine alone showed dose-dependent inhibition of cell growth, with 1 nM and
5 nM concentrations decreasing normalized confluency by 13% and 33%, respectively, after 52 h.
The initial slow growth of cells treated with 5 nM vinblastine suggests the presence of a resistant
population of cells, as an appreciable increase in normalized confluency was not seen until 18 h
post-treatment.

No cytotoxic effect relative to control was seen for 42 at 1 M. The combination of 1 M 42 with
1 nM or 5 nM vinblastine resulted in 20% and 10% decreases, respectively, in normalized
confluency at 52 h relative to cells treated with vinblastine alone (Figure 4.16A). No cytotoxic
effect was observed for the pyrimidine-based compound 49 at the highest concentration tested (5
M, Figure 4.16 B).
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Figure 4.15: Real time analysis of the effects of vinblastine/6-HMA analogue combinations on
MDA-MB-231 cell growth. Representative images from each treatment group were acquired every
2 h under a 10X objective using the Incucyte ZOOM Live-Cell Analysis System. All data are
normalized relative to their respective confluence at time point zero (~ 30 min after initial drug
treatment).
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No significant effects of 49 in combination with vinblastine were observed, with confluency
tracking closely relative to cells treated with vinblastine alone. Data from combinations of
vinblastine with 0.25 M 42 and 49 were omitted due to their similarity to that obtained with the
compounds present at 1 M.

Phase contrast photomicrographs taken 52 h post-treatment illustrate the effects of
42/vinblastine combinations on MDA-MB-231 morphology (Figure 4.17). Cytotoxic effects of 42 at
5 M are evident in panels A-C, where the remaining cells show greatly reduced cell area, rounded
appearance and high granularity. Lower doses of 42 did not alter morphology relative to vehicle
treated controls. Cells treated with 1 M or 0.25 M 42 in combination with 5 nM vinblastine
displayed a smaller, more rounded morphology and decreased cell number relative to cells treated
with 5 nM vinblastine alone. Cells treated with 1 nM vinblastine in the presence 1 M or 0.25 M
42 showed a similar appearance to matched combinations at 5 nM vinblastine, albeit with slightly
increased cell area. Vinblastine alone at 5 nM and 1 nM induced cells towards a tightly packed
‘cobblestone-like’ appearance compared to control cells, which displayed a more elongated and
polarized morphology.

In general, the vinblastine/6-HMA analogue combinations did not show notable potentiation
relative to vinblastine-treated MDA-MB-231 cells. The modest potentiation of 5 nM vinblastine by
42 may be anomalous as the readout for cells treated with this dose of vinblastine alone appears
to be high relative to similar treatments in matched experiments (Figure 4.14A rightmost black bar
c.f. 4.14 B-D).
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Figure 4.16: Phase contrast photomicrographs of MDA-MB-231 human breast adenocarcinoma cells treated with combinations of 6-HMA analogue
42 and vinblastine. Representative images from each treatment group were acquired 52 h post-treatment under a 10X objective using the Incucyte
ZOOM Live-Cell Analysis. Yellow bars represent scale (100 m).
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Paclitaxel is an atypical antimitotic agent used in the treatment of aggressive cancers, including
ovarian and breast.317,318 In contrast to microtubule destabilizing drugs like vinblastine, paclitaxel
promotes formation of -tubulin heterodimers upon binding to -tubulin, causing the
stabilization of microtubules and consequent cell cycle arrest during late G2 or M phase. 94
Paclitaxel in combination with cisplatin is a standard therapy for patients with triple-negative and
HER2+ metastatic breast carcinomas who have relapsed following first line chemotherapy.96,319
NHE1 downregulation by paclitaxel via the PKA/p38 MAPK signaling pathway is thought to be a
mediator of proapoptotic effects of paclitaxel.99 NHE1 inhibition by the 5-substituted amiloride
analogue DMA 28 has been shown to increase paclitaxel-induced cell death in MDA-MB-435
melanoma-like cells.99,320

More recently, low dose HMA (10 nM) was shown to potentiate the cytotoxic and anti-migratory
effects of paclitaxel in aggressive, hormone receptor triple-negative MDA-MB-231 breast
adenocarcinoma cells.112 Similar results were reported using the NHE1 specific inhibitor EMD
87580 (Rimeporide), supporting NHE1 inhibition as the mechanism underlying potentiation. Given
the relevance to this thesis work, combinations of 6-substituted HMA analogues, HMA and the
NHE1-specific inhibitor cariporide with paclitaxel were investigated for their effects on MDA-MB231 cells.

As found previously, 5 M concentrations of 2-benzofuranyl analogues 42 and 43 caused
immediate and complete cell death, when administered alone and in combination with 0.5 nM or
5 nM paclitaxel (Figure 4.18). No cytotoxicity was observed in cells treated with the 5-pyrimidinyl
analogues 48 or 49 (5 M), HMA (5 M) or cariporide (1 M).
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Disappointingly, no potentiation of paclitaxel cytotoxicity was observed in combination with HMA,
6- HMA analogues or cariporide at any of the concentrations tested (Figure 4.18).

Figure 4.17: Effects of paclitaxel/6-HMA analogue combinations on MDA-MB-231 cell viability.
MTS assays were conducted as described in Figure 4.14.
Cell viability assays using real-time analysis of cell growth following compound/combination
treatments showed that 43 and 49 produced no synergistic effects when used with paclitaxel
(Figure 4.19). Similar results seen with the 6-HMA analogues 43 and 49, co-administration of
cariporide did not potentiate paclitaxel induced cytotoxicity.
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Combinations of HMA with paclitaxel were found to show the greatest effects on cell confluency
(Figure 4.20). Normalized confluency decreased ~ 20% in cells receiving 5 nM paclitaxel + 5 M or
1 M HMA relative to cells treated with 5 nM paclitaxel alone. Greater effects on confluency were
observed for 0.5 nM paclitaxel combinations with 1 M HMA or 5 M HMA, where 23% and 30%
reductions in confluency were seen, respectively. These effects on confluency did not coincide
with decreases in cell viability, as shown for HMA in Figure 4.18F. Data from 43, 49 and HMA at
0.25 M +/- paclitaxel were omitted due to similarity with to data obtained at 1 M.
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Figure 4.18: Real time analysis of the effects of Paclitaxel/6-HMA analogue combinations on MDAMB-231 cell growth. Images were acquired as described in Figure 4.15.

It is challenging to understand why we were not able to reproduce results similar to those
reported by Amith et al. with HMA and MDA-MB-231 cells.112 Misidentification of the cell line used
for the assays was ruled out using short tandem repeat analysis of cell DNA (92.8% match to ATCC
standard c.f.; 95% match for cells used in reference 112, L. Fliegel personal communication).
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Figure 4.20: Real time analysis of the effects of paclitaxel/HMA or paclitaxel/cariporide
combinations on MDA-MB-231 cell growth. Images were acquired as described in Figure 4.15.

One difference between experimental protocols, however, was the use of far greater compound
concentrations in our experiments relative to those reported for HMA (10 nM). Intuitively, it
would be expected that synergistic effects of HMA or 6-HMA analogues with paclitaxel should be
larger at higher concentrations. To rule out the possibility that synergy is only observed at low
concentrations, HMA 42, 48 and 49 were examined at 25 nM in combination with paclitaxel at 0.5
nM (Figure 4.21).
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Figure 4.219: Effects of low-dose combinations of HMA and analogues 42, 48 and 49 with
paclitaxel on cell viability in MDA-MB-231 cells. Assays were conducted as described in Figure
4.14.

No significant effect was observed for any compound, either alone or in combination with
paclitaxel, relative to vehicle treated control cells.

4.5 Inhibitory effects of 6-HMA analogues on ENaCs
The diuretic and antikaliuretic properties of amiloride arise through inhibition of epithelial sodium
channels (ENaCs) in the distal nephron of the kidney.189 Loss of ENaC inhibitory effects upon
substitution at the amiloride 5-position have been documented with alkyl substitution of the 5NH2 group resulting in large decreases in potency.242 As diuretic and antikaliuretic activities would
be undesirable in an anticancer drug, a key hope in this project was to establish that substitution
of HMA at the 6-position would produce compounds that lack activity against ENaCs. Amiloride,
HMA and a representative subset of 6-HMA analogues were screened for inhibitory activity
against HEK-293 cells that transiently express the ,  and  subunits of Human ENaC (Figure 4.22).
The assays used a fluorescent membrane potential dye kit and an automated fluorescence plate
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reader (FLIPRTETRA, Molecular Devices, Sunnyvale, California, USA). The experiments were
performed under contract by Charles River Laboratories, Cleveland, Ohio, USA. My role was to
liaise with the company, advising on compound solubility and other experimental parameters.

Figure 4.20: Inhibition of ENaC activity in ENaC-overexpressing recombinant HEK-293 human
embryonic kidney cells. All cells were stimulated with ENaC agonist S3969. All compounds were
present at 10 M. Data were normalized to uninhibited (0%) and benzamil treated (ENaC
antagonist, 100%) controls. Data represent the mean ± SD (n = 4).

Substitution of the 6-position of HMA had no effect on ENaC activity, with HMA and all 6-HMA
analogues showing similar effects (12-21% inhibition). In comparison, amiloride showed 68%
inhibition at the same concentration. The results clearly demonstrate that 6-HMA analogues retain
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the low ENaC potency previously noted for HMA. As such, it is unlikely that 6-HMA analogues
would display the antikaliuretic and diuretic properties of amiloride in vivo. This is a key finding in
this work as it implies that if anticancer therapeutics were eventually developed from this class
they would be unlikely to carry the potentially life-threatening cardiac effects associated with K+
retention, as observed with amiloride overdose.
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4.6 Summary and conclusions
Cell viability and proliferation assays conducted with a variety of human and murine cell
lines revealed a large difference in the intrinsic cytotoxicity of compounds from the two lead
classes of 6-HMA amiloride analogues. In general, members of the 2-benzofuranyl class (42
and 43) showed greater in vitro cytotoxic effects than the 5-pyrimidine analogues (48, 49
and 50) with complete cell death observed for compounds 42 and 43 at concentrations as
low as 5 M. In contrast the 5-pyrimidines showed no significant effects on cell viability up
to 100 M against the majority of human cell lines. In the case of 42, caspase 3/7 activity
assays revealed that the cytotoxicity observed with this class was mediated through
induction of apoptosis.

2-Benzofuranyl analogue 42 showed modest inhibition of SKOV-3 cell invasion in a 3D
organotypic cell invasion model. Potentiation of the cytotoxic effects of the standard
chemoptherapy drugs vinblastine and paclitaxel was not observed with analogues from
either lead class. A selection of 6-substituted analogues, including representatives from both
lead classes, were found (like HMA) to not inhibit ENaC, providing evidence that the diuretic
effects of the parent amiloride had been removed.

Taken together, these findings show that compounds from both lead classes do not possess
potent cytotoxic effects and are unlikely to show diuretic activity in vivo. As such, they are
well suited for further investigation as potential non-cytotoxic antimetastatic candidates.

159

CHAPTER 5: Development of a 96-well plate-based assay for
measuring NHE1 inhibition

5.1 Introduction
Na+/H+ exchange activity has been measured using a variety of techniques, including 22Na+flux, patch clamping, atomic absorption spectroscopy (AAS) and fluorescence-based
methods.321-323 The major disadvantages of radiometric, electrophysiological and AAS
approaches are the requirement for expensive, specialist equipment and expertise and low
throughput. Confocal microscopic and flow cytometry-based fluorescence methods suffer
from similar limitations.324,325 Fluorescence plate readers, on the other hand, are designed
for high sample throughput (up to 1536-well capability in some cases) and are common
instruments in academic and industrial cell biology laboratories. The development of a new
plate-based method for medium throughput screening of compounds for NHE1 activity
would constitute a significant contribution to the field. This chapter describes the first
reported 96-well plate-based fluorescence assay for the quantitation of NHE1 activity and
inhibition in the presence of antagonists.

5.2 Fluorescence plate assay and comparison to gold standard
Fluorescence-based methods for measuring NHE1 activity have typically used the ratiometric
dye

(2’,7’-Bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein

(BCECF).

The

poly

acetoxymethyl ester form (BCECF-AM) is able to diffuse across plasma membranes and enter
the cytosol, where it is cleaved by non-specific esterases to an active, charged form that
becomes trapped within cells. The pH sensitivity of the fluorescence properties of the
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‘trapped’ BCECF allows dynamic measurement of changes in pHi. pHi can be calibrated by
exposing dye-loaded cells to buffer solutions at set pH values containing the membrane
permeable H+ ionophore nigericin. Nigericin acts to shuttle protons across the cell
membrane, causing rapid equilibration of pHi with pHe, and allowing the creation of a
standard curve. BCECF features pH-sensitive and insensitive (isobestic point) fluorescence
excitation maxima at 500 nm and 439 nm, respectively, and an emission maximum at 535
nm (Figure 5.1).

Figure 5.1: Excitation spectra of BCECF showing the pH sensitivity across the physiological
range of its maximum at ~ 500 nm. Excitation at 500 nm increases with increasing pH. pHinsensitive isobestic point is present at 439 nm (shown at 10x magnification). Adapted from
Molecular Probes BCECF Technical Manual.

Using dual-excitation with single emission measurements, ratiometric calculations (e.g. pH
sensitive signal/isobestic signal) are able to be employed to correct for sample variability;
e.g. degree of dye loading, activity of esterases, photobleaching etc.326
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Fluorescence plate reader assays utilizing the pH-sensitive ratiometric dye BCECF to measure
intracellular pH have been reported with a variety of cell types, including S. pneumoniae
(bacteria), S. cerevisiae (yeast), Trypanosoma (parasitic protist) and primary and established
mammalian epithelial cells (Obexer et al., 1997).327-330 Of these reports, Obexer et al. 1997 is
the only example that exploited the high throughput capacity of a multiwell plate reader.
This report used BCECF-AM to screen a library of anti-trypanosomal compounds and
determine IC50 values.

In addition to assays using standard fluorescence plate readers, there have been reports
using a proprietary automated fluorescence plate reader (FLIPR) to measure NHE activity.
The FLIPR High-throughput Cellular Screening System (Molecular Devices, Sunnyvale,
California, USA) is a robotically controlled fluorescence plate reader specifically designed for
screening compound libraries against transmembrane ion channels and GPCR targets.
Despite the FLIPR system being well suited to the aims of this work, its prohibitive cost
(+$800K AUD) limits broad uptake (G. Monteith, personal communication). To our
knowledge, a straightforward assay for quantitating NHE1 inhibitory potency of compounds
in adherent mammalian cells using commonly available fluorescence plate readers has not
been described.

Validation of the novel plate-based assay required comparison of the data produced to data
derived from currently accepted standard methods. To obtain such validation, a
collaboration was established with Prof. Larry Fliegel at the University of Alberta, Canada, an
internationally renowned expert in the molecular and cellular biology of NHE1.189,192,331,332
The Fliegel lab uses a traditional cuvette-based fluormetric method for determination of
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NHE1 activity in adherent cell monolayers. This method is considered ‘gold standard’ for the
evaluation of NHE1 inhibitor potency and is used by Prof. Fliegel in a number of active
collaborations with groups developing NHE1-targeting compounds within academia and
industry. Figure 5.2 shows a pHi calibration trace as it varies in response to different
treatments throughout an experiment conducted using the Fliegel fluorimeter protocol.
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Figure 5.2: pHi calibration trace for MDA-MB-231 breast adenocarcinoma cells using a
fluorimeter-based NHE activity assay. Figure adapted from reference 112. See text for
details.

Cells are initially exposed to Na+-containing buffer, allowing them to equilibrate pHi to a
resting state value (1). Introduction of NH4Cl to the buffer causes immediate alkalinization of
pHi (2), as NH3 rapidly enters the cell and establishes a new NH3 ⇄ NH4+ equilibrium as NH3
molecules sequester H+ in the cytosol. This transient alkalinization diminishes over time
extracellular NH4+ crosses the plasma membrane. This process is orders of magnitude slower
than NH3 passage due the species positive charge. Switching the buffer quickly to a Na+free/NH4Cl-free solution causes rapid acidification of pHi (3) as NH3 rushes out of the cell
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down its concentration gradient. The absence of Na+ in the system deprives NHE1 of the Na+
gradient necessary to drive NHE1-mediated translocation of intracellular H+, thus preventing
recovery of pHi. Reintroduction of Na+ (4) to the buffer switches on NHE1 activity, restoring
pHi to a new steady state within minutes.128

The fluorometric method involves culturing adherent epithelial cells on cell culture treated
coverslips in complete media. Once 80% confluence is achieved, cells are serum starved
(cultured in 0.2% FCS-containing media) for approximately 24 h to stimulate NHE1 activity.
Cells are then incubated for 20 min with the cell membrane-permeable fluorescent dye
BCECF-AM. After dye loading, the coverslips are transferred to a custom-made glass cuvette
designed to position the cell monolayer in the light path of a fluorimeter (PTI Deltascan
Illumination System, Photon Technology International, New Jersey, USA). The cuvette is
filled with Na+-containing assay buffer for 3 minutes, allowing the cells to equilibrate pH i
through the action of NHE1. Cells are then subjected to a transient acid load with a pulse of
NH4Cl (50 mM) before being transferred to a second cuvette containing Na+-free media. This
results in a rapid decrease in pHi as NH3 diffuses out of the cells. pHi remains acidic until Na+
is reintroduced, causing NHE1 function to be restored and returning pHi to resting values.
Following NHE1-mediated pH recovery, intracellular pH signal is calibrated by sequentially
equilibrating the cells in nigericin-containing buffers at set pH values. By measuring initial
recovery of pHi in the presence of different concentrations of inhibitors, dose-response
curves can be plotted and IC50 values for inhibition of NHE obatined.

A plate reader assay could follow the same general principles with key modifications to
adapt the assay to a 96-well plate format. All liquid addition steps were performed using a
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multichannel air-displacement pipette. Liquids were removed by vigourously shaking out the
plate into a receptacle followed by visual inspection of wells to ensure total removal of
liquids. A schematic overview of the assay is presented in Figure 5.3.

Figure 5.3: Summary of fluorescence plate assay for determining NHE activity/inhibition.

Cells were plated at a density of 2x104 cells/well in black cell culture-treated 96-well plates
and cultured in RPMI 1640/10%FCS for ~ 42 h to ensure formation of a confluent monolayer.
On the day of experiments, cells were starved for 3-4 h in low serum (0.2% FCS) media. Cells
were then loaded with 5 M BCECF-AM in serum-free media and incubated for 30 min. The
dye solution was then removed and cells washed once with 100 L Na+-containing buffer
and equilibrated for 3 min with additional Na+-containing buffer (Step 1). The buffer was
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then replaced with Na+-containing buffer containing 50 mM NH4Cl and equilibrated for 3 min
(Step 2). NH4Cl-containing buffer was replaced by 100 L Na+-free buffer, decreasing pHi as
NH3 diffuses out of the cell (Step 3). Compounds diluted in Na+- containing buffer in a
separate 96-well plate were then added allowing measurement of NHE1-driven recovery in
the presence or absence of inhibitors. (Step 4, n = 3 wells for each compound
concentration). Intrinsic fluorescence of compounds was corrected for by including
identically treated dye-free control cells at each compound concentration. Finally, control
cells were successively equilibrated using nigericin-containing buffers at set pH values (Steps
5-7), allowing initial rates of recovery (pH/s) to be calculated for each compound
concentration with normalization against untreated control cells. Throughout Steps 1-7
readings were obtained using a POLARstar Omega Fluorescence plate reader with the
settings outlined in Table 5.1

Table 5.1: POLARstar OMEGA settings used for plate-based NHE1 inhibition assays.
Setting
Measurement type
Read Mode
No. of cycles
Cycle time
Scan mode
Scan diameter/No. flashes
Filter settings
1. pH-sensitive couple
2. Isobestic couple
Assay Temperature

Value
Fluorescence Intensity, top optic
Plate, multichromatic
1-3 dependent on step
107 seconds
Orbital averaging
1 mm/ 8 flashes per well
Excitation
Emission
Gain
1. 485 ± 12 520 nm
1450
nm
2. 440 nm
520 nm
1450
37 C

In addition to Na+/H+-exchange, HCO3-driven processes (e.g. Cl-/HCO3- exchanger and
Na+/HCO3- co-transporters) are also contributors to transmembrane pH homeostasis.130
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Dependence on HCO3- or Na+-driven processes for regulating transmembrane pH has been
shown to vary between established neoplastic cell lines, with some lines displaying a
preference for one pathway over the other.132 MDA-MB-231 breast adenocarcinoma cell
were chosen for this work due to their reliance on Na +/H+-exchange driven regulation of
pHi.112,333 MDA-MB-231 cells also express NHE1 exclusively over other plasma membrane
NHE isoforms (L. Fliegel, personal communication). HCO3-driven contributions to pH
recovery were negated by using HCO3--free solutions in all experiments. Identical buffer
compositions were used in all experiments across both NHE1 measurement techniques
(Table 5.2).

Table 5.2: Composition of buffers used in NHE1 activity assays. The membrane-impermeant
N-Methyl-D-glucamine was used in place of Na+ to maintain isotonicity in Na+-free buffers.
Buffer
Na+-containing buffer
Na+/NH4Cl-containing buffer
Na+-free buffer

pH calibration buffer

Composition
135 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 1
mM MgSO4, 5.5 mM glucose, 10 mM HEPES.
135 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 1
mM MgSO4, 5.5 mM glucose, 10 mM HEPES,
50 mM, NH4Cl.
135 mM N-methyl-D-glucamine, 5 mM KCl,
1.8 mM CaCl2, 1 mM MgSO4, 5.5 mM
glucose, 10 mM HEPES.
5 mM N-methyl-D-glucamine, 135 mM KCl,
1.8 mM CaCl2, 1 mM MgSO4, 5.5 mM
glucose, 10 mM HEPES, 2 M nigericin.
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5.3 Results
A representative pH calibration curve obtained from the successive equilibration of vehicle
control cells in nigericin-containing buffer at pH 6-8 is presented in Figure 5.4. By performing
linear regression analysis on the respective fluorescence ratios (pH sensitive signal/isobestic
signal) at each pH, an equation relating pHi to the observed fluorescence ratio was derived.
Using the equation, observed fluorescence ratios were converted to discrete pH values,
allowing determination of pH/s for each sample. Calibration was performed each time in
each Individual assay to account for interassay variations.

Figure 5.4: Representative pH calibration curve from fluorescence plate reader assay.
Fluorescence ratios from pH sensitive/isobestic signals were determined for control cells
equilibrated in nigericin-containing buffers at different pHs. Linear regression analysis was
performed and the resulting linear equation used to calibrate fluorescence ratios relative to
pHi. Data represent mean  SEM (n = 6).

Data were obtained from both the plate-based and traditional cuvette assays and doseresponse curves were calculated using GraphPad PRISM 6.0v. Representative dose-response
curves from the two assay types are presented in Figure 5.5.
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Figure 5.5: Representative dose response curves for standard NHE1 inhibitors from A)
cuvette and B) fluorescence plate reader assays. Data represent: A) mean  SEM (n = 3-4); B)
mean  SEM (n = 3). MDA-MB-231 cells were used in all assays. Fluorescence measurements
were obtained using: A) PTI Deltascan Illumination System (Photon Technology
International, New Jersey, USA) B) POLARstar OMEGA Fluorescence Plate reader (BMGLabtech). Data were analyzed using Graphpad PRISM v.6.0 and fitted using log inhibitor vs
normalized response – variable slope algorithm to calculate IC50 values. Data in A) was
provided by J.Wilkinson (Fliegel Lab), University of Alberta, Canada.

IC50 values obtained for selected 6-HMA analogues and known NHE1 inhibitors using each
technique are provided in Table 5.3. Goodness of fit analysis of curves generated from the
two assay types revealed that the fluorescence plate technique generally yielded more
sigmoidal dose-response relationships (fluorimeter R2 range: 0.5745-0.8326, mean: 0.7009 n
= 6; plate R2 range: 0.7553-0.9580, mean: 0.8877, n = 5). Standard errors of the mean for
each data point were found to be significantly lower in the plate-based assay compared to
the fluorimeter assay (fluorimeter SEM range: 1.71%-18.46%, Plate SEM range: 0.81%11.10%; mean Fluorimeter SEM = 7.866 ± 0.6912, n = 37, mean plate SEM = 4.070 ± 0.4663,
n = 28, p <0.0001).
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Table 5.3: Comparision of inhibitory potencies of amiloride, HMA, selected 6-HMA
analogues and known NHE1 inhibitors (EMD87580 and cariporide) as determined using
traditional cuvette and plate-based fluorometric assays in MDA-MB-231 breast
adenocarcinoma cells. N/D = not determined.
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Concordance between IC50 values and order of NHE1 inhibitory potencies among the 6-HMA
analogues obtained from the two assays was not evident. HMA and 2-benzofuranyl analogue
42 were found to be nearly equipotent in the cuvette-based protocol (IC50 = 523 nM vs. 553
nM), whereas HMA was 3.9-fold more potent (IC50 = 240 nM) then 42 (IC50 = 932 nM) in the
plate-based method. Poor agreement was observed between assays for 5-pyrimidinyl
analogue 48, which appreared as the most potent 6-HMA analogue via the cuvette assay
(IC50 = 397 nM) but showed 5-fold lower activity in the plate assay (IC50 = 2,046 nM). Good
agreement between both techniques was observed, however, for the p-methoxy-5pyrimidinyl analogue 49, the least potent NHE1 inhibitor of the series (IC50cuvette = 21,512 nM
vs IC50plate = 19,650 nM).

A wider selection of 6-HMA analogues were subsequently screened for NHE1 inhibition at a
single concentration (10 M) as a way of quickly identifying active compounds (Figure 5.6).
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Figure 5.6: Inhibition of NHE1 activity in MDA-MB-231 cells using the plate-based assay. All compounds were present at a single concentration
(10 M). Data represent the mean  SEM (n = 3-6). Normalized data were pooled across multiple assays.
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Results from the single concentration assays revealed similar trends to those observed in the
fluorimetric and plate-based dose-response assays. In agreement with the plate-based
experiments, HMA was the most active inhibitor. 2-Benzofuranyl analogue 42 showed ~ 2fold lower activity than HMA. Fluorination at the 4-position of the benzofuran to give 43
decreased activity a further 2-fold. Substitution of the furanyl oxygen with S to give
benzothiophene 41 or NH indole 40 decreased inhibition 2- to 3-fold relative to 42. 2-Furanyl
and 3-furanyl isomers 46 and 47 showed only slightly decreased activity relative to HMA (~ 2
to 3-fold). In contrast, pyrazole compound 38 was ~ 10-fold less active than HMA.

As noted in the fluorimetric dose-response experiments, 5-pyrimidinyl analogue 48 showed
strong activity and was, being equipotent with HMA. p-Methoxy substitution of the
pyrimidine to give 49 decreased activity considerably (~ 7-fold). Trifluoromethylphenyl 35,
3,5-dimethoxyphenyl 54, 2,4-dimethoxypyridinyl 51 and 2,5-dimethoxypyridazinyl 55
derivatives all showed some activity at 10 M. Isoquinolinyl analogue 37 was a poor
inhibitor, as was p-methoxypyrimidinyl analogue 49. The 6-phenylethynyl analogue 56
showed the lowest activity, being ~ 15-fold less potent than HMA.

These results provide the first insights into SAR at the 6-position of HMA against NHE1.
Generally speaking, substitution with 2-benzofuranyl (42 and 43) or 5-pyrimidinyl
substituents (48) was well tolerated, with potency varying within 2-fold of HMA in the
cuvette-based assay. Substitution of 48 with a single methoxy group between the two
pyrimidine nitrogens to give 49 resulted in a remarkable decrease in NHE1 inhibitory
potency (IC50cuvette = 21,512 nM, ~ 55-fold loss relative to 48). Compounds 42 and 43 both
feature bulky benzofuran moieties at the 6-position, which would project beyond the region
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of space occupied by the p-methoxy group of 43. As such, it is unlikely that the deleterious
interactions formed by the p-methoxy group are purely steric. This supposition, of course,
assumes that the two compounds adopt similar poses in the NHE1 binding site.

5.4 Discussion
Increased sample throughput enabled by the 96-well plate assay format for NHE1 inhibitor
screening is a major advantage relative to the labour and time-intensive cuvette assay,
where maximum throughput for a skilled worker generates IC50 determinations for 2
compounds per day only (n = 3-4 replicates at each concentration, L. Fliegel personal
correspondence). In contrast, 7-point dose-response curves (n = 3 at each concentration)
can be obtained by a single person for 8+ compounds per day using the plate-based
technique. Throughput could be further increased to 14 compounds in triplicate per plate (~
112 per day) at a single concentration (for screening purposes) without alterations to the
protocol.

NHE1-mediated recovery of pHi begins almost instantaneously upon reintroduction of
extracellular Na+ following NH4Cl acid challenge. Ideally, rates of pHi-recovery should be
determined from the linear portion of plots comparing pHi versus time. The manual addition
of solutions via a standard 8-channel pipette creates a delay in time between each preceding
row of cells, reaching a total of ~ 45-60 sec between rows A and H. This delay is accounted
for by configuring the reader to reach each row in the order A-H in a left to right fashion.
Nevertheless, NHE1 will have been active for between 45-60 sec before initial readings are
obtained for any well. A second read is required to calculate the rate of pH recovery, which
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occurs 107s after the initial read. It is possible that pHi recovery may have started to plateau
by this point and, as such, rates calculated may not be truly representative of the initial
(linear) rate period.

This potential shortcoming might be mitigated by conducting experiments on unstimulated
cells under standard serum concentrations (5-10% FCS), as serum starvation increases NHE1
activity and hence the rate of pHi recovery. The rate of pHi recovery is likely to be cell line
dependent and vary with the conditions used. Efforts should thus be made to measure
baseline rates of NHE activity when optimizing the assay for new cell types. The traditional
fluorimeter protocol does not suffer from this issue as pHi recovery is measured immediately
and continuously after reintroduction of Na+, allowing a real-time analysis of recovery
kinetics.

A confluent cell monolayer was found to be essential for cell adherence throughout the
assay. Seeding density was optimized to ensure confluence on the day of experimentation (~
42 h post seeding). An appropriate shakeout technique was also crucial as residual liquid in
wells were found to increase variability in the signals. Liquid removal via multichannel
pipette was trialed but found to be too slow. Pipetting must be performed such that all
replicates of a particular sample receive solutions at the same time to prevent staggering of
equilibration/pHi across a treatment group. The time taken to add Na+-containing
buffer/drug dilutions to wells must also be kept to an absolute minimum to prevent large
differences in the start time of pHi recovery.
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When using the ‘plate multichromatic’ read mode, the plate is first read using the pHsensitive filter couple, which is followed by a second read cycle using the isobestic filter
couple. The time lag between reading a particular well using each filter couple (~ 30-50s
depending on the exact protocol used) is inconsequential given the static nature of the
isobestic signal across the relevant pH range. This was verified using the alternative ‘well
multichromatic’ read mode, in which each individual well is read rapidly using both filter
couples prior to moving to the next well. While this approach decreases the potential for
changes in the sample that may accrue over time it was not used because of the large
increase in time per read cycle relative to the ‘plate multichromatic read mode’.

The limitations due to reliance of this assay on manual handling for the addition and removal
of buffers were apparent. As such, automation of these steps using liquid handling robotics
would likely improve the accuracy and reproducibility of NHE1 activity measurements. The
Illawarra Health and Medical Research Institute (Ranson Lab) has recently acquired a
Molcular Devices FlexStation 3 Multimode plate reader. The FlexStation 3 is a multimode
fluorescence/luminescence plate reader with an integrated liquid handling microfluidics
system capable of automating all liquid addition steps in the assay. Use of the FlexStation 3
should allow for a large increase in data density as the minimum time needed to read plates
at both wavelengths is ~ 30s (c.f. 107s for the POLARstar assay). These advantages may
support the POLARstar system as the preferred platform for performing this assay. Efforts to
optimize the assay for use with the FlexStation 3 are targeted for the near future.
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In conclusion, the protocols described in this chapter constitute a novel, straightforward and
affordable means for medium-throughout determination of NHE1 inhibition by small
molecule antagonists.
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CHAPTER 6: Thesis conclusions and Future Directions
The potassium-sparing diuretic drug amiloride shows robust anticancer activities in animal
models. We proposed that this anticancer side activity arises from amiloride’s moderate
inhibition (low M) of two unrelated biological targets; the pro-metastatic serine protease
uPA and the Na+/H+ exchanger isoform 1 (NHE1), a key driver of oncogenic transformation.

The primary aim of this work was to develop novel (and patentable) uPA/NHE1 dualtargeting amiloride analogues suitable for advancement towards anticancer drugs. A library
of 24 6-HMA analogues was successfully synthesized and evaluated, with compounds
showing sub-M potency against uPA identified. As it was unknown whether substitution at
the 6-position would affect the high potency of HMA against the pro-carcinogenic ion
channel NHE1, a secondary aim was to evaluate whether 6-HMA analogues retained activity
against this target.

Development of novel synthetic methodology allowed the expeditious generation of
structurally diverse 6-heteroaryl-HMA analogues. Recent efforts in the Kelso laboratory have
led to the development of a superior acyl guanidinylation method utilizing a 2M solution of
free guanidine in MeOH with DMF as solvent. Final products were easily obtained in good
yields as the free base form without the need for further purification, avoiding costly amd
labourious preparative HPLC.
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Evaluation of the uPA inhibitory potency of these compounds via enzyme activity assays
identified 15 analogues with improved potency over the parent HMA, with gains ranging
from 1.03 to 32-fold. From these, active analogues, two physicochemically diverse lead
classes; the 2-benzofuranyl and 5-pyrimidinyl analogues (exemplified by compounds 42 and
49 respectively, Figure 6.1) were further examined in enzyme selectivity and cell assays.

Figure 6.1: Properties of lead compounds 42 and 49.

Favourable cytotoxicity profiles for both lead classes were seen across a variety of human
and murine cell lines. Preliminary organotypic cell invasion assays demonstrated the ability
of 42 to inhibit epithelial cell invasion in a physiologically relevant context. X-ray cocrystallographic analysis of uPA:6-HMA analogue complexes enabled the rationalization of
SAR trends and shed light on the structural requirements for favourable occupancy of the
S1 subsite by 6-substituents on analogues.

Development of a novel fluorescence-based high throughput assay allowed elucidation of
SAR around the 6-position of the HMA scaffold. Excitingly, the high potency of HMA against
NHE1 was maintained in several 6-substituted analogues, with the exception of 49, which
represents a selective uPA inhibitor (uPA IC50 = 86 nM; NHE1 IC50 = 21 M). This new

179

technique will soon be submitted for publication, providing the NHE1 drug discovery
community with a rapid and straightforward method for the screening of compounds
against this important target.

The work has satisfied the aims described in Chapter 1 and provides a wealth of exciting
avenues for future research. Analogues from both lead classes met activity, selectivity and
toxicity endpoints necessary for entry into in vivo efficacy models. In addition to the
discovery of leads with dual uPA/NHE1 potency, identification of p-methoxypyrimidine
analogue 49, which shows activity only for uPA (not NHE1), provides scope for the
examination of truly uPA selective pharmacological probes. This separation of uPA/NHE1
activity for members of the amiloride class is a significant advance given the abundance of
reports using amiloride and its 5-substituted analogues to study diverse physiological
phenomena and the potential of these activities, namely inhibition of uPA and NHE1, to
simultaneously effect the processes studied. We hope to make these improved probes
available to the broader research community.

It is worthwhile noting that while this work satisfied aims, the medicinal chemistry described
herein is by no means exhaustive. Further work could involve synthesis of an expanded
library of 6-HMA analogues using the Suzuki-Miyaura and other transition metal-catalyzed
cross-coupling chemistries (e.g. Sonogashira chemistry, as well as ‘click’ chemistry), with the
goal of expanding the set of active analogues against both targets with varying ADMET
properties.
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This project formed part of a larger campaign focused on the development of novel dualtargeting anticancer and anti-tuberculosis compounds from amiloride. Parallel efforts from
other group members have resulted in the generation of analogous 6-substituted and 5,6disubstituted amiloride analogues that possess similar activity, selectivity and toxicity
profiles to those described herein. Competitive grant funding from the Australian National
Health and Medical Research Council and the Health Research Council of New Zealand has
provided the resources necessary to advance development of promising 6-AML and 6-HMA
analogues. Recent in vivo ADMET experiments revealed that compounds 42 and 49 possess
desirable pharmacokinetic parameters (e.g. plasma t1/2 3-7 h, favourable Vds, no indication
of acute toxicities etc.), with some compounds showing similar profiles to amiloride.
Pharmacokinetic parameters will be used to inform dose scheduling for in vivo efficacy
experiments planned over the next 6-18 months.

In vitro studies confirmed that the 6-HMA and 6-AML analogues are not active against ENaC,
the diuretic and antikaliuretic target of amiloride, suggesting success in our efforts to
selectively optimize amiloride’s side activity with loss of the original clinically-relevant
interaction. Studies to confirm the lack of effect of these leads on urinary Na +/K+ levels in
animals will commence shortly.

In vivo anticancer activity of 42 and 49 will be evaluated using orthotopic xenograft models
of pancreatic and breast (highly uPA/uPAR overexpressing) metastasis in mice, as well as in a
spontaneous model of metastatic breast carcinoma. The finding that 6-HMA analogues show
pronounced species specificity, where inhibitory activity is substantially decreased against
the murine enzyme, is a concern for these studies as the lower inhibition of MuPA may lead
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to an underestimation of the anticarcinogenic/antimetatstatic effects. Ultimately, the
species selectivity issue may be redundant as the robust anticancer effects of high-dose
amiloride across various murine cancer models has been repeatedly observed despite
amiloride showing only moderate inhibitory potency against both human and murine uPA
(e.g. low M, similar to the potency of 6-HMA analogues against MuPA). Future work will
involve the design of analogues where interspecies specificity has been addressed, namely 6HMA analogues that replace the 5-azepane ring with smaller groups.

It is hoped that a demonstration of in vivo efficacy will enable selection of genuine preclinical candidates for further study and entry into first-in-man studies within the next 24
months. In addition, it is hoped that the broader research community will relish the
opportunity to screen novel members of a long-studied class of compounds against the
known and undiscovered targets of amilorides. Further elucidation of the SAR around 6substituted amilorides against such targets, may result in the discovery of leads for the
treatment of other disease indications.
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CHAPTER 7: Experimental

7.1 Synthesis – General
Reagents and solvents were used as obtained from suppliers without further purification,
unless otherwise stated. Toluene and N,N-dimethylformamide (DMF) were decanted from a
PureSolv Solvent purification system (InertTechnology Inc., Amesbury, Massachusetts, USA)
immediately prior to use. iPrOH was distilled from BaO powder and stored over 4 Å
molecular sieves under Ar. Boronic acids/pinacol esters were obtained from various
suppliers and used without further purification. All other reagents were obtained from
Sigma Aldrich (St. Louis, MI, USA).

Compounds were weighed using a Sartorius Extend 220g electronic balance (Sartorius AG,
Göttingen, Germany) or an OHAUS Adventurer Analytical electronic balance (Cat. #AX224,
OHAUS Corporation, Parsippany, New Jersey, USA). Solvents were removed in vacuo at RT60 C with a Büchi RotavaporR-200 rotary evaporator (Büchi Labortechnik AG, Flawil,
Switzerland) attached to a Vacuubrand CVC2 vacuum pump (Vacuubrand GmbH, Wertheim,
Germany). Solvent residues were removed in vacuo using a Javac Vector RD-90 double stage
high vacuum pump (JAVAC Pty. Ltd., Homebush, NSW, Australia). Fractions collected from
preparative rp-HPLC purifications were concentrated by lyophilization using a freeze-drying
system consisting of a Christ Alpha 1-4 LOC-1M (MartinChrist GmBH, Osterode am Harz,
Germany) condenser attached to an Alcatel Pascal 2015 SD high vacuum pump (Pfeiffer
Vacuum GmbH, Annecy, France). Analytical thin layer chromatography was performed on
Merck 0.2 mm silica gel 60 F254 coated aluminium plates (Merck Millipore, Massachusetts,
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USA). Compounds on silica plates were visualized under UV light ( = 254 nm). Flash column
chromatography was performed on Merck silica gel 60 (230-400 mesh). All compounds were
purified to >95% purity for biological evaluation using a Waters PLC/DSC LC150 system
(Waters Corporation, Milford, Massachusetts, USA) with dual detection at 254 nm and 210
nm. Purifications were performed using gradient elutions with solvents A (100% H2O, 0.1%
TFA) and B (100% ACN, 0.1% TFA) on a Waters Sunfire PREP C18 OBD 5 µm (dimensions)
column at a flow rate of 20 mL.min-1. Purity analysis of fractions collected was performed
using a Shimadzu CLASS-VP LC10 Analytical HPLC system (Shimadzu Corporation, Kyoto,
Japan) with detection at 254 nm, gradient elutions of solvents A and B on a Waters VisionHT
3 µm C18 column (150 mm x 4.6 mm) and at a flow rate of 0.5 mL.min-1.

Melting points were obtained using a Griffin Analogue Melting Point Apparatus (ThermoFisher Scientific, Waltham, Massachusetts, USA). Electrospray ionization mass spectra were
obtained using a Shimadzu LCMS-2010 (Shimadzu Corporation, Kyoto, Japan). High
resolution electrospray ionization mass spectra were obtained using a Waters XEVO QToF
mass spectrometer (Waters Corporation, Milford, Massachusetts, USA) with leucine
encephalin as the internal standard.

7.2 Compound Characterization
1

H and

13

C NMR spectra were obtained using Varian Inova 500 MHz or Varian Premium

Shielded 500 MHz spectrometers at 25 C. Chemical shift values are reported in  (ppm)
relative to TMS ( 0.00 ppm), internal standards (CDCl3,  = 7.26 ppm) or other residual
solvent peaks. The following abbreviations are used throughout: Ar = aryl, bs = broad singlet,
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s = singlet, d = doublet, t = triplet and m = multiplet, SM = starting material, RM = reaction
mixture and RT = room temperature. All compounds in this work bear several exchangeable
protons attached to nitrogen atoms. The 1H chemical shifts for these protons were
temperature and concentration dependent. Compounds marked with * denote structures
previously described in the literature for which full characterization data was not reported.

Methyl 3-amino-5-(azepan-1-yl)-6-phenylpyrazine-2-carboxylate (33a)*
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32
(101 mg, 3.54x10-4 mol) was combined with K2CO3 (488 mg, 3.53x10-3
mol), phenylboronic acid (65 mg, 5.32x10-4 mol) and Pd(Ph3)4 (21 mg,
18.0x10-5 mol) and the reaction vessel purged with Ar. Anhydrous toluene (12 mL), followed
by MeOH (3 mL) were added via syringe and the mixture heated at reflux for 1 h. TLC
analysis indicated absence of SM and the presence of a UV active spot (Rf = 0.95, 1:4
EtOAc:Pet. spirit) after 1 h. The RM was allowed to cool to RT, vacuum filtered through celite
and washed through with CH3CN (3x20 mL) to remove catalyst. Solvent was removed under
reduced pressure. The crude product was re-dissolved in EtOAc and adsorbed onto silica gel
under reduced pressure. The product was isolated via silica gel flash chromatography (5:95
EtOAc:Hexane) to yield 33a as a light yellow solid (106 mg, 91%). 1H NMR (500 MHz, CDCl3) δ
7.50 (d, J = 7.5 Hz, 2H, ArC2” and ArC6”), 7.38 (t, J = 7.5 Hz, 2H, ArC3” and ArC5”), 7.29 (t, J =
7.5 Hz, 1H, ArC4”), 3.89 (s, 3H, Ester CH3), 3.33 (t, J = 5.75 Hz, 4H, C2’H2 and C7’H2), 1.61 (s,
4H, C3’H2 and C6’H2), 1.47 (s, 4H, C4’H2 and C5’H2). 13C NMR (126 MHz, CDCl3) δ 167.67 (Ester
C=O), 154.99 (ArC5), 153.66 (ArC3), 140.99 (ArC1”), 132.03 (ArC5), 128.63 (ArC3” and ArC5”),
128.09 (ArC2” and ArC6”), 127.52 (ArC4”), 112.45 (ArC2), 52.13 (Ester CH3), 51.12 (C2” and
C7”), 28.11 (C3” and C6”), 27.20 (C4” and C5”). LR ESI-MS (M + H)+ 327.
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Methyl 3-amino-5-(azepan-1-yl)-6-(4-(methylthio)phenyl)pyrazine-2-carboxylate (34a)
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32
(102 mg, 3.60x10-4 moles), (4-(methylthio)phenyl)boronic acid (93
mg, 5.45x10-4 moles), K2CO3 (508 mg, 3.87x10-3 moles)

and

Pd(PPh3)4 (9.9 mg, 1.05x10-5 moles) were added to a round bottom flask. Anhydrous toluene
(12 mL) followed by MeOH (3 mL) were added via syringe and heated to reflux. After 15 min
a UV active spot (Rf = 0.5, 1:4 EtOAc:Pet spirit) was detected via TLC, with disappearance of
SM after 1 h. After 30 min the RM was allowed to cool to RT, stirred for 1 h, filtered through
celite and washed with EtOAc (4x20 mL). Solvent was removed under reduced pressure. The
crude material was dissolved in EtOAc and adsorbed to silica and purified by silica gel flash
column chromatography (gradient elution:2.5:97.5 EtOAc:Pet. Spirit  5:95 EtOAc:Pet.
Spirit) to give 34a as a yellow solid (104 mg, 77%): MP: 132-134° C; 1H NMR (500 MHz,
CDCl3) δ 7.42 (d, J = 8.1 Hz, 2H, ArH3” and ArH5”), 7.25 (d, J = 8.1 Hz, 2H, ArH2” and ArH6”),
6.20 (bs, 2H, Ar3NH2), 3.88 (s, 3H, Ester CH3), 3.36 (t, J = 5.5 Hz, 4H, C2’ H2 and C7’ H2), 2.48
(s, 3H, thioetherCH3), 1.62 (s, 4H, C3’ H2 and C6’ H2), 1.43 (s, 4H, C4’ H2 and C5’ H2);

13

C

NMR (126 MHz, CDCl3) δ 167.42 (Ester C=O), 154.77 (ArC5), 153.43 (ArC3), 137.77 (ArC4”),
137.47 (ArC1”), 131.19 (ArC6), 128.29 (ArC2” and ArC6”), 126.77 (ArC3” and ArC5”), 112.45
(ArC2), 51.90 (Ester CH3), 51.01 (C2’ and C7’), 27.96 (C3’ and C6’), 27.08 (C4’ and C5’) 16.05
(thioetherCH3); HRESI-MS m/z (M + H)+: Calc 373.1698, Obs 373.1688. Anal-HPLC (70:30 A:B/
100% B over 30 min, tr = 36.1 min).
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Methyl 3-amino-5-(azepan-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrazine-2-carboxylate (35a)
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32
(100 mg, 3.53x10-4 mol) was combined with K2CO3 (501 mg, 3.62x103

mol), 4-trifluoromethylphenylboronic acid (100 mg, 5.26x10-4 mol)

and Pd(Ph3)4 (21 mg, 18.0x10-5 mol) and the reaction vessel purged with Ar. Anhydrous
toluene (12 mL), followed by MeOH (3 mL) were added via syringe and the mixture heated
to reflux for 10 min. TLC analysis indicated absence of SM and the presence of a UV active
spot (Rf = 0.90, 1:4 EtOAc:Pet. spirit) after 10 min. The RM was allowed to cool to RT,
vacuum filtered through celite and washed through with CH3CN (3x20 mL) to remove
catalyst. Solvent was removed under reduced pressure. The crude product was re-dissolved
in EtOAc and adsorbed onto silica gel under pressure. The product was isolated via silica gel
flash column chromatography (5:95 EtOAc:Hexane) to yield 35a as a light brown solid (101
mg, 72%): mp 154-156˚C; 1H NMR (500 MHz, CDCl3) δ 7.63 (s, 4H, Ar”Hs) 3.89 (s, 3H, Ester
CH3), 3.34 (s, 4H, C2’H2 and C7’H2) 1.65 (s, 4H, C3’H2 and C6’H2), 1.44 (s, 4H, C4’H2 and C5’H2);
13

C NMR (126 MHz, CDCl3) δ 167.40 (Ester C=O), 154.89 (ArC5), 153.72 (ArC3), 144.58

(ArC1”), 129.42 (ArC2” and ArC6”), 129.16 (ArC3” and ArC5”), 128.23 (ArC4”), 125.58 (ArCF3), 123.35 (ArC6), 113.11 (ArC2), 52.20 (Ester CH3), 51.26 (C2’ and C7’), 28.04 (C3’ and C6’),
27.30 (C4’ and C5’); HRESI-MS m/z (M + Na)+: Calc. 417.1526, Obs 417.1514. Anal-HPLC (100
A:B 100% B over 30 min, tr = 29.3 min).
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Methyl 3-amino-5-(azepan-1-yl)-6-(benzo[d][1,3]dioxol-5-yl)pyrazine-2-carboxylate (36a)
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32
(99 mg, 3.49x10-4 mol), benzo[d][1,3]dioxol-5-ylboronic acid (85 mg,
5.15 x10-4 mol), K2CO3 (486 mg, 3.70 x10-3 mol) and Pd(PPh3)4 (20
mg, 1.70 x10-5 mol) were added to a stoppered two-neck round bottom flask and the flask
was charged with Ar. The flask was fitted to a reflux condenser followed by addition of
anhydrous toluene (12 mL) and MeOH (3 mL) via syringe. The flask was heated to reflux for 1
h. A UV active spot (Rf = 0.75, 1:4 EtOAc:Pet. Spirit) was detected via TLC. After 1 h the RM
was allowed to cool to RT, filtered through celite and washed through with EtOAc (4x20 mL).
Solvent was removed under reduced pressure. The crude material was re-dissolved in EtOAc
and adsorbed to silica prior to purification by silica gel flash column chromatography (2.5
EtOAc:97.5 Pet spirit – 10:90 EtOAc:Pet. spirit) to give 36a as a yellow solid (66 mg, 51%
yield); MP: 156-158° C; 1H NMR (500 MHz, CDCl3) δ 7.02 (s, 1H, ArH2”), 6.93 (d, J = 8.0 Hz,
1H, ArH9”), 6.80 (d, J = 8.0 Hz, 1H, ArH8”), 5.96 (s, 2H, C5”H2), 3.88 (s, 3H, Ester CH3), 3.38 (s,
4H, C2’H2 and C7’H2) 1.63 (s, 4H, C3’ H2 and C6’ H2), 1.44 (s, 4H, C4’ H2 and C5’ H2); 13C NMR
(126 MHz, CDCl3) δ 167.55 (Ester C=O), 154.89 (ArC5), 153.46 (ArC3), 147.86 (ArC3”), 147.05
(ArC7”), 134.93 (ArC1”), 131.51 (ArC6), 121.69 (ArC9”), 112.20 (ArC2), 108.73 (ArC2”),
108.34 (ArC8”), 101.12 (C5”), 51.94 (Ester CH3), 50.99 (C2’ and C7’), 28.08 (C3’ and C6’),
27.10 (C4’ and C5’); HRESI-MS m/z (M + H)+: Calc. Mass 371.1719. Obs 371.1734; Anal-HPLC
(100% A:  100% B over 30 min, tr = 31.8 min).
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Methyl 3-amino-5-(azepan-1-yl)-6-(isoquinolin-4-yl)pyrazine-2-carboxylate (37a)
Methyl

3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate

32

(203 mg, 7.12x10-4 mol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)isoquinoline (271 mg, 1.06x10-3 mol), K2CO3 (970 mg, 7.01x10-3 mol)
and Pd(PPh3)4 (40 mg, 3.44x10-5 mol) were added to a round bottom flask. Anhydrous
toluene (24 mL) followed by MeOH (6 mL) were added via syringe and heated to reflux. After
2 h a UV active spot (Rf = 0.25, 1:4 EtOAc:Pet. Spirit) was detected via TLC along with
disappearance of SM after 2.5 h. After 1 h the RM was allowed to cool to RT, filtered through
celite and washed through with EtOAc (4x20 mL). Solvent was removed under reduced
pressure. The crude material was re-dissolved in EtOAc and adsorbed to silica prior to
purification by silica gel flash column chromatography (5:95 EtOAc:Pet. Spirit  10:90
EtOAc:Pet. Spirit) to give 37a as a brown solid (156 mg, 58%); MP 140-142° C; 1H NMR (500
MHz, CDCl3) δ 9.23 (s, 1H, ArH2”), 8.58 (s, 1H, ArH4”), 8.00 (d, J = 8.0 Hz, 1H ArH6”), 7.81 (d, J
= 8.0 Hz, 1H. ArH9”), 7.68 (t, J = 7.5 Hz, 1H, ArH7”), 7.62 (t, J = 7.5 Hz, 1H, ArH8”), 3.86 (s, 3H,
EsterCH3), 3.21 (t, J = 5.5 Hz, 4H, C2’ H2 and C7’ H2), 1.47(s, 4H, C3’ H2 and C6’ H2), 1.38 (s,
4H, C4’ H2 and C5’ H2);

13

C NMR (126 MHz, CDCl3) δ 167.29 (Ester C=O), 155.77 (ArC5),

154.02 (ArC3), 152.06 (ArC4”), 143.01 (ArC2”), 134.26 (ArC10”), 131.78 (ArC1”), 130.82
(ArC6”), 128.42 (ArC6), 127.97 (ArC8”), 127.37 (ArC7”), 126.66 (ArC5”), 124.50 (ArC9”),
112.90 (ArC2), 52.02 (Ester CH3), 50.38 (C2’ and C7’), 27.87 (C3’ and C6’), 26.83 (C4’ and C5’);
HRESI-MS m/z (M + Na)+: Calc. 400.1749, Obs. 400.1747. Anal-HPLC (100% A  100% B over
30 min, tr = 22.3 min).
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Methyl 3-amino-5-(azepan-1-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxylate (38a)
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32
(101 mg, 3.53x10-4 mol), (1-methyl-1H-pyrazol-4-yl)boronic acid (110
mg, 5.26 x10-4 mol ), K2CO3 (526 mg, 3.70 x10-3 mol) and Pd(PPh3)4 (21
mg, 1.76 x10-5 mol) were added to a round bottom flask. Anhydrous toluene (12 mL)
followed by MeOH (3 mL) were added via syringe and heated to reflux. A UV active spot (Rf =
0.5, EtOAc) was detected via TLC along with disappearance of SM. After 1 h the RM was
allowed to cool to RT, filtered through celite and washed through with EtOAc (4x20 mL).
Solvent was removed under reduced pressure. The crude material was re-dissolved in
acetone and adsorbed to silica prior to purification by silica gel flash column
chromatography (5:95 EtOAc:Pet spirit – 10:90 EtOAc:Pet. spirit) to give 38a as a yellow solid
(89 mg; 77%); MP: 134-136°; 1H NMR (500 MHz, CDCl3) δ 7.64 (s, 1H, ArH2”), 7.57 (s, 1H,
ArH6”), 6.17 (bs, 2H, 3NH2), 3.91 (s, 3H, 4”CH3), 3.89 (s, 3H, Ester CH3), 3.47 (t, J = 6 Hz, 4H,
C2’ H2 and C7’ H2), 1.66 (s, 4H, C3’ H2 and C6’ H2), 1.47 (s, 4H, C4’ H2 and C5’ H2); 13C NMR
(126 MHz, CDCl3) δ 167.34 (Ester C=O), 155.54 (ArC5), 153.40 (ArC3), 138.73 (ArC6”), 129.11
(ArC2”), 125.25 (ArC1”), 122.56 (ArC6), 112.42 (ArC2), 52.08 (Ester CH3), 51.16 (C2’ and C7’),
39.00 (C4” CH3), 28.00 (C3’ and C6’), 27.17 (C4’ and C5’); HRESI-MS m/z (M + H)+: Calc
331.1882, Obs. 331.1894. Anal-HPLC (70:30 A:B 100% B over 30 min, tr = 25.2 min).
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Methyl
3-amino-5-(azepan-1-yl)-6-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)pyrazine-2carboxylate (39a)

Methyl

3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-

carboxylate 32 (99 mg, 3.48x10-4 mol), 4-(2-(4-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1yl)ethyl)morpholine (165 mg, 5.36x10-4 mol), K2CO3 (522 mg, 3.78 x10-3 mol) and Pd(PPh3)4
(21 mg, 1.77 x10-5 mol) were added to a stoppered two-neck round bottom flask and the
flask was charged with Ar. The flask was fitted to a reflux condenser followed by addition of
anhydrous toluene (12 mL) and MeOH (3 mL) via syringe. The flask was heated to reflux for
16 h. A UV active spot (Rf = 0.44, 85:10:5 EtOAc:MeOH:NH3) was detected via TLC, along with
the disappearance of SM (Rf = 0.95) after 16 h. After 17 h the RM was allowed to cool to RT,
filtered through celite and washed with CH3CN (4x20 mL). Solvent was removed under
reduced pressure. The crude material was dissolved in CH3CN and adsorbed to silica prior to
purification by silica gel flash column chromatography (EtOAc  6% MeOH:EtOAc) to give
39a as a yellow solid (119 mg, 80%): MP: 132-134° C; 1H NMR (500 MHz, CDCl3) δ 7.70 (s, 1H,
ArH5”), 7.61 (s, 1H, ArH2”), 6.24 (bs, 2H, ArNH23), 4.25 (s, 2H, C7H2), 3.89 (s, 3H, Ester CH3),
3.69 (s, 4H, C11H2 and C13H2), 3.46 (s, 4H, C2’H2 and C7’H2), 2.84 (s, 2H, C8H2) 2.50 (s, 4H,
C10H2 and C14H2), 1.65 (s, 4H, C3’ H2 and C6’ H2), 1.47 (s, 4H, C4’ H2 and C5’ H2); 13C NMR
(126 MHz, CDCl3) δ 167.20 (Ester C=O), 155.50 (ArC5), 153.33 (ArC3), 138.62 (ArC5”), 128.67
(ArC2”), 125.13 (ArC1”), 122.10 (ArC6), 112.41 (ArC2), 66.94 (C11CH2 and C13CH2), 58.19
(C8CH2), 53.68 (C10CH2 and C14CH2), 51.91 (Ester CH3), 51.05 (C2’ and C7’), 49.55 (C7CH2),
27.94 (C3’ and C6’), 27.02 (C4’ and C5’); HRESI-MS m/z (M + H)+: Calc. 430.2567, Obs.
430.2553. Anal-HPLC (70:30 A:B 100% B over 30 min, tr = 21.6 min).
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Methyl 3-amino-5-(azepan-1-yl)-6-(1H-indol-2-yl)pyrazine-2-carboxylate (40a)
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32
(201 mg, 7.06x10-4 moles), (1H-indol-2-yl)boronic acid (278 mg,
1.73x10-3 moles), K2CO3 and Pd(PPh3)4 (41 mg, 3.52x10-5 moles)
were added to a round bottom flask. Anhydrous toluene (24 mL) followed by MeOH (6 mL)
were added via syringe and heated to reflux. After 30 min a UV active spot (R f = 0.85, 2:3
EtOAc:Pet. Spirit) was detected via TLC along with disappearance of SM after 1 h. After 1 h
the RM was allowed to cool to RT, filtered through celite and washed with EtOAc (4x20 mL).
Solvent was removed under reduced pressure. The crude material was re-dissolved in EtOAc
and adsorbed to silica prior to purification by silica gel flash column chromatography (10:90
EtOAc:Pet. Spirit  20:80 EtOAc:Pet. Spirit) to give 40a of a orange solid (88 mg, 34%); MP
152-154° C; 1H NMR (500 MHz, CDCl3) δ 9.14 (s, 1H, ArNH2”), 7.57 (d, 1H, J = 7.7 Hz, ArH7”),
7.37 (d, 1H, J = 7.7 Hz, ArH4”), 7.16 (t, 1H, J = 7.0 Hz, ArH5”), 7.08 (t, 1H, J = 7.0 Hz, ArH6”),
6.52 (s, 1H, ArH9”), 3.93 (s, 3H, Ester CH3), 3.58 (t, J = 5.75 Hz, 4H, C2’ H2 and C7’ H2), 1.70 (s,
4H, C3’ H2 and C6’ H2), 1.50 (s, 4H, C4’ H2 and C5’ H2); 13C NMR (126 MHz, CDCl3) δ 167.18
(Ester C=O), 155.09 (ArC5), 153.15 (ArC3), 135.96 (ArC3”), 135.68 (ArC1”), 128.95 (ArC8”),
124.51 (ArC6), 122.36 (ArC5”), 120.67 (ArC7”), 119.92 (ArC6”), 112.71 (ArC2), 111.06
(ArC4”), 101.95 (ArC9”), 52.05 (Ester CH3), 51.65 (C2’ and C7’), 28.12 (C3’ and C6’), 27.53 (C4’
and C5’); HRESI-MS m/z (M + H)+: Calc. 388.1730, Obs. 388.1731; Anal-HPLC (100%A  100%
B over 30 min, tr = 29.8 min).
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Methyl 3-amino-5-(azepan-1-yl)-6-(benzo[b]thiophen-2-yl)pyrazine-2-carboxylate (41a)
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32
(203 mg, 7.12x10-4 mol), benzo[b]thiophen-2-ylboronic acid (193
mg, 1.08x10-3 mol), K2CO3 (1.02 g, 7.39x10-3 mol) and Pd(PPh3)4 (41
mg, 3.57x10-5 mol) were added to a round bottom flask. Anhydrous toluene (24 mL)
followed by MeOH (6 mL) were added via syringe and heated to reflux. After 10 min a UV
active spot (Rf = 0.85, 2:3 EtOAc:Pet. Spirit) was detected via TLC along with disappearance
of SM after 30 min. After 30 min the RM was allowed to cool to RT, filtered through celite
and washed with EtOAc (4x20 mL). Solvent was removed under reduced pressure. The crude
material was re-dissolved in EtOAc and adsorbed to silica prior to purification by silica gel
flash column chromatography (2.5:97.5 EtOAc:Pet. Spirit  10:90 EtOAc:Pet. Spirit) to give
41a of a bright yellow solid (245 mg, 90% yield); MP 146-148 °C; 1H NMR (500 MHz, CDCl3) δ
7.80 (d, J = 7.5 Hz, 1H, ArH4”), 7.71 (d, J = 7.5 Hz, 1H, ArH7”), 7.22 (m, 2H, ArH5” and ArH6”),
7.21 (t, J = 7.0 Hz , 1H, ArH9”), 3.91 (s, 3H, Ester CH3), 3.51 (t, J = 5.75 Hz, 4H, C2’ H2 and C7’
H2), 1.69 (s, 4H, C3’ H2 and C6’ H2), 1.48 (s, 4H, C4’ H2 and C5’ H2); 13C NMR (CDCl3): δ 167.10
(Ester C=O), 155.01 (ArC5), 153.40 (ArC3), 143.09 (ArC8”), 140.02 (ArC5”), 139.90 (ArC6”),
125.22 (ArC8”), 124.23 (ArC5”), 123.63 (ArC6”), 123.46 (ArC6), 122.15 (ArC7”), 122.83
(ArC4”), 112.98 (ArC2”), 52.18 (Ester CH3), 51.10 (C2’ and C7’), 27.98 (C3’ and C6’), 27.23 (C4’
and C5’). HRESI-MS m/z (M + Na)+: Calc. 405.1394. Obs. 405.1361; Anal-HPLC (100% A
100% B over 30 min, tr = 31.9 min).
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Methyl 3-amino-5-(azepan-1-yl)-6-(benzofuran-2-yl)pyrazine-2-carboxylate (42a)
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32
(250 mg, 8.78x10-4 mol), benzofuran-2-ylboronic acid (490 mg, 3.02
x10-3 mol), K2CO3 (485 mg, 3.70 x10-3 mol) and Pd(PPh3)4 (51 mg,
4.39 x10-5 mol) were added to a round bottom flask. Anydrous
toluene (12 mL) followed by MeOH (3 mL) were added via syringe and heated to reflux. A UV
active spot (Rf = 0.45, 1:4 EtOAc:Pet. spirit) was detected via TLC after 1 h. Methyl ester SM
was not detectable by TLC after 21 h. After 24 h the RM was allowed to cool to RT and
filtered through celite, washed through with EtOAc (4x20 mL). Solvent was removed under
reduced pressure. The crude material was re-dissolved in EtOAc and adsorbed to silica prior
to purification by silica gel flash column chromatography (1 EtOAc:99 Pet spirit – 15:85
EtOAc:Pet. spirit) to give 42a as a bright yellow solid (116 mg, 36%); MP: 118-120 °C; 1H NMR
(500 MHz, CDCl3) δ 7.57 (d, J = 7.5 Hz, 1H, ArH4”) 7.47 (d, J = 7.5 Hz, 1H, ArH7”), 7.25 (m, 2H,
ArH5”and ArH6”) 6.92 (s, 1H, ArH9”), 3.90 (s, 3H, Ester CH3), 3.46 (t, J = 5.8 Hz, 4H, C2’ H2
and C7’ H2) 1.68 (s, 4H, C3’ H2 and C6’ H2), 1.48 (s, 4H, C4’ H2 and C5’ H2);

13

C NMR (126

MHz, CDCl3) δ 167.13 (Ester C=O), 154.79 (ArC5), 154.64 (ArC3”), 154.47 (ArC1”), 154.11
(ArC3), 129.16 (ArC8”), 124.30 (ArC5”), 123.07 (ArC6”) 121.38 (ArC6), 121.18 (ArC7”), 112.84
(ArC2), 111.46 (ArC4”), 105.07 (ArC9”), 52.24 (Ester CH3), 50.16 (C2’ and C7’), 28.11 (C3’ and
C6’), 27.24 (C4’ and C5’); HRESI-MS m/z (M + H)+: Calc. 367.1831, Obs. 367.1770; Anal-HPLC
(70:30 A:B 100% B over 30 min, tr = 29.5 min).
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Methyl 3-amino-5-(azepan-1-yl)-6-(4-fluorobenzofuran-2-yl)pyrazine-2-carboxylate (43a)
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32
(101 mg, 3.55x10-4 mol), (4-fluorobenzofuran-2-yl)boronic acid (95
mg, 5.31x10-4 mol), K2CO3 (485.0 mg, 3.51x10-3 mol) and Pd(PPh3)4
(22 mg, 1.89x10-5 mol) were added to a round bottom flask. Anhydrous toluene (12 mL)
followed by MeOH (3 mL) were added via syringe and heated to reflux. After 1 h a UV active
spot (Rf = 0.25, 20:80 EtOAc:Pet. Spirit) was detected via TLC along with disappearance of SM
after 2 h. After 2 h the RM was allowed to cool to RT and filtered through celite, washed
through with EtOAc (4x20 mL). Solvent was removed under reduced pressure. The crude
material was re-dissolved in EtOAc and adsorbed to silica prior to purification by silica gel
flash column chromatography (10:90 EtOAc:Pet. Spirit  20:80 EtOAc:Pet. Spirit) to give 43a
as a yellow solid (80 mg, 58%); MP: 108-110° C; 1H NMR (500 MHz, CDCl3) δ 7.27 (d, 1H,
ArH5”), 7.20 (m, 1H, ArH7”), 6.99 (s, 1H, H3”), 6.93 (t, 1H, J = 8.5 Hz, ArH6’), 3.91 (s, 3H,
EsterCH3), 3.46 (s, 4H, C2’ H2 and C7’ H2), 1.69 (s, 4H, C3’ H2 and C6’ H2), 1.49 (s, 4H, C3’ H2
and C6’ H2); 13C NMR (126 MHz, CDCl3) δ 167.0 (Ester C=O), 156.9 (ArC5), 156.2 (ArC3), 154.7
(ArC8”), 154.0 (ArC4”), 138.3 (ArC1”), 124.6 (ArC6”), 120.5 (ArC6), 118.0 (ArC2), 115.9
(ArC3”), 110.4 (ArC5”), 108.6 (ArC7”), 107.6 (ArC2”), 52.2 (Ester CH3), 50.0 (C2’ and C7’), 28.0
(C3’ and C6’), 27.1 (C4’ and C5’); HRESI-MS m/z (M + Na)+: Calc. 407.1495, Obs. 407.1504
Anal-HPLC (70:30 A/B 100% B 30 min, tr = 21.2 min).
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Methyl 3-amino-5-(azepan-1-yl)-6-(thiophen-2-yl)pyrazine-2-carboxamide (44a)
Methyl

3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate

32

(100 mg, 3.52 x10-4 mol) was combined with K2CO3 (512 mg, 3.70x10-3
mol), thiophene-2-ylboronic acid (70 mg, 5.49x10-4 mol) and Pd(Ph3)4
(20 mg, 17.5x10-5 mol) and the reaction vessel purged with Ar. Anhydrous toluene (12 mL),
followed by MeOH (3 mL) were added via syringe and the mixture heated towards reflux for
3 h. TLC analysis indicated absence of SM and the presence of a UV active spot (Rf = 0.80, 1:4
EtOAc:Pet. spirit) after 3 h. The RM was allowed to cool to RT. The RM was vaccuum filtered
through celite and washed through with CH3CN (3x20 mL) to remove catalyst. Solvent was
removed under reduced pressure. The crude product was re-solubilized in MeOH and
adsorbed onto silica gel under reduced pressure. The product was isolated via silica gel flash
column chromatography (gradient elution, 5:95 to 10:90 EtOAc:Hexane) to yield 44a as a
light yellow solid (99 mg, 85%): MP: 118-120 °C; 1H NMR (500 MHz, CDCl3) δ 7.27 (d, J = 5 Hz,
1H, ArH3”), 7.03 (d, J = 3 Hz, 1H, ArH5”) 6.98 (m, 1H, ArH4”) 3.89 (s, 3H, Ester CH3), 3.43 (t, J
= 5.7 Hz, 4H, C2’H2 and C7’H2), 1.67 (s, 4H, C3’H2 and C6’H2), 1.47 (s, 4H, C4’H2 and C5’H2); 13C
NMR (126 MHz, CDCl3) δ 167.28 (Ester C=O), 155.24 (ArC5), 153.52 (ArC3), 142.83 (ArC1”),
126.89 (ArC3”), 125.96 (ArC4”), 125.78 (ArC5”), 125.54 (ArC6), 112.70 (ArC2), 52.13 (Ester
CH3), 51.11 (C2’ and C7’), 28.15 (C3’ and C6’), 27.26 (C4’ and C5’); HRESI-MS m/z (M + Na)+:
Calc. 355.1205, Obs. 355.1193. Anal-HPLC (100% A: 100% B over 30 min, tr = 28.8 min).
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Methyl 3-amino-5-(azepan-1-yl)-6-(thiophen-3-yl)pyrazine-2carboxylate (45a)
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32
(100 mg, 3.55x10-4 mol) was combined with K2CO3 (492 mg, 3.56x10-3
mol), thiophen-3-ylboronic acid (75 mg, 5.84x10-4 mol) and Pd(Ph3)4 (20 mg, 1.73x10-5 mol)
and the reaction vessel purged with Ar. Anhydrous toluene (12 mL), followed by MeOH (3
mL) were added via syringe and the mixture heated to reflux for 2 h. TLC analysis indicated
absence of SM and the presence of a UV active spot (Rf = 0.75, 1:4 EtOAc:Pet. Spirit) after 2
h. The RM was allowed to cool to RT, vacuum filtered through celite and washed through
with CH3CN (3x20 mL) to remove catalyst. Solvent was removed under reduced pressure.
The crude product was re-solubilized in MeOH and adsorbed onto silica gel under reduced
pressure. The product was isolated via silica gel flash column chromatography (gradient
elution, 5:95 to 10:90 EtOAc:Hexane) to yield 45a as an off white solid (100 mg, 85%). MP:
118-120°C: 1H NMR (500 MHz, CDCl3) δ 7.38 (s, 1H, ArH2”), 7.29 (m, 1H ArH4”), 7.25 (d, J = 5
Hz, 1H, ArH5”), 3.88 (s, 3H, Ester CH3), 3.38 (t, J = 5.8 Hz, 4H, C2’H2 and C7’H2), 1.63 (s, 4H,
C3’ H2 and C6’ H2), 1.44 (s, 4H, C4’ H2 and C5’ H2); 13C NMR (126 MHz, CDCl3) δ 167.35 (Ester
C=O), 155.30 (ArC5), 153.53 (ArC3), 141.34 (ArC1”), 128.06 (ArC5”), 127.86 (ArC6), 125.39
(ArC4”), 122.83 (ArC2”), 112.16 (ArC2), 51.97 (Ester CH3), 50.90 (C2’ and C7’), 28.01 (C3’ and
C6’), 27.05 (C4’ and C5’); HRESI-MS m/z (M + H)+: Calc. 355.1205, Obs. 355.1197; Anal-HPLC
(100%A 100% B over 30 min, tr = 28.3 min).
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Methyl 3-amino-5-(azepan-1-yl)-6-(furan-2-yl)pyrazine-2-carboxylate (46a)
Methyl

3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate

32

(102 mg, 3.59x10-4 mol) was combined with K2CO3 (519 mg, 3.76x10-3
mol), furan-2-ylboronic acid (59 mg, 5.26x10-4 mol) and Pd(Ph3)4 (20
mg, 1.75x10-5 mol) and the reaction vessel purged with Ar. Anhydrous toluene (12 mL),
followed by MeOH (3 mL) were added via syringe and the mixture heated to reflux for 1.5 h.
TLC analysis indicated absence of SM and the presence of a UV active spot (Rf = 0.90, 1:4
EtOAc:Pet. spirit) after 2 h. The RM was allowed to cool to RT, vacuum filtered through celite
and washed through with CH3CN (3x20 mL) to remove catalyst. Solvent was removed under
reduced pressure. The crude product was solubilized in MeOH and adsorbed onto silica gel
under reduced pressure. The product was isolated via silica gel flash column
chromatography (gradient elution, 5:95 to 15:85 EtOAc:Hexane) to yield 46a as an off white
solid (111 mg, 98%): MP: 114-116 °C; 1H NMR (500 MHz, CDCl3) δ 7.41 (s, 1H, ArH3”), 6.54 (d,
J = 2.75 Hz, 1H, ArH5”), 6.45 (s, 1H, ArH4”), 3.89 (s, 3H, Ester CH3), 3.37 (t, J = 5.8 Hz ,4H,
C2’H2 and C7’H2), 1.66 (s, 4H, C3’H2 and C6’H2), 1.47 (s, 4H, C4’H2 and C5’H2); 13C NMR (126
MHz, CDCl3) δ 167.16 (Ester C=O), 154.76 (ArC5), 154.00 (ArC3), 152.24 (ArC1”), 141.49
(ArC3”), 122.04 (ArC6), 112.15 (ArC2), 111.68m (ArC4”), 108.73 (ArC5”), 52.11 (Ester CH3),
50.06 (C2’ and C7’), 28.11 (C3’ and C6’), 27.03 (C4’ and C5’); HRESI-MS m/z (M + Na)+: Calc.
339.1418, Obs. 339.1433. Anal-HPLC (100% A 100% B over 30 min, tr = 27.1 min).
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Methyl 3-amino-5-(azepan-1-yl)-6-(furan-3-yl)pyrazine-2-carboxylate (47a)
Methyl

3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate
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(107 mg, 3.89x10-4 mol), furan-3-yl boronic acid (81 mg, 4.16 x10-4
mol), K2CO3 (483 mg, 3.68 x10-3 mol) and Pd(PPh3)4 (20 mg, 1.69 x10-5
mol) were added to a round bottom flask. Anhydrous toluene (12 mL) followed by MeOH (3
mL) were added via syringe and heated to reflux. A UV active spot (Rf = 0.55, 1:4 EtOAc: Pet
spirit) was detected via TLC along with disappearance of SM. After 1 h the RM was allowed
to cool to RT, filtered through celite and washed through with EtOAc (3x20 mL). Solvent was
removed under reduced pressure. The crude material was re-dissolved in EtOAc and
adsorbed to silica prior to purification by silica gel flash column chromatography (5:95
EtOAc:Pet spirit – 10:90 EtOAc:Pet. spirit) to give 47a of a yellow solid (114 mg , 93%); MP:
122-124° C; 1H NMR (500 MHz, CDCl3) δ 7.64 (s, 1H, ArH2”), 7.41 (s, 1H, ArH4”), 6.61 (s, 1H,
ArH5”), 6.20 (Ar3NH2), 3.89 (s, 3H, Ester CH3), 3.48 (t, J = 5 Hz, 4H, C2’ H2 and C7’ H2), 1.66 (s,
4H, C3’ H2 and C6’ H2), 1.47 (s, 4H, C4’ H2 and C5’ H2); 13C NMR (126 MHz, CDCl3) δ 167.30
(Ester C=O), 155.56 (ArC5), 153.60 (ArC3), 142.62 (ArC4”), 140.63 (ArC2”), 125.82 (ArC1”),
124.77 (ArC6), 112.55 (ArC2), 111.15 (ArC5”), 51.97 (Ester CH3), 50.99 (C2’ and C7’), 28.02
(C3’ and C6’), 27.10 (C4’ and C5’); HRES-MS m/z (M + H)+: Calc. 316.1614, Obs. 316.1604;
Anal-HPLC (70:30 A:B B over 30 min, tr = 30.9 min).

Methyl 3-amino-5-(azepan-1-yl)-6-(pyrimidin-5-yl)pyrazine-2-carboxylate (48a)
Methyl

3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate
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(100 mg, 3.50x10-4 mol), pyrimidin-5-ylboronic acid (69 mg, 5.58x10-4
mol), K2CO3 (508 mg, 3.67x10-3 mol) and Pd(PPh3)4 (25 mg, 2.12x10-5
mol) were added to a round bottom flask. Anhydrous toluene (12 mL) followed by MeOH (3

199

mL) were added via syringe and heated to reflux. After 15 min a UV active spot (R f = 0.25, 2:3
EtOAc:Pet. Spirit) was detected via TLC along with disappearance of SM after 40 min. After
45 min the RM was allowed to cool to RT, filtered through celite and washed through with
EtOAc (3x20 mL). Solvent was removed under reduced pressure. The crude material was redissolved in EtOAc and adsorbed to silica prior to purification by silica gel flash column
chromatography (10:90 EtOAc:Pet. Spirit  40:60 EtOAc:Pet. Spirit) to give 48a as an off
white solid (95 mg, 83%); MP 178-180° C; 1H NMR (500 MHz, CDCl3) δ 9.13 (s, 1H, ArH4”),
8.89 (s, 2H, ArH2” and ArH6”), 3.91 (s, 3H, EsterCH3), 3.35 (t, J = 5.0 Hz, 4H, C2’ H2 and C7’
H2), 1.68 (s, 4H, C3’ H2 and C6’ H2), 1.48 (s, 4H, C4’ H2 and C5’ H2); 13C NMR (126 MHz, CDCl3)
δ 167.06 (Ester C=O), 157.05 (ArC4”), 155.63 (ArC2” and ArC6”), 155.22 (ArC5), 153.82
(ArC3), 134.85 (ArC1”), 124.47 (ArC6), 114.38 (ArC2), 52.25 (EsterCH3), 51.45 (C2” and C7”),
27.95 (C3” and C6”), 27.35 (C4” and C5”). HRESI-MS m/z (M + Na)+: Calc. 351.1545, Obs.
351.1535; Anal-HPLC (70:30 A:B B over 30 min, tr = 23.4 min).

Methyl 3-amino-5-(azepan-1-yl)-6-(2-methoxypyrimidin-5-yl)pyrazine-2-carboxylate (49a)
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32
(100 mg, 3.50x10-4 mol), 2-methoxypyrimidin-5-ylboronic acid (79
mg, 5.13 x10-4 mol), K2CO3 (479 mg, 3.60 x10-3 mol) and Pd(PPh3)4
(20 mg, 1.74 x10-5 mol) were added to a round bottom flask. Anhydrous toluene (12 mL)
followed by MeOH (3 mL) were added via syringe and heated to reflux. After 20 min a UV
active spot (Rf = 0.13, 1:4 EtOAc: Pet spirit) was detected via TLC along with disappearance of
SM. After 20 min the RM was allowed to cool to RT, filtered through celite and washed
through with EtOAc (3x20 mL). Solvent was removed under reduced pressure. The crude
material was re-dissolved in EtOAc and adsorbed to silica prior to purification by silica gel
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flash column chromatography (10:90 EtOAc:Pet. Spirit  20:80 EtOAc:Pet. Spirit) to give
49a as a light yellow solid (111 mg, 88%); MP: 141-143° C; 1H NMR (500 MHz, CDCl3) δ 8.66
(s, 2H, ArH2”and ArH6”), 4.05 (s, 3H, p-methoxyCH3), 3.90 (s, 3H, Ester CH3), 3.38 (t, J = 6 Hz,
4H, C2’ H2 and C7’ H2), 1.67 (s, 4H, C3’ H2 and C6’ H2), 1.48 (s, 4H, C4’ H2 and C5’ H2);

13

C

NMR (126 MHz, CDCl3) δ 167.03 (Ester C=O), 164.54 (ArC4”), 158.09 (ArC2” and ArC6”),
155.14 (ArC5), 153.67 (ArC3), 128.66 (ArC6), 125.05 (ArC1”), 113.75 (ArC2), 55.06 (pmethoxyCH3), 52.03 (Ester CH3), 51.21 (C2’ and C7’), 27.85 (C3’ and C6’), 27.16 (C4’ and C5’);
HRESI-MS m/z (M + H)+: Calc. 359.1832, Obs. 359.1848; Anal-HPLC (70:30 A:B 100% B over
30 min, tr = 28.0 min).

Methyl

3-amino-5-(azepan-1-yl)-6-(2,4-dimethoxypyrimidin-5-

yl)pyrazine-2-carboxylate (50a)
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32
(101 mg, 3.53x10-4 mol), 2,4-dimethoxypyrimidin-5-ylboronic acid
(100 mg 5.13x10-4 mol), K2CO3 (479 mg, 3.65x10-3 mol) and Pd(PPh3)4 (12 mg, 1.02x10-5 mol)
were added to a round bottom flask. Anhydrous toluene (12 mL) followed by MeOH (3 mL)
were added via syringe and heated to reflux. After 30 min a UV active spot (Rf = 0.8, EtOAc)
was detected via TLC along with disappearance of SM. After 30 min the RM was allowed to
cool to RT, filtered through celite and washed through with EtOAc (3x20 mL). Solvent was
removed under reduced pressure. The crude material was re-dissolved in EtOAc and
adsorbed to silica prior to purification by silica gel flash column chromatography (10:90
EtOAc:Pet. Spirit  20:80 EtOAc:Pet. Spirit) to give 50a of a light yellow solid (124 mg, 91%):
MP: 150-152° C; 1H NMR (500 MHz, CDCl3) δ 8.36 (s, 1H, ArH6”), 4.03 (s, 3H, p-methoxyCH3),
3.94 (s, 3H, o-methoxyCH3), 3.87 (s, 3H, Ester CH3), 3.39 (s, 4H, C2’ H2 and C7’ H2), 1.60 (s,
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4H, C3’ H2 and C6’ H2), 1.46 (s, 4H, C4’ H2 and C5’ H2); 13C NMR (126 MHz, CDCl3) δ 168.30
(ArC2”), 167.18 (Ester C=O), 164.76 (ArC4”), 158.09 (ArC6”), 155.34 (ArC5), 154.05 (ArC3),
123.75 (ArC6), 117.06 (ArC1”), 112.64 (ArC2), 54.96 (p-methoxyCH3), 54.10 (m-methoxyCH3),
51.95 (Ester CH3), 50.06 (C2’ and C7’), 27.98 (C3’ and C6’), 26.95 (C4’ and C5’); HRESI-MS m/z
(M + H)+: Calc. 389.1937, Obs. 389.1929; Anal-HPLC (70:30 A:B B over 30 min, tr = 27.1
min).

Methyl 3-amino-5-(azepan-1-yl)-6-(2,6-dimethoxypyridin-3-yl)pyrazine-2-carboxylate (51a)
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32
(200 mg, 7.03x10-4 moles), 2,6-dimethoxypyridin-3-ylboronic acid
(200 mg, 1.09x10-3 moles), K2CO3 (1.04 g, 7.53x10-3 moles) and
Pd(PPh3)4 (35 mg, 3.30x10-5 moles) were added to a 10 mL glass sample vial charged with Ar.
To the flask was added anhydrous toluene (4 ml) followed by MeOH (1 mL) and the mixture
stirred at RT for 18 h. After 18 h a UV active spot (Rf = 0.3 40:60 EtOAc: Pet spirit) was
detected via TLC along with SM (Rf = 0.5, 1:4 EtOAc:Pet. Spirit). After 18 h the RM was
filtered through celite and washed through with EtOAc (3x20 mL). Solvent removed under
reduced pressure. The crude material was dissolved in EtOAc and adsorbed to silica prior to
purification by silica gel flash column chromatography (10:90 EtOAc:Pet. Spirit  20:80
EtOAc:Pet. Spirit) to give 51a as a yellow solid (115 mg, 42%); MP: 134-136° C; 1H NMR (500
MHz, CDCl3) δ 7.66 (d, J = 8.0 Hz, 1H, ArH5”), 6.38 (d, J = 8.0 Hz, 1H, ArH4”), 3.92 (s, 3H, pmethoxyCH3), 3.87 (s, 3H, Ester CH3), 3.86 (s, 3H, m-methoxyCH3), 3.45 (bs, 2H, C2’ and C7’),
3.31 (bs, 2H, C2’ and C7’), 1.57 (s, 4H, C3’ H2 and C6’ H2), 1.44 (s, 4H, C4’ H2 and C5’ H2); 13C
NMR (126 MHz, CDCl3) δ 167.52 (Ester C=O), 162.79 (ArC6”), 159.68 (ArC2”), 155.29 (ArC5),
153.92 (ArC3), 141.52 (ArC4”), 127.61 (ArC6), 116.24 (ArC3”), 112.21 (ArC2), 101.33 (ArC5”),
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53.72 (p-methoxyCH3), 53.48 (o-methoxyCH3), 51.90 (Ester CH3), 50.14 (C2’ and C7’), 28.12
(C3’ and C6’), 27.07 (C4’ and C5’); HRESI-MS m/z (M + H)+: Calc. 388.1985, Obs. 388.1983;
Anal-HPLC (70:30 A:B 100% B over 30 min, tr = 31.6 min).

Methyl

3-amino-5-(azepan-1-yl)-6-(2-fluoropyridin-3-yl)pyrazine-2-

carboxylate (52a)
Methyl

3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate

32

(100 mg, 3.52x10-4 mol), 2-fluoropyridin-3-ylboronic acid (75 mg,
5.29x10-4 mol), K2CO3 (519 mg, 3.75x10-3 mol) and Pd(PPh3)4 (21 mg, 1.77x10-5 mol) were
added to a stoppered two-neck round bottom flask and the flask was charged with Ar. The
flask was fitted to a reflux condenser followed by addition of anhydrous toluene (12 mL) and
MeOH (3 mL) via syringe. The flask was heated to reflux for 45 min. A UV active spot (R f =
0.55, 2:3 EtOAc:Pet. spirit) was detected via TLC after 3 min. TLC at 45 min revealed the
disappearance of methyl ester SM (Rf = 0.8, 2:3 EtOAc:Pet. spirit). The RM was allowed to
cool to RT, filtered through celite and washed through with CH3CN (3x20 mL). Solvent
removed under reduced pressure. The crude product was re-solubilized in MeOH and
adsorbed onto silica gel under reduced pressure. The product was isolated via silica gel flash
column chromatography (gradient elution, 5:95 to 15:85 EtOAc:Hexane) to give 52a as a
light brown solid (92 mg, 76%): MP: 156-158°C; 1H NMR (500 MHz, CDCl3) δ 8.17 (d, J = 4.3
Hz, 1H, ArH6”) 8.06 (m, 1H, ArH5”), 7.29 (t, J = 5.5 Hz, 1H, ArH4”), 3.89 (s, 3H, Ester CH3),
3.36 (s, J = 5.7 Hz, 4H, C2’H2 and C7’H2), 1.63 (s, 4H, C3’H2 and C6’H2), 1.46 (s, 4H, C4’H2 and
C5’H2).
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C NMR (126 MHz, CDCl3) δ 167.21 (Ester C=O), 161.32 (ArC2”), 155.23 (ArC5),

154.10 (ArC3), 146.80 (ArC6”), 141.07 (ArC4”), 124.54 (ArC5”), 123.84 (ArC6), 122.15
(ArC3”), 113.34 (ArC2), 52.27 (Ester CH3), 50.34 (C2’ and C7’), 28.13 (C3’ and C6’), 27.29 (C4’
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and C5’); HRESI-MS m/z (M + Na)+: Calc. 368.1499, Obs. 368.1489. Anal-HPLC (100% A
100% B 30 min, tr = 26.3 min).

Methyl 3-amino-5-(azepan-1-yl)-6-(2,4-dimethoxyphenyl)pyrazine-2-carboxylate (53a)
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32
(201 mg, 7.07x10-4 mol), 2,4-dimethoxyphenylboronic acid (128 mg,
7.02x10-4 mol), K2CO3 (1.02 g, 7.41x10-3 mol) and Pd(PPh3)4 (40 mg,
3.48x10-5 mol) were added to a round bottom flask. Anhydrous toluene (24 mL) followed by
MeOH (6 mL) were added via syringe and heated to reflux. After 1 h a UV active spot (Rf =
0.4, 1:4 EtOAc:Pet. Spirit) was detected via TLC along with disappearance of SM after 2 h.
After 2.75 h the RM was allowed to cool to RT, filtered through celite and washed through
with EtOAc (3x20 mL). Solvent was removed under reduced pressure. The crude material
was re-dissolved in EtOAc and adsorbed to silica prior to purification by silica gel flash
column chromatography (10:90 EtOAc:Pet. Spirit  20:80 EtOAc:Pet. Spirit) to give 53a as a
light yellow solid (143 mg, 53%): MP: 106-108 °C; 1H NMR (500 MHz, CDCl3): 1H NMR (500
MHz, CDCl3) δ 7.33 (d, J = 8.3 Hz, 1H, ArH6”), 6.54 (dd, J = 8.3 Hz, J = 2.1 Hz 1H, ArH5”), 6.42
(d, J = 2.1 Hz, 1H, ArH3”) 3.85 (s, 3H, p-methoxyCH3), 3.82 (s, 3H, o-methoxyCH3), 3.70 (s, 3H,
Ester CH3), 3.44 (s, 2H, C2’ H2 and C7’ H2), 3.26 (s, 2H, C2’ H2 and C7’ H2), 1.58 (s, 2H, C3’ H2
and C6’ H2), 1.53 (s, 2H, C3’ H2 and C6’ H2), 1.46 (s, 2H, C4’ H2 and C5’ H2), 1.39 (s, 2H, C4’ H2
and C5’ H2). 13C NMR (126 MHz, CDCl3) δ 165.95 (Ester C=O), 160.93 (ArC4”), 158.21 (ArC2”),
155.42 (ArC5), 153.99 (ArC3), 131.10 (ArC6”), 129.22 (ArC1”), 123.71 (ArC6), 111.77 (ArC2),
105.07 (ArC5”), 98.67 (ArC3”), 55.74 (d, J = 2.1 Hz, p-methoxyCH3), 55.66 (d, J = 2.1 Hz, mmethoxyCH3), 51.99 (EsterCH3), 50.62 (C2’ and C7’), 27.81 (C3’ and C6’), 26.93 (C4’ and C5’).
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HRESI-MS m/z (M + Na)+: Calc. 409.1852, Obs. 409.1866; Anal-HPLC (100%A 100% B over
30 min, tr = 28.6 min).

Methyl 3-amino-5-(azepan-1-yl)-6-(3,5-dimethoxyphenyl)pyrazine-2-carboxylate (54a)
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32
(200 mg, 7.02x10-4 mol), 3,5-dimethoxyphenylboronic acid (128 mg,
7.02x10-4 mol), K2CO3 (1.02 g, 7.41x10-3 mol) and Pd(PPh3)4 (40 mg,
3.48x10-5 mol) were added to a round bottom flask. Anhydrous toluene (24 mL) followed by
MeOH (6 mL) were added via syringe and heated to reflux. After 1 h a UV active spot (R f =
0.4, 1:4 EtOAc:Pet. Spirit) was detected via TLC along with disappearance of SM after 3 h.
After 3 h min the RM was allowed to cool to RT, filtered through celite and washed through
with EtOAc (3x20 mL). Solvent was removed under reduced pressure. The crude material
was re-dissolved in EtOAc and adsorbed to silica prior to purification by silica gel flash
column chromatography (2.5:97.5 EtOAc:Pet. Spirit  10:90 EtOAc:Pet. Spirit) to give 54a of
a light yellow solid (166 mg, 61%); MP: 96-98° C; 1H NMR (500 MHz, CDCl3) δ 6.64 (s, 2H,
ArH2” and ArH6”), 6.40 (s, 1H, ArH4”), 3.88 (s, 3H, Ester CH3), 3.81 (s, 6H, m-methoxyCH3),
3.38 (t, J = 6.0 Hz, 4H, C4’ H2 and C5’ H2), 1.64 (s, 4H, C3’ H2 and C6’ H2), 1.44 (s, 4H, C4’ H2
and C5’ H2);
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C NMR (126 MHz, CDCl3) δ 167.50 (Ester C=O), 160.98 (ArC3” and ArC5”),

154.73 (ArC5), 153.67 (ArC3), 142.75 (ArC1”), 131.59 (ArC6), 111.97 (ArC2), 106.32 (ArC2”
and ArC6”), 99.95 (ArC4”), 55.61 (m-methoxyCH3), 51.98 (EsterCH3), 50.89 (C2’ and C7’),
28.09 (C3’ and C6’), 27.14 (C4’ and C5’). HRESI-MS m/z (M + Na)+: Calc. 409.1852, Obs.
409.1867. Anal-HPLC (70:30 A:B 100% B over 30 min, tr = 30.0 min).
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Methyl

3-amino-5-(azepan-1-yl)-6-(3,6-dimethoxypyridazin-4-yl)pyrazine-2-carboxylate

(55a)
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32
(102 mg, 3.59x10-4 mol), 3,6-dimethoxypyridazin-4-ylboronic acid
(97 mg, 5.26x10-4 mol), K2CO3 (485 mg, 3.51x10-3 mol)

and

Pd(PPh3)4 (22 mg, 1.89x10-5 mol) were added to a round bottom flask. Anhydrous toluene
(24 mL) followed by MeOH (6 mL) were added via syringe and heated to reflux. After 1 h a
UV active spot (Rf = 0.5, 2:3 EtOAc:Pet. Spirit) was detected via TLC along with disappearance
of SM after 2 h. After 2 h the RM was allowed to cool to RT, filtered through celite and
washed through with EtOAc (3x20 mL). Solvent was removed under reduced pressure. The
crude material was re-dissolved in EtOAc and adsorbed to silica prior to purification by silica
gel flash column chromatography (10:90 EtOAc:Pet. Spirit  20:80 EtOAc:Pet. Spirit) to give
55a as a yellow solid (94 mg, 68%): MP: 152-154° C; 1H NMR (500 MHz, CDCl3) δ 7.17 (s, 1H,
ArH2”), 4.08 (s, 3H, o-methoxyCH3), 4.00 (s, 3H, m-methoxyCH3), 3.88 (s, 3H, EsterCH3), 3.43
(s, 2H, C2’ H2 and C7’ H2), 3.29 (s, 2H, C2’ H2 and C7’ H2), 1.63 (s, 4H, C3’ H2 and C6’ H2), 1.44
(s, 4H, C3’ H2 and C6’ H2); 13C NMR (126 MHz, CDCl3) δ 166.97 (Ester C=O), 162.75 (ArC3”),
159.61 (ArC6”), 154.70 (ArC5), 154.14 (ArC3), 135.05 (ArC1”), 122.88 (ArC6), 119.39 (ArC2”),
113.08 (ArC2), 54.82 (o-methoxyCH3), 54.62 (m-methoxyCH3), 52.07 (Ester C=O), 49.74 (C2”
and C7”), 27.98 (C3” and C6”), 27.20 (C4” and C5”); HRESI-MS m/z (M + Na)+: Calc. 411.1757,
Obs. 411.1762. Anal-HPLC (70:30 A:B 100% B over 30 min, tr = 21.2 min).
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Methyl 3-amino-5-(azepan-1-yl)-6-(phenylethynyl)pyrazine-2-carboxylate (56a)
Methyl 3-amino-5(azepan-1-yl)-6-pyrazine-2-carboxylate 32 (101
mg, 3.53x10-4 mol), Pd(PPh3)Cl2 (12 mg, 1.65x10-5 mol) and CuI (9.9
mg, 5.2 x10-5 mol) were added dry to a 10 mL round bottom flask
and dissolved in anhydrous THF (3.5 ml). To this solution Et3N (147
µL, 1.05 x10-3 mol) and phenylacetylene (58 µL, 5.27 x10-4 mol) were added via pipette. The
solution was sparged with N2 and heated to reflux with vigorous stirring. After 24 h the
reaction was allowed to cool to RT. The crude RM was filtered through celite and washed
through with EtOAc (3x20 mL). Solvent was removed under reduced pressure. The product
was isolated via silica gel flash column chromatography (gradient elution 1-7.5%
EtoAc:petroleum spirit) to yield 56a as a brown solid (73 mg, 59%): MP: 126-128 °C; 1H NMR
(500 MHz, CDCl3) δ 7.50 (m, 2H, ArH2” and ArH6”), 7.32 (m, 3H, ArH3”, ArH4” and ArH5”),
4.00 (t, J = 5.5 Hz, 4H, C2’H2 and C7’H2), 3.91 (s, 3H, Ester CH3), 1.87 (s, 4H, C3’H2 and C6’ H2),
1.58 (s, 4H, C4’H2 and C5’ H2);
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C NMR (126 MHz, CDCl3) δ 166.65 (Ester C=O), 155.26

(ArC5), 153.79 (ArC3), 131.45 (ArC4”), 128.41 (ArC3” and ArC5”), 128.34 (ArC2” and ArC6”),
123.43 (ArC1”), 113.71 (ArC2), 113.47 (ArC6), 90.44 (C7), 89.04 (C8), 52.15 (Ester CH3), 50.44
(C2’ and C7’), 28.60 (C3’ and C6’), 26.84 (C4’ and C5’); HRESI-MS m/z (M + H)+: Calc.
351.1829, Obs. 351.1821; Anal-HPLC (70:30 A:B 100% B over 30 min, tr = 36.8 min).
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General Method for acyl guanidinylation:

General Method
Free guanidine was generated via neutralization of guanidine.HCl with Na+ iPrO- in iPrOH to
create a 2-fold molar excess relative to the 6-substituted pyrazinoyl methyl ester. A stock
solution of iPrO- was prepared by adding Na(s) (typically 30-70 mg) in anhydrous iPrOH under
N2 and heated at 70 °C for 30 min. From this stock solution an amount of iPrO- was removed
via syringe and made up to 10 mL in anhydrous iPrOH. To this solution was added a
stoichiometric amount of guanidine hydrochloride and the mixture stirred at 70 °C for 30
min. This solution was gravity filtered onto the neat 6-substituted pyrazinoyl methyl ester.
Once filtration was complete, the mixture was heated to reflux and allowed to react for
between 1-6 h. The reactions were monitored by MS and TLC and terminated by removal of
solvent under reduced pressure. Final products were isolated by rp-HPLC. All compounds
were isolated as TFA salts and exchanged to their respective HCl salts by stirring with
quaternary ammonium Cl- anion exchange resin in MeOH prior to biological evaluation.
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3-amino-5-(azepan-1-yl)-6-phenylpyrazine-2-carboxamide (33)
The compound was prepared using the General Method (2.5 h
reaction

time)

with

methyl

3-amino-5-(azepan-1-yl)-6-

phenylpyrazine-2-carboxylate 33a (70 mg, 2.14x10-4 mol). The
residue was taken up in solvent A:B (2 mL) and purified by preparative HPLC (70:30
A:B100% B over 30 min). Collected fractions containing purified product were pooled
concentrated via freeze drying to yield 33 as a bright yellow solid (TFA salt, 7.3 mg, 7%) after
HPLC); MP: 126-130 °C; 1H NMR (500 MHz, CD3OD) δ 8.98 (s, 1H, Amide NH), 8.26 (bs, 2H
Guanidine NH2), 7.59 (bs, 2H Guanidine NH2) 7.45 (d, J = 7.5 Hz, 2H, ArH2” and ArH6”), 7.40
(d, J = 7.5 Hz, 2H, ArH3” and ArH5”), 7.33 (d, J = 7.5 Hz, 1H, ArH4”), 3.38 (t, J = 5.0 Hz 4H,
C2’H2 and C7’H2), 1.63 (s, 4H, C3’H2 and C6’H2), 1.45 (s, 4H, C3’H2 and C6’H2).
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C-APT δ

167.93 (Amide C=O), 160.25 (Guanidine C), 155.77 (ArC5), 155.04 (ArC3), 145.55 (ArC1”),
130.13 (ArC6), 130.01 (ArC2” and ArC6”), 129.88 (ArC3” and ArC5”), 125.23 (ArC6), 124.78
(Ar-CF3), 112.89 (ArC2), 51.61 (C2’ and C7’), 28.63 (C3’ and C6’), 27.58 (C4’ and C5’). LRESIMS m/z (M + H)+ 353; Anal-HPLC (70:30 A:B 100% B over 30 min, tr =25.4 min).

3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(4-(methylthio)phenyl)pyrazine-2carboxamide (34)
The compound was prepared using the General Method (3 h
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(4(methylthio)phenyl)pyrazine-2-carboxylate 34a (81 mg, 2.16x104

mol). The residue was taken up in A:B (2 mL) and purified by preparative HPLC (70:30

A:B100% B over 30 min). Collected fractions containing purified product were pooled
concentrated via freeze drying to yield 34 as a yellow solid (TFA salt, 5.5 mg, 5% after HPLC)
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MP 152-154°C; 1H NMR (500 MHz, CDCl3) δ 10.31 (s, 1H, Amide NH), 9.44 (s, 2H, Guanidine
NH2), 8.47 (s, 2H, Guanidine NH2), 7.44 (d, J = 8.1 Hz, 2H, ArH3” and ArH5”), 7.28 (d, J = 8.1
Hz, 2H, ArH2” and ArH6”), 3.40 (t, J = 5.5 Hz, 4H, C2’H2 and C7’H2), 1.60 (s, 4H, C3’H2 and C6’
H2), 1.46 (s, 4H, C4’H2 and C5’ H2). 13C NMR (126 MHz, CDCl3) δ 166.04 (Amide C=O), 156.63
(Guanidine C), 155.71 (ArC5), 153.56 (ArC3), 138.99 (ArC4”), 136.40 (ArC1”), 131.19 (ArC6),
128.14 (ArC2” and ArC6”), 126.61(ArC3” and ArC5”), 110.96 (ArC2), 51.47 (C2’ and C7’),
27.89 (C3’ and C6’), 27.11 (C4’ and C5’), 15.45. (thioetherCH3). HRESI-MS m/z (M + H)+ 400,
Anal. for C19H26N7OS: Calc. 400.1920, Obs. 400.1935. Anal-HPLC (70:30 A:B100% B over 30
min, tr =28.4 min).

3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(4-(trifluoromethyl)phenyl)pyrazine-2carboxamide (35)
The compound was prepared using the General Method (2.5 h
reaction

time)

with

methyl

3-amino-5-(azepan-1-yl)-6-(4-

(trifluoromethyl)phenyl)pyrazine-2-carboxylate 35a (101 mg,
2.56x10-4 mol). The residue was taken up in solvent A:B (2 mL) and purified by preparative
HPLC (70:30 A:B100% B over 30 min). Collected fractions containing purified product were
pooled concentrated via freeze drying to yield 35 as a bright yellow solid (TFA salt, 16 mg,
12% after HPLC); MP: 126-130 °C; 1H NMR (500 MHz, CD3OD) :7.68 (d, J = 8.0 Hz, 2H, ArH3”
and ArH5”), 7.65 (d, J = 8.0 Hz, 2H, ArH2” and ArH6”), 3.38 (t, J = 5.0 Hz 4H, C2’H2 and C7’H2),
1.65 (s, 4H, C3’H2 and C6’H2), 1.46 (s, 4H, C3’H2 and C6’H2).

13

C NMR (126 MHz, CDCl3) δ

167.93 (Amide C=O), 160.25 (Guanidine C), 155.77 (ArC5), 155.04 (ArC3), 145.55 (ArC1”),
130.13 (ArC6), 130.01 (ArC2” and ArC6”), 129.88 (ArC3” and ArC5”), 125.23 (ArC6), 124.78
(Ar-CF3), 112.89 (ArC2), 51.61 (C2’ and C7’), 28.63 (C3’ and C6’), 27.58 (C4’ and C5’). HRESI-
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MS m/z (M + H)+: Calc. 422.1911, Obs. 422.1912; Anal-HPLC (70:30 A:B 100% B over 30
min, tr =27.9 min).

3-amino-5-(azepan-1-yl)-6-(benzo[d][1,3]dioxol-5-yl)-N-carbamimidoylpyrazine-2carboxamide (36)
The compound was prepared using the General Method (3 h
reaction

time)

using

methyl

3-amino-5-(azepan-1-yl)-6-

(benzo[d][1,3]dioxol-5-yl)pyrazine-2-carboxylate 36a (54 mg,
1.46x10-4 mol). The residue was taken up in solvent A:B (2 mL) and purified by preparative
HPLC (70:30 A:B100% B over 30 min). Collected fractions containing purified product were
pooled concentrated via freeze drying to yield 36 as a yellow solid (HCl salt, 5.7 mg, 9% after
IEX) MP 154-156°C; 1H NMR (500 MHz, DMSO-d6) δ 10.39 (s, 1H, Amide NH), 8.71 (s, 2H,
Guanidine NH2), 8.27 (s, 2H, Guanidine NH2), 7.31 (s, 1H, ArC2”) 6.97 (d, J = 8.0 Hz, 1H,
ArH9”), 6.93 (d, J = 8.0 Hz, 1H, ArH8”), 6.08 (s, 2H, C5”H2), 3.40 (t, J= 5.75 Hz, 4H, C2’ H2 and
C7’ H2), 1.60 (s, 2H, C3’ H2 and C6’ H2), 1.39 (s, 2H,C4’ H2 and C5’ H2). 13C NMR (126 MHz,
DMSO-d6) δ 166.23 (Amide C=O), 155.15 (Guanidine C), 154.75 (ArC5), 153.61 (ArC3), 147.26
(ArC3”), 146.71 (ArC7”), 133.39 (ArC1”), 130.28 (ArC6), 121.43 (ArC9”), 112.73 (ArC2),
108.47 (ArC2”), 107.96 (ArC8”), 101.15 (C5”), 50.44 (C2’ and C7’), 27.21 (C3’ and C6’), 26.07
(C4’ and C5’). HRESI-MS m/z (M + H)+ 398: Calc. 398.1941, Obs. 398.1929. Anal-HPLC (70:30
A:B100% B over 30 min, tr =26.4 min).
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3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(isoquinolin-4-yl)pyrazine-2-carboxamide (37)
The compound was prepared using the General Method (2.5 h
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(isoquinolin4-yl)pyrazine-2-carboxylate 37a (156 mg, 4.13x10-4 mol). The
residue was taken up in anhydrous DMSO (2 mL) and purified by
preparative HPLC (70:30 A:B100% B over 30 min). Collected fractions containing purified
product were pooled concentrated via freeze drying to yield 37 as an orange solid (TFA salt,
31 mg, 15% after HPLC) MP 158-160°C; 1H NMR (500 MHz, CD3OD) δ 10.47 (s, exchange with
solvent, Amide NH), 9.57 (bs, 1H, ArH2”), 9.19 (s, exchange with solvent, Guanidine NH2),
9.09 (s, exchange with solvent, Guanidine NH2), 8.69 (bs, 1H, Ar4H”), exchange with solvent,
Guanidine NH2), 8.40 (d, J = 8.2 Hz, 1H ArH6”), 8.01 (t, J = 7.5 Hz, 1H ArH7”), 7.91 (t, J = 7.5
Hz, 1H ArH8”), 7.81 (d, J = 8.2 Hz, 1H ArH9”), 3.37 (s, 2H, C2’ H2 and C7’ H2), 3.23 (s, 2H, C2’
H2 and C7’ H2), 1.53 (s, 4H, C3’ H2 and C6’ H2), 1.44 (s, 4H, C4’ H2 and C5’ H2). 13C NMR (126
MHz, CD3OD) δ 167.51 (Amide C=O), 157.74 (Guanidine C), 156.87 (ArC5), 156.36 (ArC3),
149.67 (ArC4”), 137.60 (ArC1”), 136.92 (ArC2”), 136.87 (ArC10”), 136.82 (ArC6”), 131.61
(ArC8”), 131.42 (ArC7”), 129.044 (ArC6), 125.72 (ArC9”), 124.73 (ArC5”), 112.97 (ArC2),
51.58 (C2’ and C7’), 28.94 (C3’ and C6’), 27.75 (C4’ and C5’). HRESI-MS m/z (M + H)+: Calc.
405.2164, Obs. 405.2151. Anal-HPLC (70:30 A:B100% B over 30 min, tr 22.7 min).
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3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2carboxamide (38)
The compound was prepared using the General Method (2 h
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(1-methyl1H-pyrazol-4-yl)pyrazine-2-carboxylate 38a (69 mg, 2.07x10-4
mol). The residue was taken up in solvent A:B (2 mL) plus 3 drops CH3CN and purified by
preparative HPLC (70:30 A:B100% B over 30 min). Collected fractions containing purified
product were pooled concentrated via freeze drying to yield 38 as a yellow solid (HCl salt, 31
mg, 38% after IEX) MP 150-152°C; 1H NMR (500 MHz, CDCl3) δ 10.49 (s, 1H, Amide NH), 8.83
(s, 2H, Guanidine NH2), 8.52 (s, 2H, Guanidine NH2), 8.00 (s, 1H, ArH2”), 7.57 (s, 1H, ArH6”),
5.49 (bs, 2H, Ar3NH2), 3.93 (s, 3H, ArN3”CH3), 3.50 (t, J = 5.75 Hz, 4H, C2’H2 and C7’H2), 1.69
(s, 4H, C3’H2 and C6’ H2), 1.49 (s, 4H, C4’H2 and C5’ H2). 13C NMR (126 MHz, CDCl3) δ 166.57
(Amide C=O), 156.35 (Guanidine C), 156.07 (ArC5), 153.40 (ArC3), 137.39 (ArC6”), 130.73
(ArC2”), 125.04 (ArC1”), 121.70 (ArC6), 111.08 (ArC2), 51.54 (C2’ and C7’), 38.67 (ArN3”CH3),
27.85 (C3’ and C6’), 27.27 (C4’ and C5’). HRESI-MS m/z (M + H)+: Calc. 358.2104, Obs.
358.2118. Anal-HPLC (70:30 A:B100% B over 30 min, tr =21.0 min).

3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(1-(2-morpholinoethyl)-1H-pyrazol-4yl)pyrazine-2-carboxamide (39)
The compound was prepared using the General Method
(3 h reaction time) with methyl 3-amino-5-(azepan-1yl)-6-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)pyrazine-2carboxylate 39a (99 mg, 2.29x10-4 mol). The residue was taken up in solvent A:B (2 mL) and
purified by preparative HPLC (70:30 A:B100% B over 30 min). Collected fractions

213

containing purified product were pooled concentrated via freeze drying to yield 39 as an
orange solid (TFA salt, 38 mg, 30% after HPLC) MP 136-138°C; 1H NMR (500 MHz, CDCl3) δ
10.48 (s, 1H, Amide NH), 8.86 (s, 2H, Guanidine NH2), 8.65 (s, 2H, Guanidine NH2), 7.89 (s,
1H, ArH5”), 7.56 (s, 1H, ArH2”), 4.67 (s, 2H, C7H2), 3.93 (s, 4H, C11H2 and C13H2), 3.69 (s, 2H,
C8H2), 3.47 (s, 4H, C10H2 and C14H2), 3.42 (bs, 2H, C2’ and C7’), 3.05 (bs, 2H, C2’ and C7’)
1.67 (s, 4H, C3’ H2 and C6’ H2), 1.49 (s, 4H, C4’ H2 and C5’ H2). 13C NMR (126 MHz, CDCl3) δ
166.63 (Amide C=O), 156.35 (Guanidine C), 156.06 (ArC5), 153.63 (ArC3), 139.96 (ArC5”),
130.58 (ArC2”), 124.10 (ArC1”), 122.90 (ArC6), 111.31 (ArC2), 63.78 (C11CH2 and C13CH2),
57.19 (C8CH2), 53.29 (C10CH2 and C14CH2), 51.40 (C2’ and C7’), 46.38 (C7CH2), 27.89 (C3’
and C6’), 27.17 (C4’ and C5’). HRESI-MS m/z (M + H)+: Calc. 457.2788, Obs. 457.2796. AnalHPLC (70:30 A:B100% B over 30 min, tr =19.0 min).

3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(1H-indol-2-yl)pyrazine-2-carboxamide (40)
The compound was prepared using the General Method (3 h
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(1H-indol2-yl)pyrazine-2-carboxylate 40a (76 mg, 2.09x10-4 mol). The
residue was taken up in solvent A:B (4 mL) and purified by
preparative HPLC (70:30 A:B100% B over 30 min, 2 separate 2 mL injections). Collected
fractions containing purified product were pooled concentrated via freeze drying to yield 40
as an orange solid (TFA salt, 29 mg, 31% yield after HPLC) MP 152-154°C; 1H NMR (500 MHz,
CDCl3) δ 11.09 (s, 1H, ArNH2”), 10.82 (s, 1H, Amide NH), 8.82 (s, 2H, Guanidine NH2), 7.92 (s,
2H, Guanidine NH2), 7.55 (d, 1H, J = 7.7 Hz, ArH7”) 7.41 (d, 1H, J = 7.7 Hz, ArH7”), 7.12 (t, 1H,
J = 7 Hz, ArH5”), 7.03 (t, 1H, J = 7 Hz, ArH6”), 6.44 (s, 1H, ArH9”), 3.64 (t, J = 5.0 Hz, 4H, C2’ H2
and C7’ H2), 1.73 (s, 4H, C3’ H2 and C6’ H2), 1.50(s, 4H, C4’ H2 and C5’ H2). 13C NMR (126 MHz,
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CDCl3) δ 166.66 (Amide C=O), 156.22 (Guanidine C), 155.69 (ArC5), 152.98 (ArC3), 136.62
(ArC3”), 134.89 (ArC1”), 128.32 (ArC8”), 125.72 (ArC6), 122.71 (ArC5”), 120.49 (ArC7”),
119.81 (ArC6”), 111.74 (ArC2), 110.83 (ArC4”), 102.31 (ArC9”), 52.13 (C2’ and C7’), 27.88 (C3’
and C6’), 27.55 (C4’ and C5’); HRESI-MS m/z (M + H)+: Calc. 393.2151, Obs. 393.2159. AnalHPLC (70:30 A:B100% B over 30 min, tr =24.4 min).

3-amino-5-(azepan-1-yl)-6-(benzo[b]thiophen-2-yl)-N-carbamimidoylpyrazine-2carboxamide (41)
The compound was prepared using the General Method (3 h
reaction

time)

with

methyl

3-amino-5-(azepan-1-yl)-6-

(benzo[b]thiophen-2-yl)pyrazine-2-carboxylate 41a (225 mg,
5.88x10-4 mol). The residue was taken up in solvent A:B (2 mL,
partially soluble) and purified by preparative HPLC (70:30 A:B100% B over 30 min).
Collected fractions containing purified product were pooled concentrated via freeze drying
to yield 41 as a yellow solid (HCl salt, 10 mg, 4% after IEX) MP: 220-224°C (dec); 1H NMR (500
MHz, CD3OD) δ, 7.78 (d, J = 7.5 Hz, 1H, ArH4”), 7.71 (d, J = 7.5 Hz, 1H, ArH7”), 7.31-7.26 (m,
2H, ArH5” & 6”), 7.24 (s, 1H, ArH9”), 3.48 (t, J = 6.0 Hz, 4H, C2’ H2 and C7’ H2), 1.66 (s, 4H, C3’
H2 and C6’ H2), 1.47 (s, 4H, C4’ H2 and C5’ H2). 13C NMR (126 MHz, CD3OD) δ 168.23 (Amide
C=O), 164.88 (ArC9”), 160.75 (Guanidine C), 156.54 (ArC5), 155.41 (ArC3), 144.08 (ArC1”),
141.34 (ArC8”), 141.16 (ArC3”), 125.75 (ArC5”), 125.51 (ArC6”), 124.66 (ArC6), 123.45
(ArC7”), 123.07 (ArC4”), 113.47 (ArC2), 52.01 (C2’ and C7’), 29.22 (C3’ and C6’), 28.07 (C4’
and C5’). HRESI-MS m/z (M + H)+: Calc. 410.1763, Obs. 410.1780. Anal-HPLC (70:30
A:B100% B over 30 min, tr =27.5 min).
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3-amino-5-(azepan-1-yl)-6-(benzofuran-2-yl)-N-carbamimidoylpyrazine-2-carboxamide (42)
The compound was prepared using the General Method (6 h
reaction

time)

with

methyl

3-amino-5-(azepan-1-yl)-6-

(benzofuran-2-yl)pyrazine-2-carboxylate 42a (116 mg, 3.17x10-4
mol). The residue was taken up in anhydrous DMSO (2 mL) and
purified by preparative HPLC (70:30 A:B100% B over 30 min). Collected fractions
containing purified product were pooled concentrated via freeze drying to yield 42 as a
yellow solid (TFA salt, 52 mg, 34% yield after HPLC) MP: 126-132°C; 1H NMR (CD3OD) δ 7.64
(d, J = 7.5 Hz, 1H, ArH4”), 7.50 (d, J = 8.0 Hz, 1H, ArH7”), 7.31 (t, J = 8.0 Hz, 1H, ArH6”), 7.26
(t, J = 7.5 Hz, 1H, ArH5”), 7.05 (s, 1H, ArH7”), 3.51 (t, J = 6.0 Hz, C2’ H2 and C7’ H2), 1.71 (s,
4H, C3’ H2 and C6’ H2), 1.54 (s, 4H, C4’ H2 and C5’ H2).

13

C NMR (CD3OD) δ 167.44 (Amide

C=O), 164.32 (Guanidine C), 154.61 (ArC5), 154.47 (ArC3”), 154.37 (ArC1”), 154.09 (ArC3),
129.67 (ArC8”), 124.98 (ArC5”), 123.66 (ArC6”), 121.64 (ArC6), 121.08 (ArC7”), 112.44
(ArC2), 111.52 (ArC4”), 105.63 (ArC9”), 50.31 (C2’ and C7’), 28.62 (C3’ and C6’), 27.39(C4’
and C5’).

HRESI-MS m/z (M + H)+: Calc. 394.1991, Obs. 394.1975. Anal-HPLC (70:30

A:B100% B over 30 min, tr =26.4 min).

3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(4-fluorobenzofuran-2-yl)pyrazine-2carboxamide (43)
The compound was prepared using the General Method (3 h
reaction time) using moles methyl 3-amino-5-(azepan-1-yl)-6-(4fluorobenzofuran-2-yl)pyrazine-2-carboxylate

43a

(54

mg,

1.39x10-4). The residue was taken up in anhydrous DMSO (2 mL)
and purified by preparative HPLC (100% A100% B over 30 min). Collected fractions
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containing purified product were pooled concentrated via freeze drying to yield 43 as an
orange solid (TFA salt, 15 mg, 26% yield after HPLC), MP 132-136 °C. 1H NMR (500 MHz,
CD3OD) δ 10.47 (s, exchange with solvent, Amide NH), 8.98 (s, exchange with solvent,
Guanidine NH2), 8.33 (s, exchange with solvent, Guanidine NH2), 7.36 (t, J = 8.7Hz, 1H,
ArH7”), 7.32 (q, J = 5.5Hz, 1H, ArH6”), 7.22 (s, 1H, ArH2”), 7.02 (t, J = 8.7Hz, 1H, ArH5”), 3.44
(t, J = 5.8 Hz, 4H, C2’ H2 and C7’ H2) 1.72 (s, 4H, C3’ H2 and C6’ H2), 1.51 (s, 4H, C4’ H2 and C5’
H2).

13

C NMR (126 MHz, CD3OD) δ 167.32 (Amide C=O), 158.20 (ArC8”), 157.38 (Guanidine

C), 156.89 (ArC5), 156.23 (ArC4”), 156.18 (ArC1”), 155.73 (ArC3), 126.57 (ArC6”), 121.13
(ArC3”), 118.90 (ArC6), 112.16 (ArC2), 109.75 (ArC5”), 108.65 (ArC7”), 102.44 (ArC2”), 51.08
(C2” and C7”), 29.02 (C3” and C6”), 27.88 (C4” and C5”). HRESI-MS m/z (M + H)+: Calc.
412.1897, Obs. 412.1909. Anal-HPLC (100% A100% B over 30 min, tr =25.6 min).

3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(thiophen-2-yl)pyrazine-2-carboxamide (44)
The compound was prepared using the General Method (3 h
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(thiophen-2yl)pyrazine-2-carboxylate 44a (99 mg, 2.98x10-4 mol). The residue
was taken up in 70:30 solvent A:B (2 mL) and purified by preparative HPLC (70:30 A:B100%
B over 30 min). Collected fractions containing purified product were pooled concentrated via
freeze drying to yield 44 as a bright yellow solid (TFA salt, 1.9 mg, 2% yield after HPLC); MP
1

H NMR (500 MHz, CDCl3) δ 10.10 (s, 1H, Amide NH), 10.04 (bs, 2H Guanidine NH2), 8.08 (bs,

2H Guanidine NH2), 7.26 (d, J = 5 Hz, 1H, ArH3”), 7.03 (d, J = 3 Hz, 1H, ArH5”), 3.47 (t, J = 5.75
Hz, 4H, C2’H2 and C7’H2), 1.68 (m, 4H, C3’H2 and C6’H2), 1.49 (m, 4H, C4’H2 and C5’H2).

13

C

NMR (126 MHz, CDCl3) δ 166.97 (Amide C=O), 156.30 (Guanidine C), 156.05 (ArC5), 153.39
(ArC3), 139.86 (ArC1”), 128.44 (ArC5”), 128.18 (ArC6), 125.24 (ArC4”), 124.54 (ArC2”),
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111.07 (ArC2), 51.04 (C2’ and C7’), 27.82 (C3’ and C6’), 27.12 (C4’ and C5’). HRESI-MS m/z (M
+ H)+: Calc. 360.1607, Obs. 360.1610. Anal-HPLC (70:30 A:B100% B over 30 min), tr = 24.8
min).

3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(thiophen-3-yl)pyrazine-2-carboxamide (45)
The compound was prepared using the General Method (2
reaction time) using (103 mg, 3.09x10-4 mol) moles methyl 3amino-5-(azepan-1-yl)-6-(thiophen-3-yl)pyrazine-2-carboxylate
45a. The residue was taken up in 50:50 solvent A:B (2 mL) and purified by preparative HPLC
(100% A100% B over 30 min). Collected fractions containing purified product were pooled
concentrated via freeze drying to yield 45 as a bright yellow solid (TFA salt, 24 mg, 17% yield
after HPLC); MP: 138-140°C; 1H NMR (500 MHz, CDCl3) δ 10.44 (s, 1H, Amide NH), 8.71 (bs,
4H, 2x Guanidine NH2), 7.48 (s, 1H, ArH2”), 7.29 (m, 1H ArH4” and ArH5”), 3.43 (t, J = 5 Hz,
4H, C2’H2 and C7’H2), 1.65 (s, 4H, C3’ H2 and C6’ H2), 1.46 (s, 4H, C4’ H2 and C5’ H2); 13C NMR
(126 MHz, CDCl3) δ 166.66 (Amide C=O), 156.24 (Guanidine C), 156.02 (ArC5), 153.58 (ArC3),
140.12 (ArC1”), 128.40 (ArC5”), 127.79 (ArC6), 125.88 (ArC4”), 123.57 (ArC2”), 110.74
(ArC2), 51.27 (C2’ and C7’), 27.92 (C3’ and C6’), 27.14 (C4’ and C5’). HRESI-MS m/z (M + H)+:
Calc. 360.1607, Obs. 360.1611. Anal-HPLC (100% A100% B over 30 min, tr = 25.0).

3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide (46)
The compound was prepared using General Method (2 h reaction
time) using methyl 3-amino-5-(azepan-1-yl)-6-(furan-2-yl)pyrazine2-carboxylate 46a (111 mg, 3.52x10-4 mol). The residue was taken

up

in

solvent A:B (2 mL) and purified by preparative HPLC (70:30 A:B100% B over 30 min).
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Collected fractions containing purified product were pooled concentrated via freeze drying
to yield 46 as a bright yellow solid (TFA salt, 25 mg, 16% yield after HPLC); MP: 146-150 °C.
1

H NMR (500 MHz, CD3OD), 7.50 (s, 1H, ArH3”), 6.55 (d, J = 3.0 Hz, 1H, ArH5”), 6.50 (s, 1H,

ArH4”), 3.37 (t, J = 6.0 Hz, 4H, C2’H2 and C7’H2), 1.64 (s, 4H, C3’H2 and C6’H2), 1.47 (s, 4H,
C4’H2 and C5’H2).

13

C NMR (126 MHz, CD3OD) δ 168.1 (Amide C=O), 160.7 (Guanidine C)

156.3 (ArC5), 153.4 (ArC3), 142.8 (ArC1”), 141.49 (ArC3”), 122.4 (ArC6), 112.6 (ArC2), 112.4
(ArC4”), 109.9 (ArC5”), 50.9 (C2’ and C7’), 29.2 (C3’ and C6’), 27.8 (C4’ and C5’). HRESI-MS
m/z (M + H)+ 344: Calc. 344.1835, Obs. 344.1830. Anal-HPLC (70:30 A:B100% B over 30
min, tr = 24.3 min).

3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-3-yl)pyrazine-2-carboxamide (47)
The compound was prepared using the General Method (2 h
reaction time) with moles methyl 3-amino-5-(azepan-1-yl)-6(furan-3-yl)pyrazine-2-carboxylate 47a (90 mg, 2.85x10-4). The
residue was taken up in solvent A:B (2 mL) and purified by preparative HPLC (70:30
A:B100% B over 30 min). Collected fractions containing purified product were pooled
concentrated via freeze drying to yield 47 as a bright yellow solid (HCl salt, 41 mg, 35% yield
after HPLC); MP 146-148°C; 1H NMR (500 MHz, CDCl3) δ 10.42 (s, 1H, Amide NH), 8.54 (s, 4H,
2X Guanidine NH2), 7.63 (s, 1H, ArH2”), 7.42 (s, 1H, ArH4”), 6.63 (s, 1H, ArH5”), 5.35 (bs, 2H,
Ar3NH2), 3.52 (t, J = 5.75 Hz, 4H, C2’H2 and C7’H2), 1.68 (s, 4H, C3’H2 and C6’H2) , 1.49 (s, 4H,
C4’H2 and C5’H2).

13

C NMR (126 MHz, CDCl3) δ 166.44 (Amide C=O), 156.29 (Guanidine C),

155.84 (ArC5), 153.61 (ArC3), 143.19 (ArC4”), 141.10 (ArC2”), 125.32 (ArC1”), 124.87 (ArC6),
110.82 (ArC2), 110.72 (ArC5”), 51.37 (C2’ and C7’), 27.86 (C3’ and C6’), 27.14 (C4’ and C5’) .
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HRESI-MS m/z (M + H)+: Calc. 344.1835, Obs. 344.1837. Anal-HPLC (70:30 A:B100% B over
30 min, tr =24.9 min).

3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(pyrimidin-5-yl)pyrazine-2-carboxamide (48)
The compound was prepared using the General Method (3 h
reaction time) using methyl 3-amino-5-(azepan-1-yl)-6-(pyrimidin5-yl)pyrazine-2-carboxylate 48a (86 mg, 2.63x10-4 mol). The
residue was taken up in anhydrous DMSO (2 mL) and purified by preparative HPLC (70:30
A:B100% B over 30 min). Collected fractions containing purified product were pooled
concentrated via freeze drying to yield 48 as an orange solid (TFA salt, 81 mg, 26% yield after
HPLC); MP: 186-190 °C;1H NMR (500 MHz, CD3OD) δ 10.47 (Amide NH), 9.14 (s, 1H, ArH4”),
8.98 (s, 2H, ArH2” and ArH6”), 8.83 (s, 2H, Guanidine NH2), 8.33 (s, 2H, Guanidine NH2), 3.44
(t, J = 5.75 Hz, 4H, C2’ H2 and C7’ H2) 1.72 (s, 4H, C3’ H2 and C6’ H2), 1.51 (s, 4H, C4’ H2 and
C5’ H2).

13

C NMR (126 MHz, CD3OD) δ 167.44 (Amide C=O), 157.71 (Guanidine C), 157.33

(ArC4”), 156.91 (ArC5), 156.87 (ArC2” and ArC6”), 155.84 (ArC3), 135.87 (ArC1”), 125.37
(ArC6), 113.35 (ArC2), 52.43 (C2” and C7”), 28.85 (C3” and C6”), 28.10 (C4” and C5”). HRESIMS m/z (M + H)+: Calc. 356.1947, Obs. 356.1944. Anal-HPLC (70:30 A:B100% B over 30
min, tr =20.1 min).

3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(2-methoxypyrimidin-5-yl)pyrazine-2carboxamide (49)
The compound was prepared using the General Method (3 h
reaction

time)

with

methyl

3-amino-5-(azepan-1-yl)-6-(2-
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methoxypyrimidin-5-yl)pyrazine-2-carboxylate 49a (111 mg, 3.09x10-4 mol). The residue was
taken up in solvent A:B (2 mL) and purified by preparative HPLC (70:30 A:B100% B over 30
min). Collected fractions containing purified product were pooled concentrated via freeze
drying to yield 49 as a yellow solid (HCl salt, 64 mg, 49% yield after IEX) MP 148-150°C; 1H
NMR (500 MHz, CDCl3) δ 10.76 (Guanidine NH), 9.27 (s, 2H, Guanidine NH2), 8.51 (s, 2H,
ArH2” and ArH6”), 8.48 (s, 2H, Guanidine NH2), 4.08 (s, 3H, p-methoxyCH3), 3.35 (t, J = 5.75
Hz, 4H, C2’H2 and C7’H2), 1.66 (s, 4H, C3’H2 and C6’ H2), 1.46 (s, 4H, C4’H2 and C5’ H2) 13C
NMR (126 MHz, CDCl3) δ 166.62 (Amide C=O), 163.99 (ArC4”), 161.93 (Guanidine C), 157.84
(ArC2” and ArC6”), 156.07 (ArC5), 153.87 (ArC3), 127.83 (ArC6), 124.71 (ArC1”), 112.51
(ArC2), 55.59 (p-methoxyCH3), 51.59 (C2’ and C7’), 27.76 (C3’ and C6’), 27.13 (C4’ and
C5’).HRESI-MS m/z (M + H)+: Calc. 386.2076, Obs. 386.2080. Anal-HPLC (70:30 A:B100% B
over 30 min, tr =20.7 min).

3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2carboxamide (50)
The compound was prepared using the General Method (3 h
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(2,4dimethoxypyrimidin-5-yl)pyrazine-2-carboxylate 50a (104 mg,
2.67x10-4 mol). The residue was taken up in solvent A:B (2 mL) and purified by preparative
HPLC (70:30 A:B100% B over 30 min). Collected fractions containing purified product were
pooled concentrated via freeze drying to yield 50 as a yellow solid (HCl salt, 65 mg, 54% yield
after IEX) MP 184-186°C; 1H NMR (500 MHz, CD3OD) δ 10.46 (s, exchange with solvent,
Amide NH), 8.79 (s, exchange with solvent, Guanidine NH2), 8.45 (s, 1H, ArC6”), 8.22 (s,
exchange with solvent, Guanidine NH2), 4.06 (s, 3H, p-methoxyCH3), 4.00 (s, 3H, o-
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methoxyCH3), 3.60 (bs, 2H, C2’ H2 and C7’ H2), 3.41 (s, 2H, C2’ H2 and C7’ H2), 1.64 (s, 2H, C3’
H2 and C6’ H2), 1.51 (s, 2H, C4’ H2 and C5’ H2) 13C NMR (126 MHz, CDCl3) δ 168.25 (Amide
C=O), 166.45 (ArC4”), 164.14 (ArC2”), 156.81 (ArC6”), 155.89 (ArC5), 153.92 (ArC3), 123.28
(ArC6), 111.40 (ArC2), 108.06 (ArC1”), 55.36 (p-methoxyCH3), 54.56 (o-methoxyCH3), 50.22
(C2’ and C7’), 27.84 (C3’ and C6’), 26.93 (C4’ and C5’) HRESI-MS m/z (M + H)+: Calc. 416.2159,
Obs. 416.2158. Anal-HPLC (70:30 A:B100% B min over 30 min, tr =21.2 min).

3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(2,6-dimethoxypyridin-3-yl)pyrazine-2carboxamide (51)
The compound was prepared using the General Method (3 h
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(2,6dimethoxypyridin-3-yl)pyrazine-2-carboxylate

51a

(98

mg,

2.53x10-4 mol). The residue was taken up in solvent A:B (2 mL) and purified by preparative
HPLC (70:30 A:B100% B over 30 min). Collected fractions containing purified product were
pooled and concentrated via freeze drying to yield 51 as a yellow solid (HCl salt, 15 mg, 13%
yield after IEX); MP: 152-154° C; 1H NMR (500 MHz, CDCl3) δ 10.28 (s, 1H, Guanidine NH),
8.77 (s, 2H, Guanidine NH2), 8.14 (s, 2H, Guanidine NH2), 7.61 (d, J = 8.0 Hz, 1H, ArH5”), 6.39
(d, J = 8.0 Hz, 1H, ArH4”), 3.94 (s, 3H, p-methoxyCH3), 3.87 (s, 3H, o-methoxyCH3), 3.52 (s,
2H, C2’ CH2 and C7’ CH2), 3.35 (s, 2H, C2’ CH2 and C7’ CH2), 1.60 (s, 4H, C3’ CH2 and C6’ CH2),
1.51 (s, 2H, C4’ CH2 and C5’ CH2), 1.44 (s, 2H, C4’ CH2 and C5’ CH2).

13

C NMR (126 MHz,

CDCl3) δ 166.00 (Amide C=O), 163.16 (ArC6”), 160.10 (Guanidine C), 159.19 (ArC2”), 155.44
(ArC5), 153.54 (ArC3), 141.10 (ArC4”), 127.98 (ArC6), 114.64 (ArC3”), 110.19 (ArC2), 101.28
(ArC5”), 53.82 (o-methoxyCH3), 53.54 (p-methoxyCH3), 50.39 (C2’ and C7’), 27.65 (C3’ and
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C6’), 26.81 (C4’ and C5’). HRESI-MS (M + H): Calc 415.2206, Obs. 415.2191. Anal-HPLC (70:30
A:B100% B over 30 min, tr =26.1 min).

3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(2-fluoropyridin-3-yl)pyrazine-2-carboxamide
(52)
The compound was prepared using the General Method (2.5 h
reaction

time)

with

methyl

3-amino-5-(azepan-1-yl)-6-(2-

fluoropyridin-3-yl)pyrazine-2-carboxylate 52a (100 mg, 2.90x10-4
mol). The residue was taken up in 70:30 solvent A:B (2 mL) and purified by preparative HPLC
(70:30 A:B100% B over 30 min). Collected fractions containing purified product were
pooled concentrated via freeze drying to yield 52 as a bright yellow solid (TFA salt, 18 mg,
13% yield after HPLC); MP: 1H NMR (500 MHz, CDCl3) δ 10.42 (s, 1H, Amide NH), 8.59 (bs, 4H,
2x Guanidine NH2), 8.17 (m, 2H, ArH4” and ArH6”) 7.29 (t, J = 5.4 Hz, 1H, ArH5”) 5.13 (bs, 2H,
Ar3NH2), 3.38 (s, 4H, C2’H2 and C7’H2), 1.64 (s, 4H, C3’H2 and C6’H2), 1.47 (s, 4H, C4’H2 and
C5’H2).

13

C NMR (126 MHz, CDCl3) δ 166.45 (Amide C=O), 160.67 (ArC2”), 155.98 (ArC5),

155.90 (Guanidine C), 154.01 (ArC3), 146.91 (ArC6”), 141.41 (ArC4”), 124.19 (ArC5”), 123.41
(ArC6), 122.45 (ArC3”), 111.79 (ArC2), 50.40 (C2’ and C7’), 27.86 (C3’ and C6’), 27.16 (C4’ and
C5’). HRESI-MS m/z (M + H)+ 355: Calc. 373.1901, Obs. 373.1916. Anal-HPLC (70:30
A:B100% B over 30 min, tr = 23.2 min).
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3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(2,4-dimethoxyphenyl)pyrazine-2carboxamide (53)
The compound was prepared using the General Method (3 h
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(2,4dimethoxyphenyl)pyrazine-2-carboxylate 53a (123 mg, 3.17x10-4
mol). The residue was taken up in solvent A:B (2 mL) and purified by preparative HPLC (70:30
A:B100% B over 30 min). Collected fractions containing purified product were pooled
concentrated via freeze drying to yield 53 as a yellow solid (HCl salt, 12 mg, 8.1% yield after
IEX) MP 156-158°C; 1H NMR (500 MHz, CDCl3) δ 10.19 (s, 1H, Amide NH), 9.10 (bs, 2H,
Guanidine NH2), 7.79 (bs, 2H, Guanidine NH2), 7.23 (d, J = 8.3 Hz, 1H, ArH2”), 6.58 (dd, J = 8.3
Hz, J = 2.1 Hz 1H, ArH3”), 6.48 (d, J = 2.1 Hz, 1H, ArH5”) 3.86 (s, 3H, p-methoxyCH3), 3.74 (s,
3H, o-methoxyCH3), 3.51 (s, 2H, C2’ H2 and C7’ H2), 3.36 (s, 2H, C2’ H2 and C7’ H2), 1.59 (s,
4H, C3’ H2 and C6’ H2), 1.50 (s, 2H, C4’ H2 and C5’ H2), 1.45 (s, 2H, C4’ H2 and C5’ H2) 13C NMR
(126 MHz, CDCl3) 13C NMR (126 MHz, CDCl3) δ 165.95 (Amide C=O), 161.54 (ArC4”), 157.83
(ArC2”), 155.71 (Guanidine C), 155.40 (ArC5), 153.75 (ArC3), 130.62 (ArC6”), 129.59 (ArC1”),
122.11 (ArC6), 109.78 (ArC2), 104.99 (ArC5”), 98.72 (ArC3”), 55.67 (p-methoxyCH3), 55.64
(m-methoxyCH3), 50.62 (C2’ and C7’), 27.81 (C3’ and C6’), 26.93 (C4’ and C5’). HRESI-MS m/z
(M + H)+ 414: Calc. 414.2254, Obs. 414.2269. Anal-HPLC (70:30 A:B100% B over 30 min, tr
=26.7 min).

224

3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(3,5-dimethoxyphenyl)pyrazine-2carboxamide (54)
The compound was prepared using the General Method (3 h
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(3,5dimethoxyphenyl)pyrazine-2-carboxylate 54a (147 mg, 3.81x104

mol). The residue was taken up in solvent A:B (2 mL) and purified by preparative HPLC

(70:30 A:B100% B over 30 min). Collected fractions containing purified product were
pooled concentrated via freeze drying to yield 54 as a yellow solid (HCl salt, 44 mg, 26% yield
after IEX) MP 138-140°C; 1H NMR (500 MHz, CDCl3) δ 10.75 (s, 1H, Amide NH), 8.81 (bs, 2H,
Guanidine NH2), 8.60 (bs, 2H, Guanidine NH2), 6.73 (d, J = 2.2 Hz, 2H, ArH2” and ArH6”), 6.58
(t, J = 2.2 Hz, 1H, ArH4”), 3.84 (s, 6H, m-methoxyCH3), 3.38 (s, 2H, C2’ H2 and C7’ H2), 1.64 (s,
4H, C3’ H2 and C6’ H2), 1.45 (s, 2H, C4’ H2 and C5’ H2). 13C NMR (126 MHz, CDCl3) 13C NMR
(126 MHz, CDCl3) δ 167.04 (Amide C=O), 160.96 (ArC3” and 5”), 156.35 (Guanidine C), 155.60
(ArC5), 153.77 (ArC3), 141.64 (ArC1”), 132.92 (ArC6), 110.93 (ArC2), 106.46 (ArC2” and C6”),
100.28 (ArC4”), 55.92 (m-methoxyCH3), 50.99 (C2’ and C7’), 27.95 (C3’ and C6’), 27.12 (C4’
and C5’). HRESI-MS m/z (M + H)+: Calc. 414.2254, Obs. 414.2244. Anal-HPLC (70:30
A:B100% B over 30 min, tr =25.8 min).

3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(3,6-dimethoxypyridazin-4-yl)pyrazine-2carboxamide (55)
The compound was prepared using the General Method (3 h
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(3,6dimethoxypyridazin-4-yl)pyrazine-2-carboxylate 55a (94 mg,
2.43x10-4 mol). The residue was taken up in anhydrous DMSO (2 mL) and purified by
preparative HPLC (100% A100% solvent B over 30 min). Collected fractions containing
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purified product were pooled concentrated via freeze drying to yield 55 as a bright yellow
solid (TFA salt, 21 mg, 17% yield after HPLC); MP 202-204°C; 1H NMR (500 MHz, CD3OD) δ
10.38 (s, exchange with solvent, Amide NH), 8.77 (s, exchange with solvent, Guanidine NH2),
8.21 (s, exchange with solvent, Guanidine NH2), 7.35 (s, 1H, ArH2”), 4.06 (s, 3H, omethoxyCH3), 3.99 (s, 3H, m-methoxyCH3), 3.35 (s, 4H, C2’ H2 and C7’ H2) 1.66 (s, 4H, C3’ H2
and C6’ H2) , 1.55 (s, 2H, C4’ H2 and C5’ H2), 1.45 (s, 2H, C4’ H2 and C5’ H2). 13C NMR (126
MHz, CD3OD) δ 167.31 (Amide C=O), 164.10 (ArC3”), 160.89 (ArC6”), 156.90 (Guanidine C),
156.75 (ArC5), 156.10 (ArC3), 136.33 (ArC1”), 123.95 (ArC6), 121.38 (ArC2”), 112.19 (ArC2),
55.44 (o-methoxyCH3), 55.26 (m-methoxyCH3), 50.98 (C2” and C7”), 28.89 (C3” and C6”),
27.92 (C4” and C5”). HRESI-MS m/z (M + H)+: Calc. 416.2159, Obs. 416.2150. Anal-HPLC
(100% A100% solvent B over 30 min, tr =19.0 min).

3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(phenylethynyl)pyrazine-2-carboxamide (56)
The compound was prepared using the General Method (1 h
reaction

time)

with

methyl

3-amino-5-(azepan-1-yl)-6-

(phenylethynyl)pyrazine-2-carboxylate 56a (54 mg, 1.42x10-4
mol). The residue was taken up in solvent A:B (2 mL) and
purified by preparative HPLC (70:30 A:B100% B over 30 min). Collected fractions
containing purified product were pooled concentrated via freeze drying to yield 56 as a
brown solid (TFA salt, 9.1 mg, 14% yield after HPLC) MP -°C; 1H NMR (500 MHz, CD3OD) δ
7.51 (m, 2H, ArH2” and ArH6”), 7.39 (m, 3H, ArH3”, ArH4” and ArH5”), 4.07 (t, J = 5.75 Hz,
4H, C2’H2 and C7’H2), 1.88 (s, 4H, C3’H2 and C6’ H2), 1.60 (s, 4H, C4’H2 and C5’ H2). 13C NMR
(126 MHz, CD3OD) δ 166.82 (Amide C=O), 156.97 (Guanidine C) 156.88 (ArC5), 155.57 (ArC3),
132.20 (ArC4”), 129.96 (ArC3” and ArC5”), 129.76 (ArC2” and ArC6”), 123.92 (ArC1”), 114.13
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(ArC2), 112.93 (ArC6), 91.45 (C7), 89.29 (C8), 51.66 (C2’ and C7’), 29.55 (C3’ and C6’), 27.62
(C4’ and C5’); HRESI-MS m/z (M + H)+: Calc. 378.2037, Obs. 378.2042. Anal-HPLC (70:30
A:B100% B over 30 min, tr =28.6 min).

7.3 Biology Experimental
Cell culture conditions
Human skin-derived telomerase-immortalized fibroblasts (TIFs) were sourced from Dr. Paul
Timpson and the Kinghorne Cancer Centre, Sydney, NSW, Australia. All other cells used were
subcultured from ATCC certified cell lines. SKOV-3 human ovarian adenocarcinoma, MDAMB-231 human breast adenocarcinoma, HEK-293 human embryonic kidney and RAW 264.7
murine Abelson murine leukemia virus induced macrophage and U-937 human histiocytic
lymphoma cells cell lines were cultured at 37° C, 95% humidity and 5% (v/v) CO2 in a
ThermoScientific Heracell 150i CO2 incubator (ThermoScientific). ATCC cell lines were
maintained in RPMI 1640 media supplemented with 5% (v/v) heat-inactivated FBS unless
otherwise stated (Sigma-Aldrich, St. Louis, MI, USA). TIFs were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% heat-inactivated FBS. Adherent
cells were passaged via the addition of trypsin/0.05% EDTA solution (GIBCO), followed by
centrifugation and resuspension in fresh media using a 5 mL Luerlock syringe fitted with an
18-gauge drawing-up needle (Terumo, Tokyo, Japan). U-937 cells were detached from cell
culture flasks via mechanical agitation in the absence of trypsin/EDTA detachment solution
prior to harvest. Haemocytometery with Trypan Blue staining was used to determine the
concentration of live suspended cells and to ensure a single cell suspension had been
achieved. Cells were passaged weekly and media changed every 2-3 days. Testing for the
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presence of mycoplasma was routinely performed using a MycoAlert™ Mycoplasma Test Kit
(Lonza Group, Basel, Switzerland). No mycoplasma contaminations were detected. All
experiments were conducted on cells with a passage number lower than 20.

Statistical analysis
Significance testing was performed using the unpaired parametric t-test function in
GraphPad PRISM v6.0 (GraphPad Software, San Diego, California, USA). Level of significance
was denoted as follows: * = p < 0.05, ** = p < 0.02, *** = p < 0.005. Correlation analysis was
performed using the linear regression function in GraphPad PRISM v6.0.

CellTitre 96® Aqueous One Solution Cell Proliferation Assay (MTS) assay
Sub-confluent cells (~ 70-80% confluent) were harvested and counted and dissociated into a
single cell suspension as described above. Cells were seeded at a density of 5000 cells/well
(final volume 90 L) into a Greiner CELLSTAR® 96-well plate (Greiner Bio-One GmBH,
Kremsmünster, Austria) via multichannel pipette and incubated for 18h prior to the addition
of compounds. Compounds were serially diluted from 20-50 mM DMSO stocks in RPMI 1640
media containing 5% v/v heat inactivated FBS in a separate 96-well plate under sterile
conditions to give 10x stocks (10 nM-1 mM) on the day of compound addition. 10 L of the
10x compound/media stocks or matched vehicle/media solutions (for vehicle controls) were
then transferred via multichannel pipette into the assay plate containing 90 L cell
suspension via multichannel pipette to give the treated assay plate at the final 1X drug
concentrations (1 nM-100 M, n = 4 wells at each concentration). Relevant drug blanks or
vehicle media blanks were included at each concentration to correct for the intrinsic colour
of the compounds and of the Phenol Red containing media. 200 L media was added to
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wells A1-12 and H1-12 to decrease evaporation and were not used in the assay itself.
Compound-treated plates were incubated for 48h prior to development. After 48h
treatment time, plates were removed from the incubator and 20 L CellTitre 96® Aqueous
One Solution Cell Proliferation Assay (Cat # G3581, Promega Corporation, Fitchburg,
Wisconsin, USA) was added to each well. Plates were incubated for a further 2h prior to
reading at 490 nm using a SpectraMax Plus 384-well plate reader (Molecular Devices LLC,
Sunnyvale, California, USA). Blank subtracted data was analyzed and graphed using
GraphPad PRISM v6.0 (GraphPad Software, San Diego, California, USA).

Cytotoxicity Detection Kit(PLUS) (LDH) Assay
Assay and compound dilution plates were prepared as described in Section 7.3 After 48h
treatment time assay plates were removed from the incubator and 5 L of Lysis solution
(Bottle 3) of the Roche Cytotoxicity Detection Kit(PLUS) (LDH) (Roche Diagnostics Australia Pty.
Ltd., NSW, Australia), was added to cell lysis controls. The plate was gently mixed by hand in
a circular motion atop a bench (similar to the manner one might wax a car) for 30 s and
incubated for a further 15 min. During this period 2.5 L Catalyst solution (Bottle 1) was
added to 112.5 L Dye solution (Bottle 2) to form Reaction mixture for each well to be
assayed. The plate was removed from the incubator and 100 L Reaction mixture added to
each well. The plate was then wrapped in aluminium foil and incubated for 30 min. After 30
min 50 L Stop solution was added to each well and read at 490 nm using a SpectraMax Plus
384-well plate reader (Molecular Devices LLC, Sunnyvale, California, USA). Blank subtracted
data was analyzed and graphed using GraphPad PRISM v6.0 (GraphPad Software, San Diego,
California, USA).
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Apo-ONE® Homogeneous Caspase-3/7 Assay
HEK-293 cells were harvested as described in Section x.xx and seeded into a black Greiner
CELLSTAR® 96-well plate (Cat # 655079, Greiner Bio-One GmBH, Kremsmünster, Austria) at a
density of 5000 cells/well in a volume of 40 L RPMI 1640 media with incubation for 18h. On
day of treatment 5x compound stocks in 5%DMSO/media were prepared in a separate 96well plate under sterile conditions. 10 L of each 5x compound stock was added to 40 L of
cell suspension on assay plate to give 1X compound dilutions in 1% v/v DMSO (1-30 M) and
the plate incubated for 5 h (time sufficient to trigger detectable induction of apoptosis
according to manufacturer’s instructions). Using the Apo-ONE® Homogeneous Caspase-3/7
Assay Kit (Cat # G7790, Promega Corporation, Fitchburg, Wisconsin, USA) 30 L of Z-DEVDR110 Caspase substrate was diluted into 2970 L Assay buffer and 50 L of the mixture
added to each assay well and the plate shaken using a plate shaker at 300 rpm for 2 h
followed by reading using a POLARstar OMEGA Fluorescence Plate reader (BMG-Labtech
GmBH, Ortenberg, Germany) ex. 480 nm, em 520 nm. Blank subtracted data was analyzed
and graphed using GraphPad PRISM v6.0 (GraphPad Software, San Diego, California, USA).

Solution-phase uPA inhibition assay
Urokinase from human kidney cells (Cat # U4010, Sigma-Aldrich, St. Louis, MI, USA) was
diluted to 900 nM, aliquoted and stored at -80 C until thawed for use in a series of
experiments (typically 4-5 plates assayed on the same day). Thawed enzyme stocks were
maintained at -20 C between each respective assay using a Nalgene Labtop Cooler Jr (Cat#
5115-0012, Thermo-Fisher Scientific, Waltham, Massachusetts, USA). A 5 mM stock solution
of Urokinase fluorescent substrate III (Z-Gly-Gly-Arg-AMC, Calbiochem Cat # 672159, Merck
Millipore, Massachusetts, USA) was prepared in dH2O/10% DMSO and aliquoted with
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storage at -20 C. Assay buffer (20 mM HEPES (pH 7.4), 100 mM NaCl, 0.5 mM EDTA, 0.01%
v/v Tween-20) was prepared and used within 7 days of preparation with storage at 4 C.
On the day of experimentation compound stocks (20-50 mM in anhydrous DMSO) were
serially diluted in assay buffer in a clear Greiner CELLSTAR® 96-well plate on ice (Greiner BioOne GmBH, Kremsmünster, Austria) to give each dilution at 2X the final assayed
concentration. In a separate black Greiner CELLSTAR® 96-well plate (Greiner Bio-One GmBH,
Kremsmünster, Austria) residual volumes of assay buffer were added via multichannel
pipette to compound fluorescence blanks and inhibited enzyme control wells as appropriate.
Next 90 L of dilute fluor (250 M final) was added to all wells, followed by 100 L of 2x
compound dilution to appropriate wells. Immediately prior to assay 900 nM uPA stock was
diluted to 15 nM and 10 L of this dilution was added to all relevant wells, initiating
reaction. Reaction progress was monitored using a POLARStar OMEGA fluorescence plate
reader (Fluorescence intensity mode, top-optic, ex. 355 nM em. 450 nM, 20 flashes per well,
double orbital shaking for 3s prior to every read, cycle time 60 s, 45-60 cycles, incubation at
37 C, BMG-Labtech, Ortenberg, Germany). Blank subtracted data was analyzed and graphed
using GraphPad PRISM v6.0 (GraphPad Software, San Diego, California, USA).

Chromogenic Trypsin-like serine protease activity experiments
For experiments using uPA (Cat # U4010, Sigma-Aldrich, St. Louis, MI, USA), trypsin, tPA,
thrombin and plasmin (all from Marker Gene Technologies Inc., Eugene, OR, USA)
concentrated stocks were prepared in dH2O and stored at -80 C until thawed for use.
Thawed enzyme stocks were maintained at -20 C between each respective assay using a
Nalgene Labtop Cooler Jr (Cat# 5115-0012, Thermo-Fisher Scientific, Waltham,
Massachusetts, USA). A 312.5 M stock solution of S-2288 chromogenic substrate 2288 (D-
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Ile-L-Pro-l-Arg-p-nitoraniline, Chromogenix, Massachusettes, USA) was prepared in dH2O and
aliquoted with storage at -20 C. Assay buffer (10 mM HEPES, 150 mM NaCl, 0.01% v/v
Tween-20, pH 7.4) was prepared and used within 7 days of preparation with storage at 4 C.
On the day of experimentation compound stocks (20-50 mM in anhydrous DMSO) were
serially diluted in assay buffer in a clear Greiner CELLSTAR® 96-well plate on ice (Greiner BioOne GmBH, Kremsmünster, Austria) to give each dilution at 10X the final assayed
concentration. In a separate Greiner CELLSTAR® 96-well plate (Greiner Bio-One GmBH,
Kremsmünster, Austria) residual volumes of assay buffer were added via multichannel
pipette to compound fluorescence blanks and inhibited enzyme control wells as appropriate.
Next 80 L of dilute fluor (250 M final) was added to all wells, followed by 10 L of 10x
compound dilution to appropriate wells. Immediately prior to assay concentrated enzyme
stocks were diluted to 100 nM and 10 L of this dilution was added to all relevant wells,
initiating reaction. DMSO was present at a final concentration of 1% v/v. Change in
absorbance overtime at 405 nm was measured at 37°C using a Molecular Devices
SpectraMax Plus 384-well plate reader (Molecular Devices LLC, Sunnyvale, California, USA).
IC50 values were determined by plotting percentage of residual activity (V0) versus log drug
concentration and fitted to a sigmoidal dose response curve using GraphPad Prism v.6.0
(GraphPad Software, La Jolla, CA, USA).

For experiments using Human Plasma Kallikrein, Factor Xa, Factor XIa, Activated Protein C or
uPA H99Y the chromogenic substrates S-2366 (pyroGlu-Pro-Arg-pNA) Human Plasma
Kallikrein, Factor XIa and Activated Protein C), S-2288 (H-D-Ile-Pro-Arg-pNA, Factor Xia) or S2444 (pyroGlu-Gly-Arg-pNA, uPA H99Y) were used (all substrates sourced from
Chromogenix, Massachusettes, USA). All enzymes were sourced from Marker Gene
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Technologies, Inc., Eugene, OR, USA. Enzymes were used at the following final
concentrations: Human Plasma Kallikrein 23.5 nM, Factor Xa 10 nM, Activated Protein C 10
nM, Factor Xia 2 nM and uPA H99Y 2 nM. Concentrated enzyme stocks were prepared in
dH2O and stored at -80 C until thawed for use. Experiments were conducted as described
above for experiments using other trypsin-like serine proteases. DMSO was present at a final
concentration of 1% v/v. Change in absorbance overtime at 405 nm was measured at 37°C
using a BioTek Synergy 4 384-well plate reader (BioTek Instruments Inc., Winooski, Vermont,
USA). IC50 values were determined by plotting percentage of residual activity (V0) versus log
drug concentration and fitted to a sigmoidal dose response curve using GraphPad Prism
v.6.0 (GraphPad Software, La Jolla, CA, USA).

Determination of inhibitory constant values (Ki)
Urokinase substrate III (Fluorogenic) (Cat #672159 - Merck Millipore, Merck KgaA,
Darmstadt, Germany) was serially diluted in HEPES assay buffer (20 mM HEPES, 100 mM
NaCl, 0.5 mM EDTA, 0.01% (v/v) Tween-20, pH 7.6) to give final concentrations between 2.0
M and 250 M. 200x inhibitor stocks in DMSO were diluted 1 in 100 into HEPES assay
buffer to yield a 2x working stock in 1% DMSO. The diluted substrate was added to a
Greiner CELLSTAR black 96-well microtitre plate (Cat. # M9936, Greiner Bio-One GmbH,
Kremsmünster, Austria), followed by addition of 2x working stock drug dilutions or
equivalent volumes of assay buffer for controls such that all wells contained 200 L solution,
0.5% DMSO v/v. The assay plate was allowed cool on a bed of ice and Urokinase from
human kidney cells (Cat # U4010, Sigma-Aldrich, St. Louis, MI, USA) from a 900 nM stock was
diluted in cold assay buffer to give a concentration of 15 nM. 10 L of 15 nM enzyme stock
was added to appropriate wells (final enzyme concentration = 0.75 nM) and the plate
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immediately read at ex. 355 nm, em. 460 nm using a BMG Labtech POLARStar Omega
Fluorescence Plate Reader (BMG Labtech, Ortenberg, Germany), cycle time 60 s, 45-60
cycles, 3s orbital shaking before each read). Blank subtracted data from the linear portion of
the kinetic curve was used to determine initial velocity and data plotted using GraphPad
PRISM v6.0 (GraphPad Software, La Jolla, California, USA).

Data was fitted using the

‘competitive inhibition’ function to determine Ki for each inhibitor.

xCELLigence Cell Index Assay
Sub-confluent cells (~ 70-80% confluent) were harvested and counted and dissociated into a
single cell suspension as described above. Cells were seeded at a density of 5000 cells/well
(final volume 180 L, RPMI 1640 + 10% FCS) into a ACEA Biosciences E-16 plate (Roche
Diagnostics Australia Pty. Ltd., NSW, Australia) and incubated for 18 h prior to
experimentation. On the day of experimentation the xCELLigence RTCA DP was allowed to
equilibrate at 37° C, 95% humidity and 5% (v/v) CO2 in a ThermoScientific Heracell 150i CO2
incubator (ThermoScientific). Using the ‘plate scan’ program within the xCELLigence
software package, the impendence of the cells was monitored for 24 h. The next day 10x
drug dilutions were prepared in a Greiner CELLSTAR® 96-well plate (Greiner Bio-One GmBH,
Kremsmünster, Austria). After 24 h the cell plate was removed from the xCelligence system
and 10x drug dilutions added to give the desried final concentrations in a total volume of
200 L (1% DMSO v/v final). Impedence was measured for 48 h following addition of drugs.
Data was analyzed in the RTCA 2.0 v3.4 software package and graphed using GraphPad
Prism v.6.0 (GraphPad Software, La Jolla, CA, USA).
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IncuCyte experiments
Incucyte ZOOM Live-Cell Analysis System (Essen Bio Science, Inc., Ann Arbor, MI, USA) was
maintained in at 37° C, 95% humidity and 5% (v/v) CO2 in a ThermoScientific Heracell 150i
CO2 incubator (ThermoScientific) throughout the course of all experiments. Sub-confluent
cells (~ 70-80% confluent) were harvested and counted and dissociated into a single cell
suspension as described above. Cells were seeded at a density of 5000 cells/well (final
volume 90 L) into a Greiner CELLSTAR® 96-well plate (Greiner Bio-One GmBH,
Kremsmünster, Austria) via multichannel pipette and incubated for 18h prior to the addition
of compounds. On the day of drug addition compound dilutions were prepared and added to
plates as described above for MTS assays. Images were acquired every 2 h for ~ 52 h
following the addition of comounds using a 10x objective. Cell confluency for each image
was calculated using the cell confluence processing definition inside the IncuCyte ZOOM
software package v.2016A. Cell confluence masks were optimized using representative
images to exclude cell debris and accurately measure cell area. Data from all images was
normalized to an initial image taken of the same well immediately prior to drug addition.
Data was exported from IncuCyte ZOOM and graphed using using GraphPad Prism v.6.0
(GraphPad Software, La Jolla, CA, USA). All treatments were conducted in triplicate with a
single image taken from each well at each time point.

Organotypic cell invasion assay
Tendons from excess deceased laboratory rats were surgically removed after washing in 70%
v/v ethanol/water solution. Isolated tendons were frozen at -80C and mashed using a glass
rod prior to dissolution of collagen I in 1500 mL 0.5 M Acetic acid at 4C for 48 h with
magnetic stirring. Extracted collagen was filtered through wet household paper towel to
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remove any remaining sheath. The extract was centrifuged at 10,000 rpm at 4C for 1 h and
the pellet discarded. Sufficient NaCl was added to the supernatant to form a 10% w/v NaCl
solution in a 2 L conical flask with excess NaCl added until the solution exhibited a persisting
white colour and no longer separated upon standing. The solution was centrifuged at 10,00
rpm at 4C for 30 min and supernatant discarded. The precipitate was dissolved in 0.25 M
acetic acid at a 1:1 ratio for 24 h at 4C with magnetic stirring. The resulting collagen
solution was dialyzed against 6-8 changes of 5 L 0. 17.4 mM acetic acid with changes
occurring twice daily. Dialyzed collagen was centrifuged at 20,000 rpm at 4C for 1.5 h.
Isolated collagen I was adjusted to a concentration of 2.0 mg/mL for use. Purity of extracted
collagen I was verified by SDS-PAGE. Human skin-derived telomerase-immortalized
fibroblasts were maintained in culture for 4-14 days post-confluency without changing of
media prior to harvesting to ensure quiescence. On day of collagen I seeding a collagen I
matrix solution was prepared by adding 3 mL 10x MEM solution to 25 mL collagen I solution
along with 3 mL 0.22 M NaOH and subsequent dropwise addition of NaOH until a pH of ~ 7.4
was achieved as determined by colour change of internal Phenol Red indicator. Harvested
Fibroblasts were resuspended in 3 mL FBS and seeded at a density of 1.0x106 cells/12
matrices into the neutralized collagen I matrix solution and 2.5 mL aliquoted into separate
sterile 35 mm sterile cell culture dishes, followed by. After ~ 30 min ~ 2 mL fibroblast growth
medium (DMEM/10% FBS/1xPenstrep) was added to and nascent collagen I/fibroblast
matrices were manually detached from the sides of each dish using a sterile pipette tip with
rotation of each dish. Matrices were allowed to contract for 8-12 days until they had
reached a diameter of ~ 20 mm. Following contraction matrices were transferred using
tweezers to a sterile 24-well cell culture plate. Harvested SKOV-3 ovarian adenocarcinoma
cells were seeded with a volume of 100 L of cell suspension at a density of 1x106 cells/mL.
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Seeded plugs were transferred to sterile steel mesh grids in 60 mm cell culture dishes (3
plugs per grid, 1 grid/treatment group per 60 mm dish) and ~ 10 mL media added such that
an air liquid interface was established with the bottom of the plug (as growth media diffuses
from the bottom of the plug towards the top a chemotactic gradient is established, inducing
epithelial cells seeded atop to invade downwards through the collagen matrix towards the
bulk growth media). On day of initial drug treatment, culture media was removed from each
dish and ~ 10 mL of the appropriate drug treatment/vehicle control was added to establish
an air-liquid interface as described above. After 21 days invasion time plugs were fixed in 4%
neutral buffered formalin for 24-48h. Fixed samples were processed using a Peloris Dual
Retort tissue processor (Leica, Germany). Histological staining was conducted on 4 m
sections deparfinized in xylene and rehydrated via graded washing in ethanol (70% v/v
ethanol/water-100% ethanol). Cytokeratin staining was performed using an Autostainer XL
(Leica, Germany). Ten images per treatment group were acquired using a DM4000 bright
field microscope (Leica, Germany) and analyzed for epithelial cell invasive index where
invasive index is defined as: (# epithelial cells invaded into collagen plug/ # epithelial cells
forming contiguous monolayer along top of the plug) x100. Scores for each image were
collated and statistical analysis performed using Microsoft Excel for Mac 2011 v.14.1.0.
Graphs were generated using GraphPad PRISM v6.0 (GraphPad Software, San Diego,
California, USA).
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Whole cell fluorescent membrane potential dye assay for the determination of ENaC
inhibition

HEK-293 Cells were cultured in Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12
(D-MEM/F-12) supplemented with 10% fetal bovine serum, 100 U/mL penicillin G sodium,
100 g/mL streptomycin sulfate and appropriate selection antibiotics. Semiconfluent cells
were transfected with cDNA for ENaC ,  and  subunits (genes SCNN1A, SCNN1B and
SCNN1G) prior to experimentation. Cells were plated at a density of 20,000 cells/well in a
384-well black wall, flat clear bottom microtiter plates (Type: BD Biocoat Poly-D-Lysine
Multiwell Cell Culture Plate) and incubated at 37 ºC overnight. Following manufacturer
instructions, cells were loaded with 20 µl of membrane potential dye solution for 30 min at
37 C from the FLIPR Membrane Potential Red Dye Fluorescence Assay Kit (Molecular
Devices, Sunnyvale, California, USA). This assay allows the fluorometric detection of changes
in membrane potential following modulation of transmembrane ion channel/exchanger
activity, namely antagonism of stimulated ENaC activity in this case. Drug, vehicle and
control solutions were prepared from frozen stocks in DMSO on the day of experimentation
through dilution into HEPES-buffered physiological salt solution (NaCl 137 mM, KCl 4 mM,
CaCl2 1.8 mM, MgCl2 1 mM, HEPES 10 mM, Glucose 10 mM, DMSO 0.3% v/v, pH 7.4) in a
384-well microtiter plate ready for addition to the assay plate by the FLIPR TETRA instrument.
All amiloride analogues were tested at 8 concentrations (n = 4 wells at each concentration).
Positive control cells were stimulated with 1 µM S-3969 (ENaC agonist, n = 4 wells). Negative
control cells were first stimulated with 1 µM S-3969 and then treated with 30 µM benzamil
(potent ENaC antagonist, n = 4 wells). Following dye loading cells were preincubated with 5
µl drug, vehicle or control solutions for 5 min. Next 5 µl of S-3939 solution (final [S-3969] = 1
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µM) was added to stimulate ENaC activity. All data was normalized to agonist-treated
positive and antagonist-treated negative controls such that agonist-treated signal equaled
100% activity and antagonist-treated signal equaled 0% activity. Normalized data was used
to determine IC50 values for each amiloride analogue using the log[inhibitor]-normalized
response variable slope algorithm in GraphPad PRISM v6.0 (GraphPad Software, La Jolla,
California, USA). This experiment was performed under contract by Charles River
Laboratories, Cleveland, Ohio, USA.
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Chapter 9: Appendix
Appendix 9.1: Data collection and refinement statistics of Human uPA in complex with 5-(N,N-hexamethylene)amiloride (HMA) and novel 6HMA analogues. Statistics for the highest resolution shell are shown in parentheses.
Data set
Space group
Cell dimensions
(a,b,c)

HMA
R3
120.462
120.462
42.355
34.8
1.7 (1.76
- 1.70)

38
R3
120.768
120.768
42.717
60.4 - 1.9
(1.97
1.90)

42
R3
120.51
120.51
42.403
60.26 1.62
(1.68 1.62)

47
R3
120.851
120.851
42.864
60.43 1.65
(1.71 1.65)

46
R3
120.33
120.33
42.59
23.92
1.73 (1.79
- 1.73)

48
R3
120.66
120.66
42.336
60.33 1.95
(2.02 1.95)

43
R3
120.698
120.698
42.769
60.35 1.9
(1.97 1.90)

49
R3
120.434
120.434
42.227
60.22 2.98
(3.09 2.98)

50
R3
120.35
120.35
42.28
28.82 1.65
(1.71
1.65)

Total reflections
Multiplicity
Unique
reflections

3.8 (3.8)
24667
(2487)

5.1 (5.1)
18286
(1828)

3.6 (3.6)
28904
(2839)

5.1 (5.0)
28054
(2816)

3.6 (3.8)
23162
(2419)

2.6 (2.5)
16793
(1679)

5.0 (4.7)
18272
(1839)

4.9 (5.1)
4643
(471)

3.7 (3.7)
27316
(2722)

Completeness
(%)
Overall (final
shell)

97.41
(98.07)

99.83
(98.86)

98.82
(97.83)

99.93
(100.00)

96.46
(99.88)

99.89
(99.41)

99.80
(99.78)

99.98
(99.79)

99.45
(99.82)

0.076
(0.691)
0.1977
(0.2801)
0.2268
(0.3166)

0.082
(0.553)
0.1993
(0.2486)
0.2327
(0.2306)

0.066
(0.973)
0.2166
(0.3164)
0.2355
(0.3314)

0.055
(0.522)
0.2046
(0.2691)
0.2358
(0.3037)

0.068
(0.686)
0.2394
(0.2738)
0.2760
(0.3553)

0.091
(0.591)
0.1958
(0.2591)
0.2252
(0.2541)

0.121
(0.699)
0.2031
(0.2376)
0.2347
(0.2722)

0.142
(0.628)
0.1678
(0.2606)
0.2680
(0.3668)

0.091
(0.077)
0.2115
(0.2886)
0.2387
(0.3042)

RMS deviations
from ideality
Bonds (Å)
Angles ()

0.101
3.17

0.013
1.51

0.022
1.77

0.010
1.43

0.017
1.87

0.018
1.45

0.027
1.58

0.015
1.62

0.017
1.72

Average B factors
(Å2)
Protein
Ligands
Solvent

29.50
29.60
36.20

33.70
37.20
38.30

28.10
31.10
39.90

27.40
28.20
37.20

26.50
28.70
35.00

37.70
38.60
39.40

37.90
36.20
38.40

66.40
83.60
43.60

25.10
30.10
37.10

Resolution range
(Å)

Rmerge (final shell)
R factor
Rfree
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Appendix 9.2: Data collection and refinement statistics of Human uPA H99Y in complex with
5-(N,N-hexamethylene)amiloride (HMA) and novel 6-HMA analogues. Statistics for the
highest resolution shell are shown in parentheses.
X-ray data and model
statistics
Data set
HMA
Space group
R3
Cell dimensions (a,b,c)
121.242
121.242
42.174
Resolution range (Å)
30.33 - 2.25
(2.33- 2.25)
Total reflections
Multiplicity
Unique reflections

42
R3
120.84
120.84
42.77
60.42 - 2.90
(3.00- 2.90)

50
R3
120.63
120.63
42.56
60.31 - 2.4
(2.49
–
2.40)
8939 (860)

10984 (1071)
3.8 (3.8)
24667 (2487)

4717 (479)
5.4 (2.5)

99.66
(99.07)

91.54
(94.48)

98.93
(94.61)

0.104
(0.691)
0.1933
(0.2309)
0.2536
(0.3147)

0.1754
(0.2492)
0.2647
(0.3567)

0.1774
(0.2179)
0.2374
(0.2820)

RMS deviations from ideality
Bonds (Å)
Angles ()

0.021
1.58

0.034
1.64

0.017
1.72

Average B factors (Å2)
Protein
Ligands
Solvent

50.90
68.00
47.30

31.80
42.40
20.10

33.00
33.50
35.00

Completeness (%)
Overall (final shell)

Rmerge (final shell)
R factor
Rfree
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Appendix 9.3: Concentration-response curves from solution-phase uPA inhibition assays
with HMA and the NHE1 inhibitor Cariporide. Cariporide did not inhibit uPA activity at
concentrations up to 100 M. Data points represent the mean ± SEM (n = 3).
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